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V                                 
 Summary 
Full-thickness skin loss caused by extensive burns, high energy trauma or chronic 
diabetic ulcers is not adequately addressed by current methods of wound coverage. 
Split-thickness skin autografts still represent the “gold standard” treatment to 
resurface the deep wounds. However, there are several drawbacks that are 
accompanied with the use of autologous skin graft, such as the limited availability of 
healthy area and creation of an additional injury. A vast amount of research to 
produce bioengineered skin grafts is being pursued with the aim to replace the use of 
autologous skin grafts. In this project, it is hypothesized that tissue-engineered skin 
grafts composed of biodegradable nanofiber scaffolds (NFS) enriched with bone 
marrow-derived mesenchymal stem cells (BM-MSCs) can promote wound healing 
and skin regeneration in acute full-thickness skin wounds. 
 
The differentiation potential of BM-MSCs into epidermal lineage was confirmed and 
achieved by manipulating the biochemical, environmental and physical cues in three-
dimensional (3D) organotypic coculture. BM-MSCs which were cultured in an 
optimized induction media at an air-liquid interface on contractible dermal substitutes 
for 14 days, demonstrated multi-layered epidermis-like structures with the expression 
of keratin 10 and filaggrin, the early and intermediate markers of epidermal 
differentiation, respectively. It indicates BM-MSCs may undergo epidermal 
differentiation and facilitate skin regeneration under in vivo wounding environment.  
 
NFS composed of Collagen type I and Poly (D,L)-lactic-co-glycolic acid (PLGA) 
VI                                 
 were successfully fabricated with electrospinning technique. It demonstrated a well-
controlled diameter range between 250 to 500 nm and displayed features of ECM-like 
non-woven architecture, high porosity (79.62%), small pore size (0.47 ± 0.36 µm), 
proper degradation profile and mechanical properties similar to human skin. The 
surface of blended NFS was further modified by coupling with CD29 antibody to 
achieve a rich and rapid attachment of BM-MSCs. The final construct of NFS with 
attached BM-MSCs was then used as a skin graft in a rat model to test its healing 
properties for full-thickness skin wounds.  
 
Animal studies showed that NFS with a high density (1.8 x 106/100 µl) of BM-MSCs 
significantly promoted wound healing and skin regeneration. Biomimetic NFS 
accelerated wound healing by providing a provisional matrix for cellular invasion and 
adhesion, collagen synthesis and deposition. BM-MSCs had a dose-effect on wound 
healing. Inclusion of a high amount of BM-MSCs remarkably expedited the 
epithelialization process and increased collagen synthesis. BM-MSCs were found to 
be co-located with the expression of epidermal differentiation markers and 
angiogenesis maker, which indicated the participation of BM-MSCs in epidermal 
lineage differentiation and revascularization process under in vivo wounding 
microenvironment. Therefore, this study suggests a great potential of nanofiber/stem 
cell composites as efficient skin grafts for the treatment of acute full-thickness skin 
wounds. However, such parameters as the minimum therapeutic dosage of BM-MSCs, 
functions of differentiated BM-MSCs and healing properties on a large tight-skinned 
animal model must all be ascertained before clinical application is attempted. 
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Chapter 1 






The ability of the skin to regenerate itself following minor epidermal injury is 
remarkable; however, when the injury is severe, such as loss of both epidermis and 
dermis in full-thickness skin wounds, the damaged skin can not regenerate 
spontaneously [1].  The most common cause of full-thickness skin loss is thermal 
injury, which accounts for approximately one million hospital emergency visits per 
year in the US and 3900 of them die due to shortage of suitable skin grafts [2]. Other 
causes include trauma and chronic ulcerations secondary to diabetes mellitus, 
pressure and venous stasis [3].  
 
Acute large full-thickness skin wounds not only lead to an immediate loss of wound 
coverage, but also initiate physiological instability and cause various complications. 
Without a protective barrier from injured skin, patients are easily susceptible to 
infections, especially the nosocomial infections from Pseudomonas. The metabolic 
responses in patients are complex and include electrolyte imbalance, metabolic 
acidosis, hyperventilation and respiratory alkalosis [4]. Therefore, the efficient and 
ordered process of natural repair is lost and the wounds are locked into a state of 
chronic inflammation characterized by abundant neutrophil infiltration with 
   1 
Chapter 1 
associated reactive oxygen species and destructive enzymes. Healing proceeds only 
after the inflammation is controlled by proper medical care [5]. However, due to the 
loss of epidermal and dermal layers to their full depth in full-thickness skin wounds, 
the epidermal stem cells in hair follicles for epidermal renewal, the basement 
membrane for cell migration and the blood vessels in dermis for nutrition supply are 
all destroyed, which create great difficulties in effective clinical treatment for 
improving skin regeneration. Without an adequate blood supply, the repair is 
inhibited and the wounds can only close with contraction and scar formation [1]. Scar 
tissue is preferable to no healing. However, they are not fully functional, cross-linked 
with only 80% of the tensile strength of the tissue it replaces and aesthetically 
disfiguring [5]. All of these faults justify facilitating skin regeneration and 
minimizing scar formation wherever possible.   
 
However, full-thickness skin wound is not adequately addressed by current methods 
of wound coverage. In most cases of epidermal and dermal injuries, the ‘gold 
standard’ approach is to take split-thickness autologous grafts that contain all of the 
epidermis but only part of the dermis. These are removed from healthy areas of the 
body and used to treat damaged areas on the same individual. Patients will regrow an 
epidermis from the injured sites if there is sufficient blood supply in the residual 
dermis [6]. However, this strategy is limited in the treatment of full-thickness skin 
wounds which are devoid of the dermal layer with blood vessels. Besides, if 
considerable amounts of skin are injured, tissue harvest will be circumscribed by the 
available surface area of unaffected skin and creation of an additional injury [7]. 
Therefore, allogeneic (from a non-genetically identical individual of the same species) 
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or xenogeneic (from a different species) skin grafts were developed. For example, 
allografts of cadaver skin are commonly used as a temporary cover for full-thickness 
burns, but are subject to immune rejection. Xenogeneic skin grafting involves the 
transfer of tissue between species, like allogeneic transplantation, they have problems 
of immune rejection and disease transfer [6]. All of these disadvantages give rise to 
the clinical need for tissue-engineered alternatives.  
 
Tissue-engineered skin graft is an attractive alternative substitute for clinicians to use 
for the healing of full-thickness skin wounds because they can overcome certain 
disadvantages of using autografts like insufficient donor supply and size mismatches. 
Current approaches in developing tissue-engineered skin substitutes include the use of 
biologically active scaffolds and supporting cells such as keratinocytes, hair follicle 
cells and fibroblasts etc. Many commercialized tissue-engineered skin grafts are 
available on market (Table 2.4). They offer advantages of resurfacing large wound 
area, supporting host fibroblast infiltration (PermacolTM, OrCel®, Integra®) and 
improving granulation tissue deposition (Apligraf®) etc. However, none of the 
current commercialized skin grafts can successfully fulfill the criteria for developing 
skin substitutes.  
 
There are three factors that are paramount in the development of tissue-engineered 
skin grafts: the safety of patient, clinical efficacy and convenience of use [6]. Acelluar 
skin grafts like PermacolTM results in insufficient revascularization. They can only be 
used as a temporary template (PermacolTM) and an epidermal layer is still required to 
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apply on top at a later time (PermacolTM, Integra®). For grafts using autologous 
keratinocytes, like EpicelTM, LaserskinTM, EpiDexTM, MyskinTM, two to six weeks are 
required to extract the keratinocytes via skin biopsy and expand in vitro to reach a 
sufficient cell number before covering the wound area [8]. This time interval cannot 
satisfy the urgent clinical requirement for patients with deep and extensive wounds. 
Moreover, adult primary keratinocytes have a low proliferation rate and tend to 
undergo apoptosis or lose phenotype after many cycles of expansion in monolayer 
culture [9]. Other deficiencies include donor site morbidity and graft fragility [8]. 
Whereas, allografts using allogeneic keratinocytes and/or fibroblasts, like AllodermTM, 
Dermagraft®, TranscyteTM, Apligraf®, Orcel®, avoid the limitations of donor site 
morbidity and in vitro culture. However, allografts carry a great risk of disease 
transfer and immune rejections. Besides, grafts using natural extracelluar matrix 
(ECM) materials, like collagen and/or glycosaminoglycans (GAGs) in Dermagraft®, 
Apligraf® and Orcel® have better matrix-cell interactions and improve skin 
reconstitution, however, their poor mechanical properties limit their handling and 
applications. In contrast, grafts incorporating synthetic materials like silicone and 
nylon in Integra® and TranscyteTM have good mechanical properties, but lack cell-
recognition signals and can only be used as temporary dressings. All of these 
deficiencies in current treatments for full-thickness skin wounds lead to an urgent 
necessity for the development of a novel tissue-engineered skin graft incorporating an 
alternatively effective and safe cell source in combination with a biocompatible and 
biodegradable scaffold with appropriate mechanical properties.   
 
1.2 Motivation 
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Numerous studies have found that after a skin injury, bone marrow-derived 
mesenchymal stem cells (BM-MSCs) will home to the injury sites due to chemotactic 
signals and contribute to epidermal cells for skin regeneration in vivo [10-13]. Sasaki 
et al. detected green fluorescent protein (GFP)-labeled BM-MSCs incorporated onto 
the skin of non-GFP mice after peripheral injection and indicated mesenchymal stem 
cells (MSCs) expressed several chemokine receptors, especially CCR7, which is a 
receptor of SLC/CCL21, that enhances MSCs to migrate into the injured site and 
differentiate into functional skin cells [14].  
 
In addition to differentiation potentials, BM-MSCs have exhibited a paracrine effect 
by releasing growth factors that may enhance angiogenesis and promote wound repair. 
RT-PCR analysis demonstrated MSCs are capable of expressing transforming growth 
factor beta 1 (TGF-β1), epidermal growth factor (EGF), vascular endothelial growth 
factor (VEGF), platelet-derived growth factor (PDGF), keratinocyte growth factor 
(KGF), fibroblast growth factor (FGF) and hepatocyte growth factor (HGF) 
constitutively or upon stimulation with lipopolysaccharide (LPS), interleukin-1α (IL-
1α), or tumor necrosis factor-α (TNF-α). Quantitative analysis of growth factor by 
ELISA showed that BM-MSCs secrete TGF-β1, EGF or VEGF with stimulation of 
wound tissue superfusate [15]. Besides, other studies suggest that BM-MSCs may 
mediate skin tissue repair or regeneration by promoting collagen synthesis and 
recruiting inflammatory cells and stem/progenitor cells [16-18]. 
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Other advantages of using BM-MSCs in clinical settings are relative ease in isolation 
from bone marrow and fast expansion in vitro [19]. Moreover, compared with 
embryonic stem cells, BM-MSCs have less ethical issues and show immune-
suppressive effects when allogeneic MSCs are used [20]. Therefore, the incorporation 
of BM-MSCs in skin grafts holds a great potential in promoting wound healing and 
skin regeneration in full-thickness skin defect.  
 
Recent advances in tissue engineering techniques have sparked interests in making 
scaffolds with biocompatible and/or biodegradable polymer nanofibers. The rationale 
for using nanofibers is based on the theory that cells attach and organize well around 
fibers with diameters smaller than the diameter of the cells [21]. More importantly, 
the non-woven polymeric architecture of nanofiber scaffolds (NFS) mimics the nano-
scale protein fiber meshwork in native ECM. The large surface area-to-volume ratio 
of NFS favors cell adhesion, proliferation, migration and differentiation [22]. For skin 
graft application, the high porosity of NFS provides more structural space for 
accommodation of migrating and proliferating cells and enables efficient nutrient 
delivery, gas exchange and waste excretion, while the small pore size of NFS can 
protect the wound from bacterial penetration [23]. Additionally, polymeric NFS are 
usually strong in tensile strength, so they can retain structural integrity and prevent 
wound contraction when surgeon handles and implants it into the defect site of the 
host [24]. 
 
Several fabrication techniques such as electrospinning, phase separation, melt-blown, 
template synthesis and self-assembly have been used to produce suitable polymer 
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nanofibers for different purposes. Amongst all the techniques mentioned above, 
electrospinning is the most simple and efficient method to fabricate nanofibers 
because it is relatively easy to set up in the laboratory and the resultant scaffolds have 
a large surface area-to-volume ratio with interconnected pores [25]. By controlling 
the processing parameters, fibrous scaffolds can be achieved with controllable fiber 
diameter on a nano-scale and scaffolding architectures that promote skin regeneration. 
In this project, we utilized electrospinning technique to fabricate nanofibrous 
scaffolds that were further modified for fast and rich capture of BM-MSCs and 
studied the effectiveness of the resultant NFS/stem cell composites as skin grafts to 
promote wound healing and skin regeneration in a rat model with acute full-thickness 
skin wounds. 
 




Electrospun biodegradable NFS mimicking natural ECM enriched with an 
efficient attachment of BM-MSCs promote wound healing and skin regeneration 
in acute full-thickness skin wounds. 
 
a) BM-MSCs will differentiate into epidermal lineage and facilitate skin 
regeneration and wound healing within a skin-specific environment.   
 
b) Electrospinning can be used to fabricate nano-scale architectures in tissue-
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engineered skin grafts to resemble the natural ECM structure and improve 
wound healing.   
 
c) Biodegradable synthetic polymer and natural ECM protein like collagen can 
be blended for co-electrospinning to provide the skin grafts with appropriate 
mechanical stability and biomolecular cell recognition signals for cell-scaffold 
interactions.  
 
d) A specific antibody for BM-MSCs can be chemically conjugated on the 
surface of NFS to render the NFS a high affinity for BM-MSCs and achieve 
an efficient attachment of BM-MSCs by inducing the antibody-antigen 
binding activity on the NFS surface.     
 
e) There are two temporally distinct injury-related signals for skin tissue 
regeneration: 1) induction of BM-MSCs to migrate to sites of injury; 2) 
differentiation of localized BM-MSCs into cells of skin lineage. Therefore, it 
is possible to by-pass step 1 by capturing a sufficient amount of BM-MSCs on 
a NFS carrier, applying directly to the site of injury and then the wound bed 
will be capitalized as a natural ‘bioreactor’ for the transplanted BM-MSCs to 
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• Confirm the epidermal differentiation potential of BM-MSCs by inducing 
BM-MSCs into epidermal lineage in vitro through manipulating the 
biochemical, environmental and physical conditions in an organotypic 
coculture model.  
 
• Utilize electrospinning technique to fabricate collagen type I − blended 
polymer NFS and modify its surface with antibody conjugation to achieve an 
efficient attachment of BM-MSCs. 
 
• Demonstrate the efficiency and efficacy of NFS/BM-MSCs composites as 
skin grafts to promote skin regeneration and wound healing in a rat model 
with acute full-thickness skin wounds.   
 
1.4 Research rationale and strategy  
 
The schematic illustration of research strategy in this project is depicted in Figure 1.1. 
Biodegradable electrospun NFS were fabricated by electrospinning technique using 
PLGA blended with medical grade Collagen type I. NFS were further modified by 
grafting CD29 antibody on its surface for rich and fast capture of BM-MSCs within 
30 minutes. The resultant NFS with attached BM-MSCs were used as skin grafts to 
directly apply onto the full-thickness skin wounds to promote wound healing and skin 
regeneration in a rat model.    
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Fig. 1.1 The schematic illustration of research strategy.  
 
The rationale of using NFS/BM-MSCs composites as skin grafts for the treatment of 
full-thickness skin wounds in this study are: 
 
• BM-MSCs have the potential to improve skin regeneration by differentiating 
into the phenotypes of damaged skin cells and/or enhancing repair by creating 
a microenvironment that promotes the regeneration of local cells.  
 
• Modified NFS could serve as a rapid BM-MSCs captor and carrier as well as a 
cover for acute full-thickness skin wounds. 
 
• Rapid and rich capture of BM-MSCs by modified NFS within 30 minutes 
could satisfy the emergent clinical requirements in treating acute full-
thickness wounds.  
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• The rapid and rich attachment of BM-MSCs on modified NFS can be 
achieved at room-temperature to emulate the temperature in a surgical theatre. 
 
• Avoidance of an additional injury to unaffected skin, which is the case for 
current autologous split-thickness grafts. 
 
• Allogeneic BM-MSCs with immunosuppressive properties will not elicit 
immune rejection after transplantation.  
 
• The non-woven polymeric architecture of NFS mimics the nano-scale protein 
fiber meshwork in native ECM. Its high surface area-to-volume ratio is 
efficient for cell adhesion, proliferation, migration and differentiation.  
 
• The NFS has a high porosity for efficient nutrient delivery, gas exchange and 
waste excretion after transplantation into wounded skin.  
 
• The small pore size of the nanofiber skin graft inhibits the bacterial entry.  
 
• NFS gradual biodegradation profile allows the new skin tissue to regenerate 
and reduces immunological responses.    
 
1.5 Work scope 
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In this dissertation, a detailed literature review is presented in Chapter 2 that includes 
the wound healing process, current treatments for full-thickness skin wounds, 
properties and potentials of BM-MSCs and electrospun NFS for wound healing and 
skin regeneration. Table 1.1 summarizes the project scopes from chapter 3 to chapter 
5. Conclusions for this thesis and recommendations for future work are described in 
Chapter 6.  
  
Table 1.1 Overview of project scope. 
Hypothesis Objective Descriptions Thesis 
BM-MSCs will differentiate 
into epidermal lineage 
within a skin-specific 














cells with expression of 
epidermal 
differentiation markers 
by manipulating the 
biochemical, 
environmental and 
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(1) Electrospinning can be 
used to fabricate nano-scale 
architectures in tissue-
engineered skin grafts to 
resemble the natural ECM 
structure. 
  
(2) Biodegradable synthetic 
polymer and natural ECM 
protein like collagen can be 
blended for co-
electrospinning to provide 
the skin grafts with 
appropriate mechanical 
stability and biomolecular 
cell recognition signals for 
cell-scaffold interactions.  
 
(3) A specific antibody for 
BM-MSCs can be 
chemically conjugated on 
the surface of NFS to render 
the skin grafts a high 
affinity for BM-MSCs and 
achieve their efficient 
attachment by inducing the 
antibody-antigen binding 








polymer NFS and 







(1) PLGA blended with 
Collagen type I NFS 
were electrospun and 
further characterized 







(2) CD29 antibody was 
chemically conjugated 
on NFS surface to 
achieve rapid and rich 
attachment of  
BM-MSCs.  
 
(3) The efficiencies of 
CD29 antibody grafting 
and BM-MSCs 






It is possible to by-pass the 
step of BM-MSCs migration 
into wound sites from bone 
marrow by capturing a 
sufficient amount of BM-
MSCs on a NFS carrier, 
applying directly to the site 
of injury and then the 
wound bed will be 
capitalized as a natural 
‘bioreactor’ for the 
transplanted BM-MSCs to 
differentiate into cells of 







skin grafts to 
promote skin 
regeneration and 
wound healing in 
a rat model with 
acute full-
thickness skin 
wounds.   
 
 
Animal studies on rat 
has been done to show 
the capacity of 
NFS/BM-MSCs 
composites as skin 
grafts to improve 
wound healing and skin 













2.1.1 Skin composition and functions  
 
Skin, the largest organ in the body, has a surface area of about 1.8 m² and 8% of the 
total body mass in an adult. The thickness of skin varies from 1.5 to 4.0 mm, 
depending on skin maturity (aging) and body region. Skin acts as a barrier to water 
loss, exogenous substances, pathogens, and trauma [26,27]. Its other functions 
include sensation, temperature regulation, synthesis of vitamin D and protection of 
vitamin B folates. Skin comprises two layers: the outer protective epidermis and the 
inner corium or dermis which provides the mechanical stability for skin and includes 
several important structures, such as blood and lymph vessels, nerves and appendages 
etc [8].  (Fig. 2.1).   
 
The epidermal layer is relatively thin with a depth of 0.1-0.2 mm, composed of 4-5 
layers depending on different regions of the skin [6]. Those layers in ascending order 
are the stratum basale, stratum spinosum, stratum granulosum and stratum corneum 
[28](Fig. 2.2). The stratified squamous epithelium is maintained by cell division 
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within the basal layer. Differentiating cells slowly displace outwards through the 
stratum spinosum to the stratum corneum, where anucleate corneocytes are 
continually shed from the surface. The stratum corneum is a complex tissue, which 
provides both permeability and a mechanical barrier between the outside environment 
and the internal milieu of the organism. It is composed of both corneocytes, which 
provide strength and rigidity, and an extracellular lipid-enriched matrix, which 
provides a barrier to water transit. Corneocytes are postapoptotic, anucleated cells 
that have a unique external envelope, the cornified envelope, which consists of 
proteins, such as involucrin and loricrin cross-linked by transglutaminase, and 
cytoplasmic keratin filaments aggregated into macrofibrils by filaggrin [29]. 
 
 In normal skin the rate of production equals the rate of loss, taking about 52 to 75 
days for a keratinocyte to migrate from the basal cell layer to the top layer of stratum 
corneum [30]. The upper keratinized epidermal layers provide the effective barrier to 
prevent bacterial entry, fluid and electrolyte loss. Keratinocytes in stratum basale are 
securely attached to the underlying dermis by a specialized basement membrane zone. 
Other cell types in epidermis include melanocytes, Langerhans and Merkel cells. 
Melanocytes reside in the basal layer and protect the epidermis from ultraviolet 
radiation. Langerhans cells are dendritic cells and primarily located in stratum 
spinosum. Upon infection, these cells will take up and process microbial antigens to 
become fully-functional antigen-presenting cells. Merkel cells are located in the 
stratum basale of epidermis and associated with the sense of touch [31]. The 
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epidermis has no blood vessels and must receive nutrients via diffusion from the 
adjacent dermal capillary network [6]. 
 
The dermis varies in thickness depending on different sites in the body. The outer 
papillary dermis is composed of areolar connective tissues including capillaries, loose 
elastic fibers and collagen. The inner reticular dermis consists of dense and thick 
irregular connective tissues of larger blood vessels, collagen, elastic and reticular 
fibers. Collagen Type I predominates by 80-90% followed by collagen type III with 
10-20% in this reticular layer [32]. Reticular dermis is important in providing skin 
with its overall strength and elasticity for protection against trauma as well as housing 
other important structures such as hair follicles, lymphatic vessels, sebaceous, 
apocrine and sweat glands. The dermis also contains receptors for touch, temperature 
and pain [6]. The primary dermal cells are fibroblasts, which synthesize collagen, 
elastin and other ECM composed of mucopolysaccharides, chondroitin sulfate and 
glycoproteins. Dermal fibroblasts also excrete many cytokines and growth factors, 
such as KGF and granulocyte macrophage colony-stimulating factor (GM-CSF), to 
mediate the epidermal proliferation and differentiation for skin regeneration [33]. 
 
The subcutaneous layer or hypodermis is not part of the skin and lies below dermis. 
Its function is to attach dermis to the deeper structures of the body like fascia and 
muscles etc. and supply it with blood vessels and nerves. Hypodermis is mainly 
composed of adipose tissue which serves as padding and insulation for the body [34]. 
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Fig. 2.1 The architecture of human skin (Reprinted from Figure 1 of [8], Copyright 
2007, with permission from Royal Society Publishing).  
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Fig. 2.2 The structures of stratified epidermis (Reprinted from [28], Copyright 2008, 
with permission from Wiley-Blackwell) 
 
2.1.2 Wound healing in vivo 
 
2.1.2.1 Four basic responses to skin injury 
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Many reasons could lead to the skin injury, such as high energy trauma, burn injury, 
chronic wounds (venous, diabetic wounds and pressure ulcers) etc. There are four 
basic responses that can occur following a skin injury (Fig. 2.3). Regeneration is the 
elegant process of restoring the interrupted continuity by synthesis of the missing 
organ at the original anatomical site with normal structure and function. Lower forms 
of life, such as the salamander and crab, can regenerate tissues in this manner. As 
man has evolved, we have lost the capacity of complete regeneration and can only 
replace a limited amount of damaged skin tissues by the process of regeneration 
[5,35].  The epidermis and basement membrane can regenerate spontaneously, 
provided that there is residual stroma in the wound bed, for example, in the 
superficial skin injury. However, in full-thickness skin loss, wound is difficult to heal 
as adult dermal stroma cannot regenerate spontaneously. Normal repair is an adaptive 
response to loss of normal organ mass and leads to restoration of the interrupted 
continuity by synthesis of scar tissue without reconstitution of normal tissues. This is 
the typical response that adult human beings experience following acute deep wounds 
[5]. The pathological responses to tissue injury stand in sharp contrast to the normal 
repair response. In excessive healing, there is too much deposition of connective 
tissue that results in altered structure and loss of function [36]. Fibrosis, adhesions 
and contractures are examples of excessive healing. Keloids and hypertrophic scars in 
the skin are examples of fibrosis [37]. Contraction is part of the normal process of 
healing but if excessive, it becomes pathologic and is known as a contracture. 
Deficient healing is the opposite of fibrosis; it exists when there is insufficient 
deposition of connective tissue matrix and the tissue is weakened to the point where it 
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can fall apart. Chronic non-healing ulcers are examples of deficient healing [38].  
 
 
Fig. 2.3 Four possible responses after skin tissue injury (Reprinted by permission 
from Frontiers in Bioscience [5]).  
 
2.1.2.2 Acute wound healing in vivo  
 
Acute wound healing is an ordered, dynamic and interactive skin repair process 
involving soluble mediators, formed blood elements, ECM, stromal and parenchymal 
cells. The various cellular processes in wound healing are mediated by cytokines, 
growth factors and collagen digesting enzymes like matrix metalloproteinases (MMPs) 
(Fig. 2.4). Cytokines are direct regulatory peptides in wound healing conditions 
crucial for chemotactic migration of inflammatory cells, mitosis of fibroblast, 
keratinocytes and vascular endothelial cells, revascularization, synthesis and 
degeneration of ECM components. These include interleukins (IL) and several 
growth factors which are involved in tissue repair and chemotaxis to inflammatory 
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cells. Cytokines may act on producer cells (autocrine stimulation), adjacent cell 
(paracrine stimulation) or distant cells (endocrine stimulation) [39]. 
 
The normal healing response begins the moment the tissue is injured. As the blood 
components spill into the site of injury, the platelets come into contact with exposed 
collagen and other elements of the ECM. This contact triggers the platelets to release 
clotting factors as well as essential growth factors and cytokines such as PDGF and 
TGF-β. The neutrophils then enter the wound site and begin the critical task of 
phagocytosis to remove foreign materials, bacteria and damaged tissue. The 
macrophages appear and continue the process of phagocytosis as well as releasing 
more PDGF and TGF [5].  24h to 48h after the injury, epidermal keratinocytes 
proliferate over the dermis surface, and dermal fibroblasts and endothelial cells 
invade the blood clot to form a new dermis (granulation tissue) and new blood vessels 
(angiogenesis) on the third day. The dermal fibroblasts and myofibroblasts proliferate 
and establish the new ECM within the next 5-10 days. After the epidermis is 
reestablished by the keratinocytes, the desiccated blood clot is separated and 
remodeling occurs towards scar maturation for up to 12 months [32]. 
 
The chain of events occurs in an overlapping order described in five phases: 1. 
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After injury, homeostasis has to be established to stop blood loss and dehydration. 
Firstly, vasoconstriction occurs as the blood pressure changes and damaged cells 
secrete prostaglandins. Secondly, platelets adhere to the sub-endothelium and fibrillar 
collagens. Platelets adhere to many clotting factors (i.e. fibrinogen, fibronectin, 
laminin, vitronectin, thrombospondin and von Willebrand factor VIII) released by 
damaged cells. Further alpha granules are released, which contain important 
immunomodulatory and proteinaceous factors, such as TGF α and β, PGDF and FGF 
for early and late phase of healing, and dense bodies are released as well into the 
cytoplasma with all healing contributing nutriments such as calcium, serotonin, ATP 
etc. Thirdly the extrinsic coagulation cascade is initiated by binding Factor VII to 
extravascular tissue. The result of the coagulation cascade is thrombin, which 
catalyses fibrinogen to fibrin. Thrombin increases vascular permeability for 
inflammatory cells, generates fibrin which is a biological glue that form a stable fibrin 
clot (Fig. 2.4). The correct fibrin formation is a key factor in wound healing that 




A signal of inflammation starts within 10 to 15 min after injury. Vasodilatation occurs 
due to endothelial products and mast cell-derived factor like histamines. The gap 
between endothelial cells increases and permits a plasma flow from the intravascular 
space to the extravascular space. Thrombin and factors of the complement system 
increase the vascular permeability. Hence a painful oedema is generated [32].  
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Then cells of immune system migrate easily through the endothelial gaps into the 
wounded area. In addition, they are lured and transformed by release of chemotactic 
factors, such as TGF-β1 [40]. Neutrophils enter the wounded area first with a 
population peak on the first or second day and then taken over by macrophages on the 
3rd day. Leukocytes are stimulated by collagen, elastin breakdown product, as well as 
TGF-β and PDGF. The chemotactic factors (e.g. thrombin, elastin, fibronectin and 
TGF-β) transform monocytes into macrophages during this process. All leukocytes 
are activated by T-lymphocytes through IL-2, before they phagocyte cell debris, 
foreign materials and bacteria. Further macrophages release MMPs such as 
collagenase and elastase to breakdown the ECM in the wounded area. Besides, 
macrophages monitor healing process by modulating cytokines and 
immunomodulatory factors, such as TGF-β, TGF-α, insulin like growth factor-1 
(IGF-1), FGF-2, PDGF and VEGF, which are involved in angiogenesis, fibroblast 
proliferation, migration and collagen production (Fig. 2.4). Macrophages and 
lymphocytes remain in the wounded area for up to 7 days in this inflammation stage 
[32]. 
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Fig. 2.4 The various cellular activities in initiating acute wound healing process 
(Reprinted by permission from Nature Publishing Group: J Invest Dermatol [3], 
copyright 2007).   
 
2.1.2.2.3 Proliferation  
 
2.1.2.2.3.1 Keratinocyte reepithalization 
 
Re-epithalization occurs at the same time with neutrophil peak point on the first or 
second day. Basal cells present at the wound edge elongate and begin to migrate as a 
monolayer either over the remaining basement membrane or over the provisional 
matrix of fibrin-fibronectin in the wounded area. If the initial injury does not destroy 
epithelial appendages such as hair follicles and sweat glands, these structures also 
contribute to the epithelia stem or progenitor cells for healing process (see details in 
section 2.1.2.3.1). Once in contact with the connective tissue, these migratory 
keratinocytes become anchored, and begin to deposit laminin 5 [42]. 
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Cellular migration and proliferation is controlled by various cytokines including EGF, 
TGF-α, IGF, PDGF and KGF [32]. The epithelial-mesenchymal interactions between 
fibroblasts and keratinocytes are reciprocal. Fibroblasts secrete KGF and in response 
to it, keratinocytes (and macrophages) secrete IL-1 and IL-6 that stimulate fibroblasts 
to secrete more KGF [43,44]. Keratinocytes re-establish themselves a basement 
membrane by secretion of tenasin, vitronectin and type I, VII and IV collagen. TGF-β 
secreted by fibroblasts induced the synthesis of collagen IV and VII by keratinocytes 
[43,44]. The migration of keratinocytes continues until they overlap, which results in 
contact inhibition and the initiation of keratinocyte differentiation (see details in 
section 2.1.2.3.3). As keratinocytes differentiate, enzymes are released to dissolve the 




Although epidermal migration along the interface between the clot and surrounding 
normal tissue begins within 24h after injury, no tissue cells have invaded the clot 
even by day 3. The new stroma, called ‘granulation tissue’ is formed from 
macrophages, fibroblasts and endothelia from day 4. Fibroblasts require fibronectin 
for the movement from periwound collagenous matrix into the fibrin/fibronectin 
wound space. They bind fibronectin through the receptors of the integrin family. EGF, 
PDGF and TGF-β released by platelets, keratinocytes and especially macrophages 
stimulate fibroblasts to migrate and up-regulate integrin receptors [41]. To facilitate 
migration through debris in wound environment, fibroblasts secrete proteolytic 
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enzymes like MMP-1, gelatinase and stromelysin.  From day 10, many fibroblasts 
develop apoptosis and initiate the transition from a fibroblast-rich granulation tissue 




The angiogenic process becomes active from day 2 after wounding. Factors that 
contribute to angiogenesis include high lactate levels, low pH, and in particular 
decreased oxygen tension (hypoxia) within the granulation tissue. bFGF, TGF-β1 and 
VEGF, released by epidermal cells, fibroblasts, macrophages and endothelial cells, 
are stimulated through tissue hypoxia [5]. During angiogenesis, endothelial sprouts 
derive from intact capillaries at the wound periphery through cellular migration and 
proliferation. Endothelial migration during angiogenesis involves binding integrin 
domains within the provisional fibrin-fibronectin matrix in a similar manner to 
fibroblast migration. VEGF-C activates the microvascular endothelial cells, which 
produce MMP-1 to digest the surrounding collagen and form capillary branching 
tubes [43]. TGF-β induces the production of fibronectin and proteoglycans in 
endothelial cells and corrects the phenotype for the formation of capillary tube [41].  
It was also found to stimulate the neo-synthesis of the VEGF family [43]. As the 
wound area becomes revascularized, the concentrations of all cytokines diminish, 
which helps to maturate the vascular system and granulation tissue. 
 
2.1.2.2.4 Protein synthesis  
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The protein synthesis begins on the 4th day after the injury and continues for 
maximum 2-4 weeks. The initial wound matrix with fibrin and fibronectin is slowly 
replaced by collagen, proteoglycans (e.g. Hyaluronan) and thrombospodine I, which 
are synthesized by the invading fibroblasts. Growth factors like TGF-β, PDGF and 
FGF-2 accelerate collagen synthesis and scar formation, whereas TGF- β3 and INF-α 
(by T-Lymphocytes) slow down the collagen expression. In normal tissue, the dermal 
collagen is a strong and highly organized molecule. In contrast, collagen fibers 
formed in scar tissue are much smaller and have a random appearance; Scar tissue is 
always weaker and the regained tensile strength in a scar tissue will never approach 
normal in adult wound healing process. Elastin is not synthesized in response to 
wound injury and therefore lacks in scar tissue. The maximum tensile strength that a 
scar tissue can ever achieve is approximately 80% of normal skin [5].  
 
Contraction begins 4 to 5 days after initial injury and continues for maximum 2 weeks. 
The rate of contraction varies among different anatomic locations and scar shapes, but 
approximately 0.6-0.7 mm per day [32]. Fibroblasts and myofibroblasts are linked to 
extracellular fibronectin, collagen matrix and linked to each other through direct 
adherence junctions. When new collagen matrix is accumulating, fibroblasts begin to 
align with collagenous fibrils. Through the cell-cell and cell-ECM interactions, the 
tractions (forces and stresses) of the fibroblasts can be transmitted through the wound. 
TGF-β induces smooth muscle actin expression in myofibroblasts and form strong 
bundle arrays to transmit the traction forces of the myofibroblasts. TGF-β and PDGF 
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provide the signal for myofibroblasts to contract and close the wound [41]. The 
down-regulation of wound contraction is controlled by HGF. TGF-β1 and HGF 
mutually inhibit each other. HGF possesses anti-fibrogenic, anti-inflammatory and 
pro-regenerative properties and strongly inhibits myofibroblastic differentiation [40]. 
Wound contraction is the biological mechanism for rapid wound closure, but across 
joints it limits mobility functions. Wound contraction is not observed in embryonic or 





The collagen matrix itself suppresses the fibroblast proliferation and collagen 
synthesis. At the same time, collagen degradation also occurs. Specific collagenase 
enzymes in fibroblasts, neutrophils and macrophages clip the molecule at a specific 
site through all three chains and break it down to characteristic three-quarter and one-
quarter pieces.  These collagen fragments undergo further denaturation and digestion 
by other proteases [5]. 
 
 The immature scar tissue consists of disorganized fine collagen fibers, which are 
gradually replaced by thicker ones arranged in stress direction. In the extracellular 
spaces, an important enzyme, lysyl oxidase, acts on the collagen to from stable cross-
links. As the collagen matures and becomes older, more and more of those 
intramolecular and intermolecular cross-links are formed and give collagen its 
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strength and stability over time [5]. Normal skin shows a basket-like weave pattern 
that is never completely reproduced during adult scar remodeling. Through 
remodeling, the quantity of water and proteoglycans diminish and the dermis 
becomes less cellular through apoptosis. The wound breaking strength increases from 
3% of normal dermis at one week after injury, to 20% at beginning of remodeling and 
to 80% after 3 months [32]. Remodeling continues up to one year, however, it can 
never achieve the same tensile strength as normal skin. It results in three different 
forms of scar: atrophic-, keloid- or hypertrophic scar, which can be assessed clinically 
using Vancouver scar scale [8]. The differences between normal skin and healed adult 
skin under contraction and scar formation are summarized in table 2.1. 
 
Table 2.1 Skin characteristics before and after healing. 
 





Langerhans cells, Melanocytes 
Keratinocytes, Skin appendages 
 
Only Keratinocytes  
Barrier function, immune activation, UV 
protection, temperature control through sweat 
glands 
 
Only barrier function and lesser 




Fibroblasts, Mast cells  
 
Nearly acellular  
Heat and touch receptor, temperature  
isolation through fat tissue 
 
No or less receptors, reduced fat 
tissue  
Mechanical properties are:  
 
1. Elastic due to elastin expression;  
2. Damp due to mainly hyaluronic acid (HA) 
and high water content; 
Mechanical properties are:  
 
1. No elastin is reproduced; 
2. The content of water and 
glycoproteins like HA is reduced;  
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3. Resistant to tensile force mainly due to   
actin and collagen alignment;  
4. Resistant to  shear force due to high cross 
linking in basket weave pattern 
 
3. The maximum tensile strength is 
about 80%  of normal skin tissue 
and basket weave pattern is not 
completely remodeled 
 
2.1.2.3 Regeneration of the epidermis in vivo  
 
Skin regeneration and skin repair (here referred to ‘acute wound healing process’) are 
two different mechanisms towards wound closure after skin injury. As dermal stroma 
cannot regenerate spontaneously, adult deep wounds heal mostly through the repair 
process by contraction and scar formation. Skin regeneration can only take place in 
epidermis and basement membrane, provided that there is residual stroma and skin 
appendages in the wound bed, such as in superficial epidermal damage [5,35]. 
Epithelial cells around the margin of the wound or in residual skin appendages such 
as hair follicles and sebaceous glands lose contact inhibition and begin to migrate into 
the wound area by the process termed ‘epiboly’ [45]. The migration continues until 
two epithelial ends meet each other and then the epidermal differentiation process 
takes place [5]. The cellular and molecular mechanism of epidermal regeneration is 
reviewed as below from literature.  
 
2.1.2.3.1 Epidermal stem cells 
 
Significant advances have been made in locating and identifying a variety of adult 
stem cell populations from the skin. The best characterized ‘stem cell niche’ lies in a 
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region of the hair follicle known as the bulge, but there are also stem cells in the 
interfollicular epidermis and, potentially, the sebaceous gland (Fig. 2.5) [45]. 
Interfollicular epidermal stem cells in the basal layer are unipotent and derived from 
multipotent stem cells in the hair follicles. In response to skin injury, subsets of these 
quiescent follicle-derived multipotent stem cells are activated, and migrate out of the 
hair follicles to the wound site and develop the new epithelium; however, they 
contribute little to the intact epidermis [46]. These hair follicle stem cells also 
participate in the formation of the follicles themselves (including the outer root sheath, 
inner root sheath and hair shaft) and the sebaceous gland. Melanocyte stem cells are 
also present in the bulge region of the hair follicle [47].   
 
The epidermal stem cell progeny that are destined to terminally differentiate can first 
undergo a few rounds of division, during which time they are known as transit-
amplifying cells [48]. At present, it is unclear whether transit-amplifying cells have 
multilineage differentiation potential or whether they are, by analogy to the 
committed progenitors in the haematopoietic system, lineage-restricted [45]. 
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Fig. 2.5 Epidermal stem cell niches. IFE − interfollicular; SG − sebaceous gland; BM 
− basal membrane; DP − dermal papillae; HF − hair follicle. (Reprinted from [45], 
Copyright 2006, with permission from Elsevier). 
 
2.1.2.3.2 Epidermal migration and proliferation 
 
There are two independent theories about epidermal migration at acute wounds. One 
principle is the superficial layer from the surrounding normal epidermis passively 
slides over the wounded area. It is speculated that the pushing force for epithelial 
migration originates from the mitotic pressure (proliferation of keratinocytes) at the 
unwounded epidermis [42]. Epidermal proliferation is controlled through adherence 
junctions. Loss of cell-cell adherence junctions stimulates the cell mitogenic 
Ras/Mitogen-Activated Protein Kinase pathway, which triggers a hyper-proliferation 
response, cytokine release and cell migration. Adherence junction protein levels also 
affect NF-κB, which, when active, results in the recruitment of immune cells to 
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protect against infection. After wound repair, regulatory feedback pathways cause 
these processes to be dampened and the system returns to normal (Fig. 2.6) [49].  
 
 
Fig. 2.6 Mechanism of cell migration and proliferation in wound response (Reprinted 
by permission from Nature Publishing Group: Nature [49], copyright 2007). 
 
The second theory about epithelial migration over the wound area is described as a 
leap-frog model. Keratinocytes at the wound margins elongate and crawl over each 
other at the tip of the progressing neoepidermis [42]. It has been suggested that the 
migrating tongue of the new epithelium contains both differentiated and proliferating 
cells in a fluid admixture [44]. The migration continues until cells overlap and most 
adherence junctions are established again. This signals the cells to return to a normal 
slow proliferation and start to differentiate [49]. 
 
2.1.2.3.3 Epidermal differentiation and stratification  
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As interfollicular epidermal stem cells in this basal layer expand due to division, 
some of these stem cells detach from the basement membrane and begin to migrate 
towards the epidermal surface, changing shape until they enter the outermost cell 
layer of stratum corneum as flattened cornified cells (see Fig. 2.2) [50]. In vitro 
studies have showed that cells with the highest integrin level had the highest 
proliferation and attachment potential, whereas cells with a low integrin level 
detached and terminally differentiated [49]. However, the mechanism why some cells 
detach while some do not is still unclear.  
 
Like all keratinocytes, cells in the stratum basale possess a network of 10-nm keratin 
intermediate filaments (IFs), but they are otherwise relatively undifferentiated. The 
outward migration of the keratinocytes forms the strengthened IF network and the 
tensile strength of the cell increases accordingly. Cells achieve this by synthesizing 
large numbers of new sets of keratins, which assemble into IFs that aggregate into 
more resilient bundles or cables of IFs [51]. IF cables anchor to cell–cell junctions 
called desmosomes, thus distributing force not over individual cells but over the 
entire tissue. As the suprabasal cells, now connected by desmosomes, move in 
tandem toward the skin surface. They deposit glutamine- and lysine-rich precursor 
proteins beneath the plasma membrane to form the cornified envelope. These cells 
also make lamellar granules filled with lipids, which are extruded onto the cornified 
envelope scaffolds, providing a water-impermeable seal that prevents the unregulated 
escape of fluids [51,52]. As the cells enter the final phases of terminal differentiation, 
a flux of calcium activates the enzyme transglutaminase, which biochemically cross-
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links the cornified envelope proteins through (glutamyl)lysine isopeptide bonds and 
which activates the extrusion of the lipid bilayers onto this scaffold. After production 
of all materials is completed, the cells cease transcriptional and metabolic activity and 
undergo a programmed cell death. The cells (squames) that are sloughed from the 
skin surface consist largely of dead proteinaceous sacs of IF cables. The cell remnants 
are continually replaced by inner cells moving outwards [51]. 
 
Many proteins including keratins and non-keratins are expressed specifically during 
the process of epidermal differentiation and stratification according to the type of the 
epithelium, the stage of differentiation and the location of the keratinocytes within the 
epidermis. Table 2.2 is an overview of the common protein markers used for 
characterization of different epithelial types and disease detection [53]. The 
underlined groups are used for the immunological analysis in this research to 




Cytokeratins (CKs) are intermediate filament keratins found in the intracytoplasmic 
cytoskeleton of epithelial tissue. There are two types of CKs: the low weight (40-65 
kDa), acidic (pI 4.5-6.0) type I CKs and the high weight (50-70kDa), basic or neutral 
(pI 6.5-8.5) type II CKs. CKs are usually found in pairs comprising a type I CK and a 
type II CK. The type II CKs comprise subtypes CK1-CK8. The type I CKs comprise 
subtypes CK 9-CK20.  Table 2.2 is a list for different types of CKs [53] (please note 
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that K11 in the original human keratin catalogue was a modified form of K10, so K11 
does not appear to exist in the human genome and is not included in Table 2.2).  
Table 2.2 Keratin markers expressed in different human epithelial types (summarized 
from [53]). 
 
Keratins Type Location Disease associated with 
gene mutation 
 
Keratin 1 Type II Spinous and granular layers paired 




erythroderma in which 
the palms and soles of 
the feet are affected. 
 









Keratin 4 Type II Differentiated layers of the mucosal 
and esophageal epithelia paired with 
keratin 13 
White Sponge Nevus, 
characterized by oral, 
anal and esophageal 
leukoplakia 
 
Keratin 5 Type II Basal layer as a heterotetramer with 




Keratin 6 Type II Paired with keratin 16 and/or keratin 
17 in the filiform papillae of the 
tongue, the stratified epithelial lining 
of oral mucosa and esophagus, the 
outer root sheath of hair follicles and 
the glandular epithelia 
 
Pachyonychia congenita 
Keratin 7 Type II Most glandular and transitional 
epithelia (ovary, lung, and breast 
epithelia) 
 
Carcinomas in glandular 
and transitional epithelia 
Keratin 8 Type II Single layer epithelial tissues paired 
with keratin 18 
 
Cryptogenic cirrhosis 
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Keratin 9 Type I Terminally differentiated 





Keratin 10 Type I Suprabasal layers (Spinous and 
granular layers) of the epidermis 
paired with keratin 1, a marker for 
early epidermal differentiation 
Variants of 
epidermolytic 
hyperkeratosis in which 
the palms and soles of 
the feet are unaffected. 
 





Keratin 13 Type I Suprabasal layers of non-cornified 
stratified epithelia paired with 
keratin 4 
Autosomal dominant 
disorder White Sponge 
Nevus 
 
Keratin 14 Type I Basal layer and appendages as a 





Keratin 15 Type I Some progenitor basal cells within 
complex epithelia, in the bulge and 
the bulb of follicle 
 
Undefined 
Keratin 16 Type I Paired with keratin 6 in 
hyperproliferative (including tissue 
culture), traumatized and wound-
healing epidermis; Buccal stratified 
squamous epithelia  








Keratin 17 Type I Nail beds, hair follicles, sebaceous 







Keratin 18 Type I Single layer epithelial tissues paired 
with keratin 8 
 
Cryptogenic cirrhosis 
Keratin 19 Type I Periderm, the transiently superficial 
layer that envelopes the developing 
epidermis; follicle bulge stem cell 
marker for epidermal stem cells in 
Undefined 
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outer root sheet, basal epidermis and 
deep rete ridges 
 
 
Keratin 20 Type I Mature enterocytes and goblet cells 
in the gastric and intestinal mucosa 
Gastrointestinal, 






The cornified envelope is formed by cross-linking of precursor molecules such as 
involucrin and loricrin to membrane proteins by transglutaminase. As cells 
differentiate in culture, there is a successive increase in involucrin, transglutaminase, 
and cornified envelope formation [54]. 
 
Involucrin is a component of the keratinocyte cornified envelope and found in the 
cytoplasm and crosslinked to membrane proteins by transglutaminase. It is a marker 
of keratinocyte terminal differentiation and is expressed only in the granular and 
cornified layers of stratified squamous epithelium [55,56]. 
 
Filaggrin is a basic histidine-rich protein in epithelia. Profilaggrin is synthesized and 
phosphorylated in the stratum granulosum. During keratinocytes maturation, the 
profilaggrin molecule is dephosphorylated and protolysed to generate filaggrin. 
Filaggrin is widely believed to promote the lateral aggregation of keratin filaments. It 
is one of the markers for intermediate keratinocyte differentiation [56].  
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Loricrin accumulates in the stratum granulosum. It is an envelope precursor and its 
cross-linking suggests that the incorporation of loricrin into the envelope is catalyzed 
by transglutaminase [56]. 
 
Collagen IV and VII are expressed by the basal keratinocytes and form the basal layer 
of the stratum basale. 
 
β-integrin is highly expressed in outer root sheath of epidermal stem cells, follicle 
bulge and basal epidermis. α6-integrin is expressed in outer root sheath, follicle bulge 
and basal epidermis. Integrin β1 and α6 are epidermal stem cell marker (non-specific) 
due to their high expression within epidermal stem cells [57]. 
 
2.2 Full-thickness skin wounds 
 
Natural skin has limited capacity to recover. The epidermis layer can easily 
regenerate itself following shallow cutaneous wounds; however, when the injury is 
severe, such as loss of both epidermis and dermis in full-thickness skin wounds, the 
damaged skin can not regenerate spontaneously [1].   
 
Many reasons can lead to full-thickness skin loss, such as trauma, diabetes mellitus, 
chronic ulcerations, burns and thermal injury, which accounts for approximately one 
million hospital emergency visits per year in the US [3]. On a worldwide scale, 27 
million burns that occur require professional treatment and of these, 7 million suffer 
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large and deep burns that require hospitalization [23]. Acute large full-thickness skin 
wounds not only cause an immediate loss of wound coverage, but also initiate 
physiological instability and give rise to various complications. Without a protective 
barrier from injured skin, patients are easily susceptible to infections, especially the 
nosocomial infections from Pseudomonas. The metabolic responses in patients are 
complex and include electrolyte imbalance, metabolic acidosis, hyperventilation and 
respiratory alkalosis. As the cellular energy levels fall after skin injury, sodium and 
potassium adenosine triphosphatase is altered, resting cell membrane potential 
decreases and cellular accumulation of sodium, calcium and water is paralleled by a 
loss of cellular potassium [4]. Therefore, the efficient and ordered process of natural 
repair is lost and the wounds are locked into a state of chronic inflammation 
characterized by abundant neutrophil infiltration with associated reactive oxygen 
species and destructive enzymes. Healing proceeds only after the inflammation is 
controlled by proper medical care [5]. However, due to the loss of epidermal and 
dermal tissue to their full depth in full-thickness skin wounds, the epidermal stem 
cells in hair follicles for epidermal renewal, the basement membrane for cell 
migration and the blood vessels in dermis are all destroyed, which creates great 
difficulties for skin regeneration. The vascular network in dermis, which is difficult to 
replace, is quite critical to wound healing. Without an adequate blood supply, the 
repair is inhibited and if revascularization cannot be achieved, the wounds can only 
close with contraction and scar formation [1]. Scar tissue is preferable to no healing. 
However, they are not fully functional, cross-linked with only 80% of the tensile 
strength of the tissue it replaces and aesthetically disfiguring (See Table 2.1). 
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Therefore, there is a great need for the development of synthetic skin which can 
facilitate skin regeneration and minimize scar formation.  
 
2.2.1 Current treatments for full-thickness skin wounds     
 
The key decision in medical treatments for skin injuries depends on the exact 
determination of wound depth and size. In case of shallow lesions, like superficial or 
partial-thickness injury, patients will heal within 2 to 3 weeks under the conservative 
treatments of cleansing and dressing. However, for deep dermal or full-thickness skin 
loss, operations including early excision, suitable grafting and coverage are always 
required [58].  
 
2.2.1.1 Autografts, allografts and xenografts 
 
Principle goals in wound management are to achieve rapid wound closure with a 
functional and aesthetic reconstituted skin. Since xenogeneic (from a different species) 
or allogeneic (from a non-genetically identical individual of the same species) skin 
grafts carry a great risk of immune rejection and disease transfer [6,8], split-thickness 
skin autografts represent the “gold standard” treatment to resurface large wounds. 
Split-thickness skin containing all of the epidermis but only part of the dermis is 
taken from healthy areas of the body and used to treat damaged areas on the same 
individual [6]. The ‘split’ refers to the fact that a substantial amount of the dermis, 
mostly reticular, is left behind, and more importantly, the bases of most epidermal 
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appendages (sebaceous and sweat glands, hair follicles) remain intact. Thus 
reepithelialization is rapid and occurs not only from the wound margin, but from 
epidermal appendages [59]. However, this strategy is not successful in the treatment 
of full-thickness skin wounds which involve the complete removal of both epidermis 
and dermis. Besides, in massive skin injuries, the autologous dressing is obviously 
limited by the available surface area of unaffected skin and creation of an additional 
injury [7]. All of these faults give rise to the clinical need for the development of 
tissue-engineered alternatives.  
 
2.2.1.2 Tissue-engineered skin grafts 
 
Tissue engineering is now emerging as a potential solution to the limitations of 
traditional therapies, whereby tissue loss or organ failure is addressed by using 
synthetic functional components (scaffolding material) cultured with appropriate cells, 
harvested from patient or donor, and then implanted in the patient’s body where tissue 
regeneration is required [60]. In this regard, the tissue-engineered skin substitute 
should be easily available, biodegradable, readily adherent and vascularized, non-
toxic, non-antigenic, impervious to bacteria, but porous for oxygen and nutrient 
diffusion, having appropriate physical and mechanical properties and regaining of lost 
skin functions including sensitivity, elasticity, pigmentation with minimal scarring [8]. 
The ultimate goal of the skin tissue engineering is to satisfy most if not all of these 
criteria when producing novel skin replacement therapies. Current approaches in 
developing tissue-engineered skin substitutes include the use of biologically active 
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scaffolds, supporting cells such as keratinocytes, fibroblasts, adult stem cells and 
growth factors etc.  
 
2.2.1.2.1 Reactants in tissue-engineered skin grafts 
 
The basic promise of tissue engineering is to combine the specific cells with a 
scaffolding material under appropriate conditions that lead to tissue formation. 
Therefore, there are three key factors to be considered for the success of tissue 
development: (i) the cells that create tissue, (ii) the scaffold that gives structural 
support to cells, and (iii) cell-matrix (scaffold) interactions that direct the tissue 
growth [60]. Among them, cells are the prime determinant factor for the success of 
tissue engineering, because they are the basic units of living organism. In sourcing 
cells for a skin substitute, there are essentially three locations from which cell types 
can be derived: local; progenitor and systemic cell populations. Local cell sources 
include fibroblasts, keratinocytes and hair follicle cells etc. [8]. Progenitor cells are 
also resident locally in the ‘epidermal stem cell niche’ such as hair follicles, 
interfollicular epidermis and sebaceous glands (See section 2.1.2.3.1). Systemic cells 
are populations of cells that are resident in the peripheral blood or bone marrow 
system (see section 2.2.2). 
 
The development strategy that is widely used in current commercialized skin grafts is 
to load allogeneic fibroblasts and/or autologous/allogeneic keratinocytes into the skin 
replacement scaffolds (See table 2.4). Human keratinocytes can be co-cultured with a 
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dermal substitute in vitro and exposed to an air-liquid interface to create a stratified 
epithelium. In organotypic culture, keratinocytes behave just as what they would in 
vivo with migration towards the air interface to form a cornified epithelial surface. 
The fibroblasts forming the majority of the dermal substitute slowly degrade the 
biopolymer and lay down their own ECM [61]. As the cell numbers increase, there is 
a concomitant increase in the number of soluble factors released into the 
microenvironment. Keratinocytes and fibroblasts are known to produce a wide variety 
of cytokines including various growth factors, inflammatory mediators, different 
matrix polymers and catabolic enzymes [62]. Allowing such cell types to interact 
stimulates paracrine mechanisms to initiate production of cell proliferation factors, 
such as IGF-1, PDGF, TGF-α, TGF-ß and basic FGF, known to be important not only 
for skin development but also for the process of wound healing and tissue 
regeneration [8].  
 
Scaffold, which basically provides a structural support for the cells to grow into a 
specific tissue, is another key reactant that is required in tissue-engineered skin 
substitutes for stromal regeneration in full-thickness skin wounds. A tissue-
engineered skin grafting scaffold should have some essential characteristics listed in 
Table 2.3.  It should be easy to handle and readily adherent to the wound sites; having 
small pore size for barrier function and a high porosity with a large surface-to-volume 
ratio for cell accommodation, nutrition infiltration, gas exchange and waste excretion. 
It should have appropriate physical and mechanical properties to withstand in vivo 
biological forces, support the cells to synthesize specific proteins and other 
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biochemical and biological processes required for a healthy tissue growth. And it is 
desirable if the degradation rate of the skin substitute scaffold matches the rate of 
tissue regeneration.  Besides, it should be sterile, non-toxic, non-antigenic; and evoke 
minimal inflammatory reactivity. Last, they should incorporate into the host tissue 
with minimal scarring and pain and facilitate angiogenesis, while still being cost-
effective, reproducible and scalable [8,60]. The ultimate goal of the skin tissue 
engineer is to satisfy most if not all of these criteria when developing novel effective 
skin grafts.  
 
Table 2.3 Essential characteristics of a tissue-engineered skin graft (Reprinted from 







Biologically compatible to host tissue (i.e., should not provoke 




The rate of degradation should perfectly match the rate of 











To maximize the space for cellular adhesion and growth, 
ECM secretion, revascularization, adequate nutrition and 
oxygen supply and waste excretion.  
 
Small pore size 
 




To accommodate high-density cells. 
Vascular supportive 
 
To provide channels for blood supply to facilitate fast and 
healthy tissue regeneration. 
 











To be easy to handle and readily adherent to the wound sites;  
To withstand in vivo stimuli;  




To avoid toxic contamination. 
Surface modifiable 
 






To regain lost functions including skin sensitivity, elasticity, 
pigmentation with minimal scarring; 
To be reproducible, economical, and scalable. 
 
 
Cell-matrix (scaffold) interactions is one more important determinant factor for the 
success of tissue engineering, because the growth of new tissue typically depends on 
the way the seeded cells interact with the scaffold. From a biomaterial point of view, 
cell-matrix interactions are governed by the chemical, topographical and surface 
properties of the implant material and their imperative interactions are found to occur 
within a few nanometers of the implant’s surface. In a biological point of view, cell-
seeding density must be optimized to acquire better cell-matrix interactions. In 
addition, several growth factors or biological molecules are also involved in cell 
adhesion, cell-cell communications, and cell-matrix interactions. Therefore, besides 
modulating the chemical, structural and surface properties of skin alternative 
scaffolds, other approaches like incorporating growth factors or cytokines in artificial 
skin substitutes have been explored to enhance cell-matrix interactions for better 
wound healing. These growth factors include PDGF [63], TGF-β [64], bFGF [65] and 
EGF [66] etc. However, to date there is no suitable matrix that can achieve a defined 
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release of specific growth factors or cytokines in both spatial and temporal 
dimensions to facilitate the rapid regeneration and integration of skin. 
 
A wide variety of natural materials, such as collagen [Biobrane™, Integra®, 
Alloderm™], fibrin [Bioseed™], HA [Laserskin™] and GAGs [Integra®] etc. have 
been used in commercialized skin grafts (Table 2.4). Collagen Type I is regarded as 
the best currently available material for facilitating wound healing. As a natural 
substrate for cellular attachment and growth, collagen-based matrix are found to 
expedite the healing process by blocking contraction, minimizing scar formation, 
promoting angiogenesis and dermal regeneration, especially in combination with 
supporting cells and other stimulatory or antimicrobial agents [8,35,67].  
 
However, the use of pure natural materials as skin grafts is limited due to their weak 
mechanical properties and fast absorption rate. Therefore, some synthetic polymers 
are incorporated because variations in the chemical and engineering properties of 
these synthetic polymers allow easy alterations in the geometric configuration, 
biocompatibility, porosity, degradation, and mechanical strength of these substitutes. 
Both non-degradable synthetic materials such as silicone [Integra®], nylon 
[Transcyte™] and biodegradable polymers such as polyglactin [Dermgraft®], 
polycaprolactone (PCL) [68] and PLGA [69] were used for fabricating skin 
substitutes. Skin grafts constituted from non-degradable synthetic materials remain in 
situ as foreign body and may elicit an inflammatory response. Therefore, they have 
limited functions for wound healing and can only be used for temporary coverage. In 
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contrast, scaffolds fabricated from biodegradable polymers offer the advantage of 
gradual absorption as wound healing proceeds and reduce the chance of inflammatory 
responses provided that these polymers and their degradation products are non-toxic 
and non-immunogenic upon implantation and degradation. 
 
2.2.1.2.2 Commercialized tissue-engineered skin grafts   
 
Table 2.4 summarizes the commercialized skin substitutes that are most commonly 
used for the treatment of skin injuries in human along with their advantages and 
disadvantages [8]. They can be classified into three categories: epidermal substitutes, 
dermal substitutes and composite substitutes. Epidermal substitutes with cultured 
autologous or allogeneic keratinocytes can be used to successfully cover partial-
thickness burns, but they fail to produce a satisfactory response in deep burns and 
other full-thickness skin wounds. The primary reasons include lack of dermal 
component and susceptibility to contractures [70]. To treat wounds of this depth in 
full-thickness skin loss, dermal substitutes and composite substitutes are commonly 
used.  
 
2.2.1.2.2.1 Dermal substitutes 
 
In 1981, a composite of bovine collagen and chondroitin-6-sulfate from shark 
cartilage, with an outer silicone covering, was engineered as an organotypic dermis 
for skin grafting [71]. After being applied onto the wounded site, the acellular 
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composite recruited host dermal fibroblasts and degraded during cell invasion. This 
organotypic dermis material, known as Integra®, has received the approval of the US 
Food and Drug Administration (FDA) in 1996 for the treatment of deep-dermal and 
full-thickness wounds [72]. However, the outer silicone sheet of Integra® is not 
biodegradable and has to be removed 2–3 weeks after placement and the wound was 
then covered with an epidermal sheet autograft [3]. 
 
Another dermal implant called TranscyteTM was produced by Advanced Tissue 
Sciences Inc. (ATS, La Jolla, CA). This composite consisted of an inner nylon mesh 
in which human foreskin fibroblasts were embedded and an outer silicone layer to 
limit evaporation. Fibroblasts were allowed to synthesize and secrete ECM materials, 
such as collagen, fibronectin, and GAGs; and cytokines including growth factors. 
After a few weeks the cells were disrupted by freeze–thawing to create the final 
product [3]. Due to the non-biodegradability of nylon and silicone, TranscyteTM can 
only be used as temporary wound coverage after excision of the eschar from burn 
wounds [73] and this indication was approved by the FDA.  
 
ATS also produced a cellular composite, called Dermgraft®. In this construct, human 
neonatal foreskin fibroblasts were cultured in a biodegradable polyglactin mesh and 
then cryo-preserved so that they remained viable. Dermagraft® had limited success in 
the treatment of diabetic foot ulcers [74]. As allogeneic neonatal fibroblasts have 
reduced response of immune rejection after implantation, Dermagraft® was first 
viewed as a dermal substitute [75]. However, the human foreskin fibroblasts 
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implanted with this material die within a few weeks after implantation; therefore, the 
product more likely acts as a delivery vehicle for growth factors and ECM produced 
by the fibroblasts while they were extant [76]. Unfortunately, ATS filed for 
bankruptcy in 2002 was acquired by Smith and Nephew and then was closed. 
Although TranscyteTM and Dermagraft® are currently off the market, these 
technologies have been licensed to Advanced BioHealing for further production and 
marketing. Problems with these products that led to their demise included difficulties 
in quality control and high expenses [3,76]. In addition, Dermagraft® was demanding 
to store and complex to use. Reports on the clinical use of Dermagraft® are relatively 
scarce [76]. 
 
2.2.1.2.2.2 Composite substitutes 
 
For the treatment of full-thickness skin wounds, composite skin substitutes have 
better healing effects than dermal subtitutes as they are bilayered composites with a 
dermal layer containing allogeneic dermal fibroblasts and an overlying epidermal 
sheet. Apligraf® was approved by FDA in 1998 for the treatment of venous leg ulcers, 
and has subsequently been approved for the treatment of diabetic foot ulcers [72]. 
This graft is composed of a bovine collagen type I gel with allogeneic human 
neonatal foreskin fibroblasts and keratinocytes. However, the allogeneic cells carry a 
risk of chronic graft rejection and disease transfer. It was found that the donor cells do 
not remain viable beyond 4-8 weeks after transplantation and this product has a shelf 
life of 5 to 10 days, therefore, it is now believed that Apligraf® works by delivering 
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growth factors and ECM to the wound bed [76]. Besides, in a large multicenter trial, 
it showed signs of wound infection in 29% of patients receiving Apligraf® versus 
14% of patients receiving standard medical care [3]. This product is provided in a 75-
mm2 tissue culture dish and has a shelf life of 5-10 days. Thus, shopping must be 
closely coordinated with the patient’s clinic visit. Like Dermagraft®, Apligraf® has a 
high cost to produce, maintain, and transport [3].  
 
Several other composite skin substitutes combining dermal and epidermal elements 
have been developed. A composite cultured skin substitute, Orcel® is composed of 
both neonatal keratinocytes and fibroblasts embedded on opposite sides of bilayered 
bovine type I collagen. This product is currently being evaluated in clinical trials for 
the treatment of burns, in patients with epidermolysis bullosa and in split-thickness 
donor sites [77]. 
 
2.2.1.2.3 Drawbacks of current commercialized skin grafts   
 
Although increased healing rates of burn and/or chronic wounds can be observed with 
current engineered constructs, several intrinsic shortcomings limit their use [3]: (a) 
epidermal grafts are fragile and therefore difficult to handle; (b) cell-populated 
matrices used in ‘skin substitutes’ are not readily scalable for manufacturing and are 
difficult to store and transport; (c) use of autologous skin cells require creation of 
fresh wounds; (d) it takes about 2 to 3 weeks for autologous skin cells to expand in 
vitro before reaching sufficient numbers for grafting. This time interval cannot satisfy 
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patients with urgent clinical requirements [8]; (e) use of allogeneic keratinocytes or 
fibroblasts may induce immune rejection; (f) allogeneic or xenogeneic skin 
substitutes may carry infectious agents including prions [78].  Therefore, it has been 
recently recommended that informed consent must be obtained from all patients 
before the implantation of such biological material [79]. All of these limitations 
suggest that further improvements are required to ensure that tissue-engineered 
constructs are less complex, more cost-effective and user-friendly, and carry minimal 
risk of infection. 
 
Table 2.4 Examples of current commercialized tissue-engineered skin substitutes with 
associated advantages and disadvantages (Reprinted from Table 1 of [8], Copyright 
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2.2.2 Potential of bone marrow-derived mesenchymal stem cells (BM-MSCs) for 
wound healing and skin regeneration 
 
Stem cells offer a unique opportunity to conceive new methods of treatment in the 
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fields of tissue engineering and regenerative medicine due to their self-renewal and 
multi-differentiation capacities. Embryonic stem cells are totipotent, originating from 
the inner cell mass of the blastocyst, and able to differentiate into any cell types 
derived from all three embryonic germ layers, including skin cells characteristic of 
the species they are taken from [80]. However, the use of embryonic stem cells 
carries a great risk of tumorigenesis and provokes ethical controversy [81]. Epidermal 
stem cells are essential to epidermal regeneration (see 2.1.2.3.1), however, they are 
destroyed in full-thickness skin wounds and difficult to isolate from healthy sites. 
Recently, many studies have suggested the participation and benefits of BM-MSCs in 
wound healing and skin tissue repair in vivo [10-12]. It was found upon injury, BM-
MSCs will be mobilized to leave the bone marrow, home to the injured tissues and 
contribute to the repair and regeneration process [10,14]. Direct injection of BM-
MSCs into wounded sites has showed improved epithelialization, enhanced collagen 
synthesis and rapid wound closure [11,17,82]. Therefore, enhanced understanding of 
these cells would help us to develop novel therapies for difficult cutaneous conditions 
such as full-thickness skin wounds.   
 
2.2.2.1 Characteristics of BM-MSCs 
 
2.2.2.1.1 Identification of BM-MSCs 
 
There are two main branches of stem cells in the bone marrow, hematopoietic stem 
cells (HSCs) and MSCs. Adult bone marrow-derived HSCs have long been 
   55 
Chapter 2 
recognized to give rise to all blood cell lineages including erythrocytes, platelets, and 
white blood cells [18]. In contrast, BM-MSCs are self-renewing, clonal precursors of 
nonhematopoietic tissues. Although they are present as a rare population of cells in 
bone marrow, constituting 0.001–0.01% of the nucleated cells, about 10-fold less 
abundant than HSCs, they are expandable in culture, and are multipotent, capable of 
differentiating into osteoblasts, chondrocytes, adipocytes, astrocytes, pneumocytes, 
hepatocytes, neurons, and cardiac myocytes [83-88].  
 
BM-MSCs are fusiform, fibroblast-like cells. During their initial growth in culture, 
they are able to form colonies (termed in analogy to HSCs): colony forming unit-
fibroblasts (CFU-F) [89]. However, at present a well-defined phenotypic criterion to 
characterize BM-MSCs does not exist. This is because till today there is not a single 
marker that can be found to specifically delineate these cells in vivo. BM-MSCs 
express various surface markers including CD9, CD13, CD29, CD44, CD54, CD90, 
CD105, CD166, Stro-1 and are negative for CD14, CD34, CD45 and CD133. A more 
extensive phenotypic profile of MSCs can be found in Table 2.5 [19]. Traditionally, 
BM-MSCs can be isolated from low-density mononuclear cell population of bone 
marrow, based on their selective adherence, compared to hematopoietic cells, to 
plastic surfaces [90]. These cells synthesize various ECM components including 
collagen type I, III, IV, V VI, fibronectin, hyaluornan, laminin, vimentin and 
proteoglycans [91]. A small fraction of the cultured cells synthesize factor VIII-
associated antigen. BM-MSCs also secret several cytokines and growth factors 
including IL-6, IL-7, IL-8, and stem cell factor (SCF) (see Table 2.6) [92,93, 212]. 
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Due to the lack of specific ‘markers’ that define the multipotent BM-MSC, these cells 
are usually defined in functional terms based on in vitro and in vivo functional assays. 
A standard in vitro assay for BM-MSCs is the CFU-F assay [92,94], in which MSCs 
obtained from bone marrow are plated to the culture well either directly or following 
gradient separation, expanded as an adherent population, and quantified by scoring 
individual foci or colonies presumed to be derived from a single precursor. Using this 
assay, several groups estimated the frequency of MSCs in bone marrow to be 
approximately one MSC in 104 to 105 marrow mononuclear cells. Besides, BM-MSCs 
are capable of differentiation under appropriate in vitro conditions, into mesoderm-
type cells, for example, osteoblasts, adipocytes and chondrocytes (Fig. 2.7) [92].  In 
addition, ‘the gold standard’ in vivo assay for MSC stemness is based on the ability of 
the cells to form ectopic bone and bone marrow microenvironment supporting 
hematopoiesis upon implantation in an open system (subcutaneous implantation) in 
immunocompromised mice [95]. This assay has also been employed to demonstrate 
the ability of the multipotential MSCs to exhibit self-renewal and maintenance of 
‘stemness’ capacity during serial implantations [89,95]. 
 
Table 2.5 Phenotypic characterization of human BM-MSCs (Reprinted from [19], 







 Integrins  
CD1a (T6) − CD49b (Very late antigen α2) + 
CD14 (Lipopolysaccharide 
receptor) 
− CD49c (Very late antigen α3) + 
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CD34 − CD49d (Very late antigen α4) − 
CD45 (Leukocyte common 
antigen) 
− CD49e (Very late antigen α5) + 
CD133 (AC133) 
 
− CD49f (Very late antigen α6) + 
Adhesion molecules  CD51 (Vitronectin R α chain) − 
CD31 (Platelet endothelial 
cell adhesion molecule-1) 
− CD61 (Vitronectin R β chain) + 
CD44 (Hyaluronate 
receptor) 




adhesion molecule 3) 
+ Other markers  
CD54 (Intercellular 
adhesion molecule 1) 
+ CD3 (CD3 complex) − 
CD56 (Neural cell adhesion 
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CD102 (Intercellular 
adhesion molecule 2) 
+ CD83 (HB15a) − 
CD106 (Vascular cell 
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CD166 (Activated leukocyte 
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Table 2.6 Expression of cytokines by human BM-MSCs (Summary of data reported 
in Azizi et al. [212]. Reprinted from [92], Copyright 2000, with permission from 
Elsevier.).  
 
Expressed in long term 
culture without induction 






IL-15 Granulocyte colony-stimulating 
Factor (G-CSF) 
Leukemia inhibitory factor 
(LIF) 
Granulocyte macrophage colony-
stimulating factor (GM-CSF) 
Macrophage colony stimulating 
factor (M-CSF) 
LIF 





Fig. 2.7 Human BM-MSCs exhibited a spindle-shaped fibroblastic morphology 
following culture expansion in vitro (top panel). Under appropriate inducing 
conditions, the culture demonstrated osteogenesis as seen by calcium conditions, 
adipogenic differentiation evidenced by fat globules, or chondrogenic differentiation 
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as measured by staining for type II collagen (Reprinted from [92], Copyright 2000, 
with permission from Elsevier). 
 
2.2.2.1.2 Immune escape and suppression by human BM-MSCs 
 
Both in vitro [96] and in vivo [13,20,97,98] studies have shown that MSCs are not 
inherently immunogenic and can surpass the major histocompatibility complex (MHC) 
barrier between genetically different individuals. This withstanding of the immune 
rejection contradicts the well-established orthodoxy and has earned them the title of 
‘universal suppressor of the immune system’ [99]. It has been suggested that MSCs 
suppression involves several subsets of immune cells [100,101]. Nevertheless, an in-
depth understanding of the underlying cellular and molecular basis of the observed 
phenomenon remains unknown. MSC may be one of the multilayer immune 
modulators and play specific roles in transplantation tolerance, autoimmunity, tumor 
evasion and metastases as well as maternal–fetal tolerance [91].  
 
MSCs share cell surface markers with the thymic epithelium and adhesion molecules 
expressed by MSCs are essential for their interaction with T cells. VCAM-1, ICAM-2 
and LFA-3 are present on unstimulated MSCs [83,92,102,103]. Although adult MSCs 
express intermediate levels of human leukocyte antigen (HLA) MHC class I 
molecules, their expression on fetal MSCs is lower [102,104,105]. HLA class II is 
detectable by western blot on whole-cell lysates of unstimulated MSCs, which 
suggests that they contain intracellular deposits of HLA class II alloantigents [104]. 
Cell surface expression can be induced by treatment of the cells with interferon-γ 
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(IFN-γ) for 1-2 days [106]. Despite IFN-γ-induced expression of class II alloantigens, 
MSCs do not stimulate alloreactivity [103-105]. Besides, no T-cell proliferation was 
observed when MSCs were co-cultured with lymphocytes in the presence of a CD28-
stimulating antibody (Ab) [103]. Infusion or implantation of allogeneic MHC-
mismatched MSCs into baboons has been well tolerated [107,108]. MSCs are not 
targets of cytotoxic lymphocytes or even killer-cell inhibitory receptor mismatched 
natural killer cells (NK cells) [109]. This suggests that MSCs escape recognition by 
alloreactive immune cells [106].   
 
The immunosuppressive effects of MSCs on T cells have confirmed by both in vitro 
and in vivo studies [107,110]. MSCs inhibit the proliferation of T cells stimulated by 
allogeneic T cells [104], cognate antigen stimuli [111] as well as non-specific 
mitogenic stimuli [112]. The inhibition affects the expression of activation markers, 
antigen-specific proliferation (both for naive and memory T cells), CTL formation, 
IFN-g production by Th1 cells and the IL-4 production by Th2 cells [111]. One 
explanation for the proliferation inhibition of T cells by MSCs is that MSCs may 
possess veto-like activity per se or act indirectly through veto cells and trigger the 
suppressive downstream signals, leading to T-cell inhibition under both allogeneic 
and xenogeneic settings [104,113]. The other explanation is that MSCs function 
through activation of suppressive T cells. Apart from two well-defined T-cell subsets, 
namely, Th cells and CTL, there is a third type of T cells termed regulatory T cells, 
which negatively regulate immune responses [114]. Other explanations include T-cell 
anergy, suppressive soluble factors, physical cell–cell contact and apoptosis. T-cell 
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recognition of an antigenic peptide–MHC complex sometimes results in a state of 
unresponsiveness called clonal anergy with the inability of cells to proliferate. 
Whether clonal expansion or clonal anergy ensues is determined by the presence or 
absence of a costimulatory signal, for example, the interaction of CD28 with B7 on 
antigen-presenting cells. As MSCs do not express some of the important 
costimulatory molecules, such as B7-1, B7-2, CD40 or CD40L, it is assumed that 
MSC carry out the suppressive effect through the induction of T-cell anergy [91].  
 
Other immune cell subsets were also reported to participate in MSCs 
immunoregulation. Dendritic cells (DC) play an exclusive role in naive T-cell 
stimulation during the primary immune response. They are also involved in the 
sensing and activation of B cells either indirectly through Th cells or directly through 
soluble factors (including IL-12) [91]. Recent evidence showed that MSCs inhibited 
the differentiation, maturation and activation of co-cultured DC. Specifically, MSCs 
inhibited the initial differentiation of monocytes to DC by downregulating the 
expression of CD1a, CD86 and HLA-DR and later DC maturation by suppressing the 
expression of CD83 [115]. For mature DC, MSCs skew their phenotype towards 
immature status by reducing CD83 expression and alter cytokine secretion, such as 
decreased TNF-α of DC1 and increased IL-10 secretion of DC2 [100]. DC have also 
been involved in an indirectly suppressive mechanism wherein MSCs are suggested 
to inhibit T cells through contact-dependent induction of regulatory antigen-
presenting cells with suppressive functions [101]. NK cells can lyse targets without 
the aid of prior immunization and are further activated by IL-2, IL-12, IL-15, IL-18, 
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IL-21, IFN-α and IFN-β [116]. MSCs are not lysed by freshly isolated allogeneic NK 
[109], but are susceptible to lysis by IL-15 activated NK [117]. It has been suggested 
that MSCs downregulate IFN-γ production of IL-2-stimulated NK [100] and suppress 
the proliferation, cytokine secretion and cytotoxicity of IL-15-stimulated NK [109]. 
 
Therefore, the immunosuppressive potential of MSCs has significant clinical 
implications in treating graft-versus-host disease (GVHD). MSCs have been shown to 
decrease GVHD when co-transplanted with HSCs [106,118]. After high-dose 
chemotherapy/radiotherapy, co-transplanted MSCs may exert a trophic effect on the 
microenvironment by producing local growth factors, cytokines and chemokines, help 
to recover damaged stroma and participate in the early developmental process of T 
lymphopoiesis [96]. In another study, MSCs were found to suppress lymphocyte 
proliferation in vitro and prolong skin graft survival in vivo [98]. So far, allogeneic 
BM-MSCs have been safely used in human for bone marrow stroma improvement or 
posttransplantation therapy without inducing significantly clinical toxicity or GVHD 
[20,97]. All of these findings and results suggest a great potential of using allogeneic 
MSCs for supporting or therapeutic purpose in clinical application. 
 
2.2.2.2 Contributions of BM-MSCs in wound healing and skin regeneration   
 
Numerous studies have indicated that after tissue injury, BM-MSCs will home to the 
injured sites and undergo site-specific differentiation to contribute to the repair or 
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regeneration process of many tissues including myocardium [86], damaged bone 
[119,120], tendon [121,122], cartilage [123], neurons [87] and skin [10-12].  
 
Tissue-specific differentiation of adult BM-MSCs is largely determined by the 
environment or biological context in which they reside, or so called ‘niche 
microenvironment’ [14,124]. Badiavas et al. found GFP-labeled MSCs incorporated 
onto the skin of non-GFP mice after peripheral injection and indicated that wounding 
could be a stimulus for MSCs to migrate from bone marrow to the injured site and 
differentiate into functional skin cells [12]. Another group further showed that in 
response to injury, approximately 4% of MSCs would engraft as keratinocytes on the 
wound sites to facilitate skin regeneration [10]. Most studies have indicated that 
differentiation is an important mechanism for keratinocytes derived from BM-MSCs 
in the epidermis [10,125] although one study suggests that cell fusion may also be a 
mechanism in vitro [126]. Using the Cre/lox system together with β-galactosidase, 
enhanced GFP expression and fluorescence in situ hybridization (FISH) analysis, it 
was found that bone marrow-derived stem cells (including BM-MSCs) differentiated 
into epithelial cells in the skin, liver, and lungs in vivo without cell fusion [10,14,125]. 
Epidermal differentiation potential of MSCs was further supported by in vitro studies 
where BM-MSCs co-cultured with airway epithelial cells were found to adopt an 
epithelial cell phenotype, which restored the epithelial monolayer and expressed 
keratin 18, an airway epithelial marker [127]. However, whether BM-MSCs could 
differentiate into skin epidermis under certain circumstances in vitro and their 
significance in skin regeneration have not been clearly investigated.  
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In addition to differentiation potentials, BM-MSCs have exhibited a paracrine effect 
by releasing growth factors that may enhance angiogenesis and promote wound repair. 
RT-PCR analysis demonstrated MSCs are capable of expressing TGF-β1, EGF, 
VEGF, PDGF, KGF, FGF and HGF constitutively or upon stimulation with LPS, IL-
1α, or TNF-α. Quantitative analysis of growth factor by ELISA showed that BM-
MSCs do not secrete TGF-β1, EGF or VEGF in response to uninjured tissue. 
However, production of these growth factors is significantly increased when cells 
were stimulated with wound tissue superfusate [15]. Besides, other studies suggest 
that BM-MSCs may mediate skin tissue repair or regeneration by promoting collagen 
synthesis and recruiting inflammatory cells and stem or progenitor cells [16-18]. 
 
As the capacity of BM-MSCs in promoting wound healing and skin regeneration has 
been suggested, BM-MSCs were tested for their potential in cutaneous constitution. 
In one study, human BM-MSCs were applied to a full-thickness skin excision wound 
in nude rats and were found to significantly enhance wound healing. Human 
pancytokeratin, which does not cross-react with rat antigens, was detected in the 
engrafted epidermis, suggesting the contribution of human BM-MSCs to 
keratinocytes [128]. The benefits of promoting wound healing and skin regeneration 
by using BM-MSCs was also shown in the treatment of other types of wounds, 
including chronic wounds [129,130], deep partial-thickness burns [131] and full-
thickness incisions [11,17,82]. All of these findings suggest that BM-MSCs have a 
great potential to regenerate skin and facilitate wound healing under appropriate 
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conditions. However, an appropriate scaffold is required to provide efficient cell 
delivery and necessary structural support for cell accommodation as well as to guide 
cell growth and differentiation for the formation of tissue structures that resemble the 
original tissue. 
 
2.2.3 Potential of electrospun nanofiber scaffolds (NFS) as tissue-engineered skin 
grafts 
 
2.2.3.1 NFS as tissue-engineered scaffolds 
 
A key principle in tissue engineering is based upon that the cells surrounding the 
damaged tissue or the cells that are involved in the spontaneous repair of the damaged 
tissue have the capacity to reorganize into structures that resemble the original tissue 
[132]. Cells live in native ECM which is a 3D network structure composed of multi-
fibrils (mainly proteins and proteoglycans) at nano-scale. This hierarchical 
organization thus presents a defined environment with nano-scale intermolecular 
binding interactions that will affect the morphological and functional development of 
the cells. Recent studies have shown the importance of nano-texture scaffolds for 
tissue engineering applications [133]. Cells that were cultured on micro-size fibrous 
scaffolds were flattened and they spread if cultured on flat surfaces (Fig. 2.8) [134]. 
Scaffolds with nano-scale architectures and a larger surface area to adsorb proteins 
and present many more binding sites to cell membrane receptors would be more 
biomimetic to support better cell-matrix interactions [134]. Thus the presentation of 
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Fig. 2.8 Scaffold architecture affects cell binding and spreading (From [134].  
Reprinted with permission from AAAS).  
 
Nanotechnology is a growing field by manufacturing materials with sizes less than 1 
µm [23], and it is particularly useful in the field of tissue engineering and 
regenerative medicine because these applications replicate components of native 
cellular environment. Nanofibers, which mimic collagen fibrils in the native ECM in 
size and form, can be created from a host of natural and synthetic compounds and 
have multiple properties that benefit the cell-matrix interactions to promote tissue 
regeneration [23]. These properties include a large surface-area-to-volume ratio to 
accommodate and interact with high-density cells, high porosity to maximize the 
space for cell adhesion, growth, migration, ECM deposition and revascularization, as 
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well as controlled degradation rates to match the rate of tissue regeneration [60].  
 
2.2.3.2 Fabrication of NFS by electrospinning 
 
Several fabrication techniques such as phase separation, self-assembly, and 
electrospinning have been used to produce suitable polymer NFS for tissue 
engineering applications. Table 2.7 compares the key aspects of these three methods.  
 
The phase-separation technique is based on thermodynamic demixing of a 
homogeneous polymer-solvent solution into a polymer-rich phase and a polymer-poor 
phase, usually by either exposure of the solution to another immiscible solvent or 
cooling the solution below a bimodal solubility curve. Solvent is removed by freeze-
drying, leaving behind the polymer as a foam. Morphology is controlled by any phase 
transition that occurs during the cooling step, i.e., liquid-liquid or solid-liquid [135]. 
The process of phase separation is simple, however, it is time-consuming and only 
limited to a few polymers and unable to produce long and continuous nanofibers [60].  
 
Self-assembly refers to a process by which reactions occur and lead to the formation 
of nano-scale structures, including nanofibers, which are bioactive [23]. The process 
may be enzymatic and poly-ethylene glycol-attached amphiphilic oligopeptides has 
been reported to assemble into organized β sheet nanofibers [136]. Self-assembly 
may also be established by the technique of sonication solution embossing [137]. 
Self-assembly takes place by noncovalent bonding, which typically includes 
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hydrogen bonding, ionic bonding, water-mediated hydrogen bonding, hydrophilic 
interaction and van der Waals interactions. The application of self-assembly is limited 
to a few polymers and its key challenge is to design molecular building blocks that 
can undergo spontaneous organization into a well-defined pattern that mimic complex 
biological system [60].  
 
Amongst all the techniques mentioned above, electrospinning is the most versatile, 
simple, cost-effective and scalable method to fabricate nanofibers. The precise merit 
of this technique is that it can produce scaffolds with most of the structural features 
required for cell growth and subsequent tissue organization. It also offers many 
advantages over conventional scaffold methodologies. For example, it can produce 
ultra-fine fibers with spatial orientation and a high surface-to-volume ratio, have 
control over fiber diameter and also give flexibility for surface modification [60]. 
This technique was first introduced by Zelency in 1914 [138]. Later, Formhals 
contributed much to the development of electrospinning and obtained several patents 
in the 1930s and 1940s. In those days it was called electrostatic spray or electrostatic 
spinning and then renamed as electrospinning in the 1990s. It has now attracted 
increasingly worldwide attention in both the academic community and industrial 
world [25]. In the field of tissue engineering, electrospun NFS have been actively 
explored for different applications such as skin [139], cartilage [140], bone [141], 
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Table 2.7 Comparison of various NFS processing methods (Reprinted from [60], 












































(2) Limited to a 
few polymers. 
 


















drying, leading to 





























   70 
Chapter 2 












































Another advantage of electrospinning to prepare ultra-fine polymer fibers is that 
almost any polymer with a sufficiently high molecular weight that forms solution can 
be electrospun. Synthetic and natural polymers, polymer blends, nanoparticles or drug 
impregnated polymers as well as ceramic precursors have been successfully 
electrospun into nanofibers. Different fiber morphologies such as beaded fibers, 
ribbon fibers, porous fibers and fibers with core-shell structure have also been 
electrospun [22].  
 
The fabrication process involves an electrostatic field of the order of 5-30 kV 
between a collector and the spinneret (usually in the form of a needle) (Fig 2.9). The 
polymer melt or solution is pumped out of the spinneret at a controlled rate. When a 
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stretching force provided by the sufficiently high electric field overcomes the surface 
tension of the polymer solution, a thin jet of the liquid flies towards the collector plate. 
The jet is only stable near the tip of the spinneret, after which it undergoes bending 
instability. As the charged jet accelerates toward regions of lower potential, the 
entanglements of the polymer chain will prevent the jet from breaking up, while the 
solvent evaporates resulting in the formation of randomly oriented nanofibers that can 
be collected on a grounded collector [22,24]. The diameters of the electrospun fibers 
are at least one order of magnitude smaller than those made by conventional extrusion 
techniques. Several parameters can affect the electrospinning process and fiber 
morphology (Table 2.8). We can therefore change various conditions to obtain 
suitable fibers for specific applications.   
 
 
Fig. 2.9 The scheme of electrospinning system (Reprinted from [60], Copyright 2007, 
with permission from Mary Ann Liebert, Inc. publishers).  
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Table 2.8 Effect of changing electrospinning process parameters on the resultant fiber 
morphology (Reprinted from [211], Copyright 2006, with permission from Mary Ann 
Liebert, Inc. publishers).  
 
Process Parameter Effect on fiber morphology 
Viscosity/concentration  Low concentrations/viscosities yielded defects in the 
form of beads and junction; increasing 
concentration/viscosity reduced the defects; 
 





 Increasing the conductivity aided in the production of 
uniform bead-free fibers; 
 
 Higher conductivities yielded smaller fibers in general, 
except poly(acrylic acid) and polyamide-6. 
 
Surface tension  No conclusive link established between surface tension 





 Increasing molecular weight reduced the number of beads 
and droplets. 
 
Dipole moment and 
dielectric constant 
 
 Successful spinning occurred in solvents with a high 
dielectric constant. 
 
Flow rate  Lower flow rates yielded fibers with smaller diameters; 
 
 High flow rates produced fibers that were not dry upon 
reaching the collector. 
 
Field strength/voltage  At too high voltage, beading was observed; 
 
 Correlation between voltage and fiber diameter was 
ambiguous. 
 
Distance between tip 
and collector 
 A minimum distance was required to obtain dried fibers; 
 
 At distance either too close or too far, beading was 
observed. 
 
Needle tip design  Using a co-axial, two-capillary spinneret, hollow fibers 
were produced. 





 Smooth fibers resulted from metal collectors;  
 
 Aligned fibers were obtained using a conductive frame, 
rotating drum, or a wheel-like bobbin collector; 
 
 Yarns and braided fibers were also obtained. 
 
Ambient parameters  Increased temperature caused a decrease in solution 
viscosity, resulting in smaller fibers; 
 
 Increasing humidity resulted in the appearance of circular 
pores on the fibers. 
 
 
2.2.3.3 Electrospun NFS as tissue-engineered skin grafts 
 
Nanofiber technology has the capacity of dramatically accelerating the development 
of innovative grafting scaffolds for wound healing. For skin graft application, the 
high porosity of electrospun NFS provides more structural space for accommodation 
of migrating and proliferating cells, facilitates temperature homeostasis and enables 
efficient nutrient delivery, gas exchange and exudates extrusion; while the small pore 
size of electrospun NFS inhibit wound infection and dehydration. The 
biodegradability of certain polymeric NFS allows it to serve as a temporary ECM 
until the natural tissue regeneration replaces the scaffold [23]. Additionally, 
polymeric NFS are usually strong in tensile strength, so they can retain mechanical 
integrity and prevent wound contraction when surgeon handles and implants it into 
the defect site of the host [24]. 
 
A wide variety of natural and synthetic materials can be electrospun into NFS for skin 
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graft application. Natural materials that were used to fabricate NFS skin grafts or 
wound dressings include collagen [139], chitosan [146], fibrinogen [147], silk [148], 
hemoglobin and myoglobin [149] and gelatin [150]. Collagen type I, composed of 
two α1 chains and one α2 chain, is a particular good candidate for constructing NFS 
skin grafts because it is the most abundant ECM substance in human skin tissue [32]. 
In native ECM, collagen exists in a 3D network structure composed of multi-fibrils in 
the nanofiber scale of 50 to 500nm. The fibrillar structure has long been known to be 
important for cell attachment, proliferation and differentiated functions through 
interactions with integrins [151].   
 
Electrospun NFS mats composed of collagen type I has demonstrated properties in 
improving wound healing. In twin full-thickness rectanglular back wounds in a rat 
model, microscopic examination revealed that early-stage healing in the collagen 
NFS group was faster than the control group [139]. The wound surface of the control 
group was covered with fibrinous tissue debris, overlying a layer with a dense 
infiltration of polymorphonuclear leukocytes and proliferating fibroblasts. In contrast, 
in the collagen NFS group, there was absence of surface tissue debris and prominent 
capillary and fibroblast proliferation. The advantage of using natural biopolymers like 
collagen is that they are biodegradable, nontoxic and tend to yield greater cell binding 
capability. However, the poor control of enzymatic degradation and weak mechanical 
performance are two major limitations to the use of naturally derived polymers [135]. 
Although chemical crosslinking has been proposed to control the stability and 
degradation rate of the matrices made from natural materials, the porosity was found 
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to be changed by both chemical and physical techniques [152,153]. 
 
Multiple synthetic materials including both nonbiodegradable and biodegradable 
polymers have also been used to manufacture NFS for promoting wound healing. 
Medical grade biostable polyurethane (PU) is a notable example of nonbiodegradable 
polymer for wound care. It has been shown that PU nanofiber dressings promoted 
faster healing compared with commercialized permeable PU (TegadermTM). 
Electrospun PU NFS was found to effectively control evaporative water loss, allow 
oxygen permeability and enhance drainage of wound exudates due to nanofiber 
porosity [154]. However, due to its long-term biostable properties, medical grade PU, 
either in nanofiber or commericialized form, can only be used as a temporary dressing 
in vivo and required to take off after completion of its functions. Although 
biodegradable PU has been recently developed for application in tissue engineering, 
their degradation products are found to be acutely toxic, carcinogenic and mutagenic 
aromatic diamines [155,156]. For the skin graft application, degraded products from 
the biodegradable polymers must be nontoxic and should not elicit any foreign-body 
reaction, because they hinder the process of tissue growth.  
 
Other biodegradable synthetic polymers include polyesters, polyanhydride, 
polyorthoester, polycarbonate, and polyfumarate [135]. The aliphatic polyesters such 
as poly(glycolic acid) (PGA), poly(lactic acid) (PLA), polycaprolactone (PCL), and       
their copolymers are most commonly used for tissue engineering [23,68,157]. FDA 
has approved the use of above mentioned polymers for certain human clinical use, 
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such as surgical sutures and some implantable devices. PLA undergoes hydrolytic 
scission to its monomeric form, lactic acid, which is eliminated from the body by 
incorporation into the tricarboxylic acid cycle. The principal elimination path for 
lactic acid is respiration, and it is primarily excreted by lungs as carbon dioxide. PGA 
can be broken down by hydrolysis, nonspecific esterases and carboxypeptidases. The 
glycolic acid monomer is either excreted in the urine or enters the tricarboxylic acid 
cycle [135]. PCL undergoes hydrolytic degradation due to the presence of 
hydrolytically labile aliphatic ester linkages [158]. All of these biodegradable 
polymers have been used to construct NFS for tissue-engineered scaffolds because of 
their favorable mechanical and biodegradation properties to promote the ingrowth of 
new tissue [135].  
 
PCL was usually used as a drug/vaccine delivery vehicle or tissue-engineered 
scaffolds for long-term transplantation as its degradation rate is very slow (2-3 years) 
[158]. PGA was found to have better than average tissue compatibility and 
reproducible mechanical properties such as strength, elongation and knot retention. 
However, it has a very fast degradation rate and it degrades from 2 to 4 weeks in vivo 
due to its hydrophilic nature, therefore, PGA is only used when fast degrading is 
required [145]. In contrast, the methyl group in the monomer makes PLA more 
hydrophobic than PGA and it also presents a steric hindrance that gives PLA a higher 
solubility in organic solvents and significantly slows down the hydrolysis of PLA 
[145]. When a single polymer does not have the properties desired for skin graft 
application, a copolymer, like PLGA were employed to achieve the desired 
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geometrical, mechanical and biodegradation properties. Blackwood KA et al. have 
investigated the in vivo degradation profiles of electrospun NFS fabricated from PLA 
and PLGA (85:15, 75:25 and 50:50) and evaluated their efficacy for dermal 
replacement. It was found an increase in the ratio of polyglycolide to polylactide 
correlated with an increase in breakdown rate. PLLA NFS were stable in vivo after 12 
months whereas NFS fabricated from PLGA 85:15, 75:25 revealed a 50% loss of 
mass after 4 and 3 months, respectively. Among all the tested materials, electrospun 
PLGA (85:15, 75:25) NFS were demonstrated to be the most favorable biodegradable 
materials for dermal replacement as they were able to match the healing rate in 
damaged tissue, support keratinocyte, fibroblast and endothelial cell growth and ECM 
production [159]. However, the major disadvantage of synthetic materials is the lack 
of cell-recognition signals. Therefore, manufacturing process of electrospun NFS 
which incorporates both biodegradable synthetic and natural materials was explored, 
such as electrospun PCL/Collagen NFS [68], PLGA/dextran NFS [160], PCL/gelatin 
NFS [27], poly(L-lactide-co-ε-caprolactone)/gelatin NFS [161] for wound healing 
and skin reconstitution.  
 
In all, current research in tissue-engineered skin grafts is approaching a major 
breakthrough due to the ability to routinely create ECM analogous electrospun 
nanofibers. However, a careful consideration of the appropriate materials for 
fabricating electrospun NFS is required to achieve the desirable biological, 
architectural, mechanical and biodegradable properties for skin graft application.  
 




In an effort to promote wound healing and skin regenerate in a full-thickness skin 
wounds, many types of skin grafts have been made in recent years, however, none of 
them is satisfactory in terms of the safety of patient, clinical efficacy and convenience 
of use. Current research focuses mainly on the creation and development of a skin 
graft that will most probably encompass several strategies such as the use of 
functional cellular components, different biodegradable materials and scaffolds with 
analogous ECM structures and components, which have been described in this 
chapter. In the present study, a biomimetic nanofibrous skin graft will be designed 
and developed by combining the functionality and flexibility of electrospun NFS with 
the physiologic activity of BM-MSCs. Biodegradable PLGA and Collagen type I will 
be blended for fabrication of the electrospun NFS. Blended NFS will be further 
modified for efficient attachment of BM-MSCs. The efficacy of resultant 
nanofiber/stem cell composites as skin grafts will be evaluated in a rat model of full-
thickness skin loss. The strategy aims to provide an advanced skin implant device to 
heal acute full-thickness skin wounds that will bring about better clinical outcomes.




In vitro Epidermal Differentiation of Human BM-MSCs  
 
3.1 Introduction  
 
BM-MSCs were reported to be able to differentiate not only into mesoderm-type cells 
such as osteoblasts, chondrocytes, adipocytes [83], but also into other cells of non-
mesoderm lineages, for example, neurocytes, hepatocytes, etc. [84,85]. MicroSAGE 
analysis of the gene expression profile in a single undifferentiated MSC showed the 
expression of mRNAs characteristic of epithelial lineages, such as keratin 8 and 
keratin 10 [162], which indicates under certain specific conditions, MSCs may enter a 
developmental program that would commit it to an epidermal cell fate.  
 
Recently, many studies have found that upon skin injury, MSCs will be recruited 
from bone marrow into the wounded sites and contribute to various skin cell types for 
skin regeneration [10-12]. Borue et al. showed that in response to injury, 
approximately 4% of BM-MSCs would engraft as keratinocytes on wound sites to 
facilitate skin regeneration [10]. A possible hypothesis for the in vivo differentiation 
of migrated MSCs into functionally specialized cells is that the tissue-specific 
microenvironment or the so-called ‘stem cell niche’ [124] can trigger the commitment 
of MSCs into a specific cell type. However, up to now, the mechanism of MSCs 
   80 
Chapter 3 
adopting epidermal phenotype upon skin injury is elusive and the in vitro induction of 
MSCs into epidermal lineage still remains a challenge. Therefore, this chapter aims to 
further confirm the epidermal differentiation potential of BM-MSCs by achieving its 
epidermal differentiation in an in vitro 3D biomimetic culture environment, and to 
identify the contributing factors that trigger BM-MSCs to differentiate into epidermal 
lineage. 
 
3D organotypic coculture approach was used in this study to build up a 
microenvironment resembling some of the injured skin conditions. MSCs were 
seeded on top of a dermal substitute composed of a fibroblast-embedded collagen 
matrix. It has been shown that fibroblasts secrete several cytokines and growth factors 
that would expedite epidermal stratification and skin development [33]. However, 
such biomolecules are not strong enough to initiate and sustain the differentiation of 
MSCs into an epidermal lineage [163]. To ensure a sufficiently potent driving force 
for MSCs epidermal differentiation, in this study we combined an optimized 
induction medium with the appropriate environmental and physical cues in 
organotypic coculture model. 
 
We optimized the induction medium by starting with the Rheinwald and Green 
keratinocytes medium [164] and varying several biomolecular supplements that are 
critical for MSCs epidermal differentiation, namely, Hydrocortisone, Insulin, 3,3’,5-
Triiodo-L-thyronine sodium (T3), EGF, 1,25-dihydroxyvitamin D3 (VD3) [54,61]. In 
vitro epidermal differentiation and stratification are highly enhanced upon the 
exposure of keratinocytes to air mimicking the physiological wet–dry environment 
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[61]. In this study, BM-MSCs were cultured under air-exposed and submerged 
conditions in an organotypic coculture to evaluate the environmental influences on 
MSCs epidermal differentiation. 
 
It has been shown that physical properties of the culture ECM, such as stiffness or 
contractibility of the culture substrate can influence the differentiation of MSCs, by 
the ability of cells to pull on their culture environment through the actomyosin 
contractibility [165]. Natural skin is a soft and elastic material with Young’s modulus 
of 15–150 MPa [166]. In conventional organotypic coculture, a glass or metal ring is 
typically placed on top of the cellular collagen gel to prevent the gel shrinkage 
induced by the proliferation and migration of the embedded fibroblasts [167]. The 
restrain of the ring significantly reduces the contractibility of the cellular collagen gel. 
In this study, we cultured MSCs on both contractible (without ring restrain) and 
noncontractible (with ring restrain) dermal substitutes to evaluate the effect of the 
contractibility of culture substrate on MSCs epidermal differentiation. 
 




Human BM-MSCs were ordered from Cambrex Bio Science Walkersville, Inc., USA. 
Human dermal fibroblasts, Fetal Bovine Serum (FBS), low glucose Dulbecco’s 
modified Eagle’s medium (DMEM), Ham’s F12 medium, Qtracker655 Cell labeling 
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Kit, penicillin–streptomycin solution, 4’,6-diamidino-2-phenylindole, dihydrochloride 
(DAPI) were all purchased from Invitrogen Corporation, USA. PureColTM collagen 
was ordered from INAMED Corporation, USA. Bovine Serum Albumin (BSA), L-
glutamine, ascorbic acid, EGF, VD3, hydrocortisone, insulin, T3, Hematoxylin and 
Eosin (H&E), mouse anti-human pan-keratin antibody (Ab), mouse anti-human 
involucrin Ab and goat anti-mouse IgG fluorescein-isothiocyanate (FITC)-conjugated 
secondary Ab were all purchased from Sigma-Aldrich Pte Ltd., USA. Mouse anti-
human keratin 10 and filaggrin antibodies were ordered from Thermo Fisher 
Scientific Inc., USA. 
 
3.2.2 Cell culture 
 
BM-MSCs (passage 4) were seeded in the concentration of 2000 cells per well of 24-
well plates in the following four types of media: (1) HIT medium: DMEM and Ham’s 
F12 medium (3:1) including 10% FBS, 100 IU/ml penicillin and 100 µg/ml 
streptomycin (basic stratification medium), supplemented with 0.4µg/ml 
hydrocortisone, 5µg/ml insulin and 1nM T3; (2) ED medium: basic stratification 
medium supplemented with 10ng/ml EGF and 1µM VD3; (3) HITED medium: basic 
stratification medium supplemented with 0.4µg/ml hydrocortisone, 5µg/ml insulin, 
1nM T3, 10ng/ml EGF and 1µM VD3. This medium can be considered as a 
combination of HIT medium and ED medium. (4) Control medium: normal MSCs 
growth medium composed of DMEM supplemented with 10% FBS, 100 IU/ml 
penicillin and 100 µg/ml streptomycin. The detailed components of these media are 
listed in Table 3.1. Samples were incubated under standard culture conditions of 37°C 
   83 
Chapter 3 
in a sterile humidified incubator with 5% CO2. The medium was changed every 
second day and samples were taken out every day for viability and proliferation 
analyses. Additional samples were used for the immunostaining analysis of pan-
keratin expression on day 7 and 10. 
 









DMEM and Ham’s F12 medium (3:1) including 10% FBS, 
100 IU/ml penicillin, 100 µg/ml streptomycin, 0.4µg/ml 
hydrocortisone, 5µg/ml insulin and 1nM T3.  
 
ED  DMEM and Ham’s F12 medium (3:1) including 10% FBS, 
100 IU/ml penicillin, 100 µg/ml streptomycin, 10ng/ml EGF 
and 1µM VD3. 
 
HITED  DMEM and Ham’s F12 medium (3:1) including 10% FBS, 
100 IU/ml penicillin, 100 µg/ml streptomycin, 0.4µg/ml 
hydrocortisone, 5µg/ml insulin, 1nM T3, 10ng/ml EGF and 
1µM VD3. 
 
Control  Normal growth medium: DMEM including 10% FBS, 100 




3.2.3 Viability and proliferation of human BM-MSCs  
 
Cell viability and proliferation within different media were quantified by MTS assay 
(CellTiter 96® aqueous One Solution Cell Proliferation Assay, Promega, Madison, 
WI, USA) every day from day 1 to day 10 of cell culture. This assay measures the 
metabolic activity due to the active agent tetrazolium which is metabolized by the 
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metabolic active cells into formazan. The amount of formazan is determined through 
the absorbance at 490nm by a microplate reader (bMG Fluorostar Optima) and is 
directly proportional to the actual cell number. 
 
To evaluate the differences of the growth rate or cell doubling time from the 
absorbance values in different groups, the real cell number has to be determined by a 
calibration curve with a known absorbance number. The calculated cell numbers (x) 
were plotted in logarithmic order and an exponential regression was computed for 
each group. The growth rate (μ) and cell doubling time (T) were calculated according 
to the following formula:  
μ= [ln(x(t)/x(0))]/t              T= ln(2)/μ 
Where t is the duration of cell growth expressed in days. 
 
3.2.4 Immunostaining analysis of human BM-MSCs  
 
On day 7 and day 10, BM-MSCs cultured in different media were fixed, washed and 
incubated with 2% BSA to block non-specific binding. Then anti-human pan-keratin 
Ab was applied to the samples for 2h at 37oC. After washing, FITC-conjugated 
secondary Ab was added and incubated for 1h at 37oC to stain cytokeratin-expressed 
cells. Samples were then observed under a fluorescence microscope (Leica DM IRB, 
ebq 100).  
 
3.2.5 Organotypic coculture 
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The dermal substitute was generated according to [168]. Briefly, eight volumes of 
ice-cold collagen type I solution (PureColTM, 3mg/ml) were mixed with one volume 
of 10-fold DMEM supplemented with 10% FBS, 200mM L-glutamine, 72g/l sodium 
bicarbonate. This mixture was adjusted to pH 7.4 with 1M NaOH and then poured 
into filter inserts of the organotypic coculture devices (12mm Transwell®, Corning 
Incorporated, USA) to form the acellular gel layer. Thereafter the cellular layer was 
prepared. 3ml of the previously mixed solution was blended with 0.16ml fibroblast 
suspension (100,000 per well, passage 4) and poured onto the acellular layer in each 
cell insert. For its gelation, the fibroblast-embedded collagen constructs were 
incubated for 2-4 h at the standard culture condition. The dermal substitute of 
acellular and cellular layers was cultured in DMEM supplemented with 10% FBS, 
50µg/ml ascorbic acid, 100 IU/ml penicillin and 100 µg/ml streptomycin. After 7 
days, the cellular gel contracted as the fibroblasts proliferated and migrated. To 
prevent its further shrinkage, a stainless ring (inner diameter: 13mm) was placed on 
top of the gel and acted as a containment for MSCs seeding. For the contractible 
substrates, no metal ring was placed on top of the cellular gel. MSCs of passage 6 at 
90% confluence were labeled with 10nmol/l quantum dots provided by Qtracker655 
Cell labeling Kit for 1h under the standard culture conditions according to the 
manufacturer’s protocol (appendix A). Quantum dot-labeled MSCs were then seeded 
inside the stainless ring onto the dermal substitute at the concentration of 5x105 per 
well. 
 
The organotypic cocultures were incubated for 24h in the HITED medium. To 
simulate the wet-dry environment, the culture was then lifted to the air-liquid 
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interface by lowering the medium level to the lower part of the collagen gels. For 
another group identified as wet-wet environment, MSCs were cultured fully 
submerged in the medium throughout the experiment. The organotypic cocultures 
were then maintained under the standard culture conditions with daily medium 
change. On day 14, samples were fixed and processed for histological and 
immunological analyses. In order to investigate the effects of environmental and 
physical properties of culture substrates on epidermal differentiation of MSCs, four 
conditions of culture substrates were established: (1) wet-wet + noncontractible; (2) 
wet-wet + contractible; (3) wet-dry + noncontractible; (4) wet-dry + contractible. The 
condition matrix is shown in Fig. 3.1.   
 
 
Fig. 3.1 Schematic illustration of experimental conditions (wet-wet & wet-dry 
environment versus noncontractible & contractible culture substrate). 
 
3.2.6 Histological and immunological analyses of organotypic coculture 
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The samples of organotypic cocultures were fixed in 2.5% paraformaldehyde at 4°C 
over night, dehydrated and then paraffin-embedded. Serial 10 µm paraffin sections 
were cut with a rotating microtome (MICROM) and stained with H&E according to 
routine histology protocol (appendix B). Immunological analysis was performed 
using primary antibodies specific for human keratin 10 (an early marker of epidermal 
differentiation), filaggrin (an intermediate marker of epidermal differentiation), 
involucrin (a terminal marker of epidermal differentiation) [167,169]. Antigen 
retrieval was achieved by pretreatment of the samples in 10mM Citrate Buffer (pH 
6.0) at 95 °C for 20 min and cooling down the samples at room temperature for 20 
min. Subsequently, the samples were blocked by 2% BSA and incubated with 
primary antibodies overnight at 4°C, followed by washing and incubation of FITC-
conjugated secondary Ab. Finally, the samples were counterstained with DAPI. Then 
H&E stained sections were observed under a phase-contrast microscope (Leica DM 
IRB, ebq 100). Samples with Ab incubation were observed under a confocal laser 
microscope (FV 500, Olympus).  
 
3.2.7 Statistical analysis 
 
Values (at least triplicate) were averaged and expressed as means ± standard 
deviation. Each experiment was repeated five times. Statistical differences were 
determined by Student’s two-sample t test and two-way analysis of variance 
(ANOVA). Differences were considered statistically significant at p < 0.05. 
 
3.3 Results 
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3.3.1 Viability and proliferation of human BM-MSCs within different media 
 
An MTS assay was used to measure the effects of different media on cell viability and 
proliferation by recording the optical densities of formazan product at 490nm 
absorbance. There was a linear response between absorbance at 490nm (x axis) and 
number of seeded cells cultured in control medium (y axis), as evidenced by the 
correlation coefficient of r = 0.991 (Fig. 3.2A). No difference was found in the linear 
response between absorbance at 490nm and number of seeded cells among the four 
different media: HIT, ED, HITED and control media (data not shown).   
 
The cell number counted in different media was calculated according to the 
absorbance at 490 nm and then converted to the cell doubling time as shown in Fig. 
3.2B. The low proliferation rate of MSCs in HIT medium is indicated by the 
statistically longer cell doubling time of 4.24 ± 0.15 days. In contrast, cells cultured in 
ED and HITED media have better proliferation rates, as demonstrated by their shorter 
cell doubling times (ED: 2.88 ± 0.20 days; HITED: 2.78 ± 0.25 days), and these were 
comparable to that of control growth medium (2.62 ± 0.27 days). Therefore, HIT 
medium is least desirable in terms of promoting cell proliferation. 
 














Fig. 3.2 The doubling time of MSCs within different media calculated from MTS 
assay. A: Calibration curve for MTS assay. The real cell number is determined by 
calibration with a known absorbance number measured by a microplate reader. B: 
Cell doubling time of MSCs cultured in different media: HIT medium, ED medium, 
HITED medium and Control medium. * represents a statistical difference between 
HIT medium and other media (p < 0.05). 
 
3.3.2 Immunostaining analysis of human BM-MSCs cultured in different media 
 
The percentages of pan-keratin expressed MSCs cultured in different media are 
shown in Fig. 3.3. It can be seen that all three induction media promoted MSCs to 
express pan-keratin when compared with the control medium. On day 7, it appeared 
that HIT medium was the most effective medium in stimulating pan-keratin 
expression (33%), followed by the HITED medium (24%). However, on day 10 for 
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the group with HIT medium, there was a significant drop (from 33% to 22%) in the 
percentage of cells expressing pan-keratin. Whereas the percentage of MSCs 
expressing pan-keratin in the other groups showed an increase on day 10 compared to 
day 7 although this is not statistically significant. Therefore, in terms of sustaining the 
expression of pan-keratin in MSCs, HIT medium is the least favorable medium.  
 
 
Fig. 3.3 Percentage of cells expressing pan-keratin on day 7 and day 10 cultured in 
different induction media: HIT medium, ED medium, HITED medium and Control 
medium. * represents a statistical difference between day 7 and day 10 in HIT 
medium (p < 0.05). 
 
We next looked at both the number and morphology of cells expressing pan-keratin in 
different culture media. From Fig. 3.4, we can see great differences in the 
morphology of pan-keratin expressed MSCs cultured in different media. Rounded or 
polygonal cell shape was seen in HIT medium (Fig. 3.4A), whereas cells cultured in 
ED medium took on an elongated morphology (Fig. 3.4B). Not unexpectedly, pan-
keratin expressing cells cultured in HITED medium showed a mixture of polygonal 
and elongated cells (Fig. 3.4C). As the rounded or polygonal cell type is closer to the 
morphology of keratinocytes in monolayer culture, we surmise that HIT medium is a 
desirable medium for inducing MSC into a keratinocyte lineage. We further surmise 
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that HITED medium is acceptable as it did promote MSCs to express pan-keratin 
even though these pan-keratin expressing cells showed a mixed morphology.  
 
In order to screen for the most effective medium that will drive BM-MSCs into the 
epidermal lineage, a combination of three criteria were used: cell proliferation, 
sustained expression of pan-keratin and keratinocyte-like morphology. From Table 
3.2, based on these three criteria, HITED medium is deemed to be the most desirable 
medium to drive BM-MSCs into epidermal cell lineage. Therefore, HITED medium 
was used for assessment of physical and environmental factors in further experiments. 
 
 
Fig. 3.4 The morphology of BM-MSCs stained by anti-pan-keratin antibody and 
FITC-conjugated secondary antibody on day 10 cultured in different induction media: 
A: HIT medium; B: ED medium; C: HITED medium; D: Control medium. Different 
cell shapes are demonstrated in different media: 1 rounded or polygonal cell shape; 2 
elongated cell shape. Scale bars: 50 µm. 
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Table 3.2 Evaluation table of different induction media. 
 HIT ED HITED Control 
Cell proliferation 
 
- + + + 
Pan-keratin expression 
 
- + ++ - 
Keratinocyte-like morphology 
 
+ - +/- - 
 
3.3.3 Histological analysis of organotypic coculture 
 
BM-MSCs were cultured in HITED medium for 14 days under different 
environmental and physical conditions. The histomorphology of MSCs was studied 
with H&E staining and the results are shown in Fig. 3.5. It clearly demonstrates that 
under wet-wet environment, a monolayer of MSCs was always formed on top of the 
collagen gel irrespective of whether it is contractible (Fig.3.5B) or not (Fig. 3.5A). 
For cells cultivated under wet-dry environment, only one layer of MSCs was formed 
on top of the collagen gel (Fig. 3.5C) when the gel was restrained from contracting, 
whereas a multi-layered cells were built up when the collagen gel was allowed to 
contract freely (Fig. 3.5D). The dermal substitute appears more cellular in Fig. 3.5D 
than in Fig. 3.5A-C, which is because the substrate under wet-dry and contractible 
condition was more contracted by fibroblasts than substrates under other conditions. 
The magnified image (Fig. 3.5E) of the middle zone in Fig. 3.5D more clearly 
demonstrates a 3D stratified cellular structure reminiscent of native epidermis. BM-
MSCs were pre-labeled with Quantum Dots. When the same sample was viewed 
under fluorescence microscope, it was found that the stratified cells were BM-MSCs 
in origin and most of the labeled cells were concentrated on top of the contracted 
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collagen gel with only a few cells migrating into the underlying collagen gel (Fig. 
3.5F).   
 
 
Fig. 3.5 H&E Staining of BM-MSCs on day 14 cultured in HITED medium under 
different environmental and physical conditions. A: BM-MSCs cultured on a 
noncontractible substrate under wet-wet environment. B: BM-MSCs cultured on a 
contractible substrate under wet-wet environment. C: BM-MSCs cultured on a 
noncontractible substrate under wet-dry environment. D: BM-MSCs cultured on a 
contractible substrate under wet-dry environment. E: Magnified image of the outlined 
zone in Fig. D. F: Fluorescence micrograph of quantum dot-labeled BM-MSCs in the 
same field as Fig. D. Scale bars: 25 µm (A-D, F), 5 µm (E). 
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3.3.4 Immunostaining analysis of organotypic coculture 
 
To assess the differentiation potential of BM-MSCs into epidermal lineage under the 
identified improved condition (wet-dry + contractible), immunostaining analysis was 
performed to determine the differentiation stage of MSCs. Three types of antibodies 
were used to detect the epidermal markers expressed at three different differentiation 
stages: keratin 10 (early), filaggrin (intermediate), involucrin (late) [167,169]. Results 
of MSCs on day 14 cultured on contractible substrates under wet-dry environment are 
shown in Fig. 3.6. The dotted lines indicate the boundary between MSCs and the 
dermal substitutes. It clearly shows the expression of keratin 10 (Fig. 3.6A) and 
filaggrin (Fig. 3.6B) in MSCs as represented by the green fluorescence. There was 
almost no involucrin expression (Fig. 3.6C). All cell nuclei of MSCs and fibroblasts 
in the organotypic coculture were counterstained by DAPI as indicated by the blue 
fluorescence in Fig. 3.6D-F. The immunostaining images (Fig. 3.6A-C) were 
superimposed on the DAPI nuclei staining images (Fig. 3.6D-F) and resulted in the 
overlay images of Fig. 3.6G-I. From the superimposed images, it is apparent that 
keratin 10 (Fig. 3.6G) or filaggrin (Fig. 3.6H) immunostain are co-located with cell 
nuclei. We further quantified the percentage of MSCs expressing epidermal markers 
and found that 90.67% ±1.16% of MSCs expressed keratin 10 and 80.51% ± 2.89% 
of MSCs expressed filaggrin, whereas no involucrin was expressed in MSCs cultured 
on contractible collagen substrates under wet-dry environment (upper panel in Fig. 
3.6). These findings indicated that, differentiated MSCs were still at the early and 
intermediate epidermal differentiation stages. However, for MSCs cultured under 
other conditions (wet-wet + noncontractible, wet-wet + contractible, wet-dry + 
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Fig. 3.6 The immunostaining and quantification of epidermal markers expression in 
BM-MSCs on day 14 cultured in HITED medium on contractible collagen gel under 
wet-dry environment. Upper Panel: Quantification of the expression of different 
epidermal differentiation markers (Keratin 10, Filaggrin and Involucrin) in BM-
MSCs. Lower Panel: A: Expression of keratin 10 with green fluorescence in BM-
MSCs. B: Expression of filaggrin with green fluorescence in BM-MSCs. C: No 
expression of involucrin with green fluorescence in BM-MSCs. D-F: Nuclear staining 
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of BM-MSCs and fibroblasts by DAPI with blue fluorescence in the same field as A-
C, respectively. G: Overlay image of A and D. H: Overlay image of B and E. I: 
Overlay image of C and F. Dash dots: Boundary between BM-MSCs and dermal 




The plasticity of adult stem cells offers a unique opportunity for new strategy of 
treatment in the field of tissue engineering and regenerative medicine. BM-MSCs, 
under certain specific microenvironment or so called ‘stem cell niche’, can proliferate 
and differentiate into specific types of specialized mature cells to ameliorate the 
injury and eventually replace the function of the injured tissue [170]. ‘Stem cell 
niche’, which is defined as ‘microenvironment of stem cell responsible for 
transdifferentiation’, has both anatomic and functional dimensions [124]. We 
attempted to create an artificial niche which simulates some of the conditions of skin 
defect both structurally and functionally. The intent is to induce BM-MSCs into an 
epidermal lineage by manipulating the biochemical cues in combination with 
environmental and physical properties of the culture substrates.  
 
Our choice of induction medium for testing was based on the following observations. 
The classic keratinocytes stratification medium (R&G medium) was developed by 
Rheinwald and Green in 1975 [164]. Subsequent research suggested that some of the 
ingredients supplemented in R&G medium were not necessary [168]. We simplified 
the original R&G medium by omitting some of the ingredients and keeping what we 
felt were the important ones, namely, hydrocortisone, insulin and T3 (HIT medium).  
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The literature suggests a combination of hydrocortisone, insulin, T3 and EGF has the 
greatest capacity to promote keratinocyte growth [171]. It was also noted that 1,25-
dihydroxyvitamin D3, the active biological form of vitamin D3, was found to enhance 
the proliferation of keratinocytes and regulate the ordered differentiation process 
through the interaction with epidermal growth factor receptor (EGFR) and vitamin D 
receptor [54,172]. The second test medium (ED medium) therefore contains both 
EGF and vitamin D3. The third test medium (HITED) contains all the previously 
named supplements and is in effect a combination of the HIT and ED medium. 
 
The proliferation results showed that MSCs cultured in medium containing EGF and 
VD3 (ED and HITED media in Fig. 3.2B) had better proliferation rates than MSCs 
cultured in HIT medium. This is most likely due to the growth stimulating effect of 
EGF. It has been reported that BM-MSCs express EGFR, which binds EGF or other 
EGFR binding metabolites to stimulate proliferation of MSCs through the 
phosphorylation of ERK and AKT kinases [173]. It follows that medium with EGF 
such as ED and HITED media are desirable for cell expansion.    
 
We studied the effect of the induction medium on differentiation by the expression of 
pan-keratin, a common marker used for epithelia-specific tissue [174]. There was a 
decrease in the ratio of pan-keratin expressed cells cultured in HIT medium from day 
7 to day 10 (Fig. 3.3). One possible explanation for this drop is that MSCs may 
differentiate into more than one cell lineage with time in HIT medium. Some of the 
MSCs may different into the adipose lineage under the influence of hydrocortisone, 
which has been reported to promote adipogenesis in BM-MSCs [175]. However, the 
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decrease in pan-keratin expression was not seen in HITED medium (Fig. 3.3). A 
possible explanation is that VD3 in the HITED medium inhibits adipose 
differentiation in MSCs [176]. Therefore, in a combined evaluation based on cell 
proliferation, pan-keratin expression and cell morphology, it appears that HITED 
medium is the most effective medium in driving MSCs to an epidermal lineage (Table 
3.2).  
 
Organotypic cocultures were used in this study to mimic the in vivo environment for 
keratinocyte stratification. Organotypic cocultures are powerful tools to investigate 
skin morphogenesis and homeostasis after wounding [61]. BM-MSCs were seeded on 
top of a dermal equivalent comprising a fibroblast-embedded collagen gel. Fibroblasts 
within dermal equivalents excrete many cytokines and growth factors, such as KGF 
and GM-CSF, to mediate the epidermal proliferation and differentiation for skin 
regeneration [33]. However, in conventional two-dimensional (2D) cocultures of 
keratinocytes and dermal fibroblasts, disordered stratification with limited life span 
was generated, whereas a superior epidermal architecture with regular growth and 
differentiation can only be achieved in 3D organotypic culture systems [61]. Similarly, 
in studies of 2D monolayer cultures for MSCs epidermal differentiation, only a single 
layer of polygonal or oblate MSCs was formed [174,177]. Therefore, our study 
analyzed the possible differentiation potential of MSCs into epidermal lineage in a 3D 
organotypic coculture model. 
 
Under physiological condition, interfollicular epidermal cells are exposed to the air 
and undergo differentiation with migration outwards from stratum basale to stratum 
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corneum. In biomimetic organotypic coculture model, the stratification and 
differentiation of keratinocytes were also reported to be much enhanced by exposure 
of the culture surface to the air [61]. Similarly, in this study we saw the formation of 
3D multi-layered epidermis-like structures after MSCs were cultivated with an air-
liquid interface on contractible collagen substrate (Fig. 3.5D and E). This observation 
indicated that direct exposure to the air was a contributing factor in the epidermal 
differentiation of MSCs. It was reported that after skin tissue injury, cells in the local 
microenvironment became metabolically more active and demonstrated a higher 
demand of oxygen for stratification and wound closure [178]. Therefore, in the 
present study, we speculated that by direct exposure of the culture surface to the air, 
we have provided a favorable oxygen-rich environment that might trigger the 
stratification process.  
 
However, the multi-layered growth pattern was not seen when the substrate was 
prevented from contracting by a metal ring, even when the BM-MSCs were exposed 
to the air (Fig. 3.5C). This suggests that the matrix contractibility is another factor 
that contributes to the formation of multi-layered growth architecture. This finding is 
consistent to the previous report that unlike mature cells, MSCs will commit to a 
particular lineage and phenotype with extreme sensitivity to tissue-specific elasticity 
[165]. Native skin is a relatively soft tissue with the elasticity of 15-150 MPa 
depending on different locations [166]. Conventional organotypic culture of 
keratinocytes involves placing a glass or metal ring on top of a dermal equivalent to 
prevent the shrinkage induced by fibroblast proliferation and migration [167]. 
However, in organotypic culture of MSCs, the ring restrain can disturb the skin-like 
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contractibility of dermal substitutes, which may account for the failure of MSCs to 
form a multi-layer growth pattern on noncontractible substrate (Fig. 3.5C). In our 
study, we can see only when MSCs were cultured on contractible collagen gel, they 
were able to anchor and pull against the culture matrix to form a concave area (picture 
not shown), which allows close cell-cell interaction and acts as a confined artificial 
niche for MSCs differentiation and stratification.  
 
We report here a necessary (but not sufficient) influence of substrate contractibility 
on epidermal differentiation of BM-MSCs in vitro. The cellular responses to cell-
exerted forces involve a feedback loop of ‘inside-outside-inside’ that couples with the 
stiffness of the excellular microenvironment [179]. At the molecular scale, MSCs first 
sense the substrate stiffness through their ability to contract the matrix and then 
transduce the signals in the form of tensioning actin structures at different levels 
through the cellular mechano-transducers, such as one or all of the nonmuscle myosin 
II isoforms (NMM IIA, B, and C). These stress actin fibers are in turn linked to the 
focal adhesions that provide the pathway of force transmission from the cell interior 
to the outside contractible matrix and associated with the transcellular adhesion 
complexes for close cell-cell interaction and stem cell specification within matrix 
stiffness-specific environment [165]. Therefore, in our experiments, only under the 
conditions onto contractile collagen matrix without any ring restrain, seeded MSCs at 
the lift-liquid interface were able to be driven into cells with epidermal phenotypes in 
terms of growth pattern as well as the expression of specific epidermal markers.     
 
In total, the differentiation of MSCs into epidermal lineage is stimulated by the 
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combined effects of soluble biochemical cues, environmental and physical properties 
of culture microenvironment. Lacking one of them, the multi-layered epidermis-like 
structures with the expression of protein markers specific to native skin cannot be 
achieved. Schneider RKM et al. has reported a similar multi-layered structure of 
MSCs when cultivated at an air-liquid interface, but failed to find the evidence of any 
skin-specific marker expression in the induced MSCs [163]. This was highly due to 
the treatment of MSCs from less effective biomolecular supplements in their induced 
medium. In contrast, our defined HITED medium herein was further confirmed to be 
efficacious in an improved organotypic coculture model for driving MSCs into 
epidermis-like cells structurally and functionally. 
 
This study confirms the differentiation potential of BM-MSCs into epidermal lineage 
and identifies the key factors that trigger its epidermal differentiation by employing a 
biomimetic organotypic coculture model, and thereby strongly indicates the potential 
application of BM-MSCs in skin tissue engineering. For patients with full-thickness 
skin loss, the conventional treatment with autologous or allogenous skin grafts is 
compromised due to the limitation of donor-site morbidity or immune rejections 
respectively. Therefore, BM-MSCs might be used as an alternative cell source for 
wound healing purpose. However, considerable work including an in vivo study needs 




In the present study, by manipulating the biochemical cues in combination of 
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environmental and physical conditions of the culture substrate, we were able to drive 
BM-MSCs into epidermal lineage with development of multi-layered epidermis-like 
structures, as further confirmed by the expression of early and intermediate epidermal 
differentiation markers. It not only provides insights into the design of a site-specific 
niche-like microenvironment for stem cell lineage commitment, but also shed lights 
on the therapeutic application of an alternative cell source – BM-MSCs, for wound 
healing and skin reconstitution.  
 
(Note: Some of the results have been published in Biomaterials and they are reprinted 
in this chapter from Biomaterials, 30(19), Ma K, Laco F, Ramakrishna S, Liao S, 
Chan CK, Differentiation of bone marrow-derived mesenchymal stem cells into 
multi-layered epidermis-like cells in 3D organotypic coculture, 3251-3258, Copyright 
2009, with permission from Elsevier.) 
 
 




Fabrication and Modification of Electrospun NFS 
 
4.1 Introduction  
 
The incorporation of a bioactive scaffold which basically provides a structural 
support for the cells to grow into a specific tissue is indispensable for the design of a 
tissue-engineered skin graft. The scaffolds can be designed to mimic complex 
biological structures, to provide the mechanical and structural support for the seeded 
cells and cells of the damaged tissue to remodel, repair and form distinct 3D tissue 
structures that resemble the original tissue [60].  
 
Recently, polymeric NFS attract more and more attention in constructing tissue-
engineered matrix due to many of their desirable properties such as a large surface-to-
volume ratio, high porosity, ECM-like architecture, biocompatibility, availability of 
surface modification and flexibility of loading growth factors or drugs [23,60]. In this 
study, we employ an easy and versatile technique of electrospinning to fabricate 
biomimetic NFS. A natural material and a FDA-approved biodegradable synthetic 
polymer were blended for electrospinning. Collagen type I was chosen as the natural 
material as it was the most abundant ECM substance in human skin tissue [32]. 
Besides, collagen-based scaffolds were found to expedite the healing process, 
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promote angiogenesis and fibroblast proliferation [8,35,67,139]. However, the poor 
control of enzymatic degradation and weak mechanical performance are two major 
limitations to the use of naturally derived polymers [135]. Therefore, in order to 
reinforce mechanical integrity and stability of a collagen-based NFS, a biodegradable 
synthetic copolymer - PLGA was blended with collagen for co-electrospinning. 
PLGA (75:25) was used because PLGA (75:25) NFS was found to have the 
appropriate degradation profile to match the healing rate in damaged tissue, support 
keratinocyte, fibroblast and endothelial cell growth as well as new ECM production 
[159].  
 
Additionally, enhancing cell-matrix interactions is crucial for successful applications 
of scaffolds for repairing and regenerating damaged tissue. Upon seeding onto 
polymeric biomaterial scaffolds, cell attachment to the scaffold is the first cellular 
event to occur. After the cells are securely adhered, other events such as cell 
migration, proliferation and differentiation will then subsequently take place [180]. 
Therefore, optimal cell adhesion is critical for favorable cellular response. In this 
study, starting from our hypothesis that both substrate topographical and biochemical 
cues could promote BM-MSCs adhesive behavior, CD29 antibody (Ab) was 
chemically conjugated on the surface of Collagen/PLGA blended NFS. CD29 
monoclonal Ab would recognize and bind with CD29 antigen expressed on the 
surface of human BM-MSCs, which render the blended NFS a great affinity for 
human BM-MSCs and achieve its efficient cell attachment on blended NFS.     
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PLGA (75:25) copolymer at a molecular weight of 90,000-126,000, 1,1,1,3,3,3-
hexafluoro-2-propanol (HFP), FITC-conjugated anti-mouse secondary Ab, BSA were 
all purchased from Sigma-Aldrich, USA. Human BM-MSCs were ordered from 
Cambrex Bio Science Walkersville, Inc., USA. Koken type I collagen powder 
(Medical Grade) was ordered from Koken, Japan. Mouse monoclonal anti-human 
CD29 Ab was purchased from BD Pharmingen, USA. Coupling reagents 2-
iminothiolane⋅HCl (Traut’s reagent) and sulfosuccinimidyl 4-[N-maleimidomethyl] 
cyclohexane-1-carboxylate (Sulfo-SMCC) were purchased from Pierce, USA.  
 
4.2.2 Fabrication of Collagen/PLGA blended NFS 
 
For fabricating Collagen/PLGA blended NFS, PLGA and collagen powders were 
mixed at a ratio of 1:1 (w:w) and fully dissolved overnight at room temperature with 
different concentrations in HFP (4.5g/ml, 5g/ml, 6g/ml, 8g/ml, 10g/ml). The mixture 
was then placed in a plastic syringe with a needle tip diameter of 0.21 mm. With the 
aid of a syringe pump, the solution was dispersed at a feeding rate of 1.2 ml/h at 
humidity of 55% -60% and temperature of 20°C-24°C. Electrospinning voltage was 
applied between the needle and collector at 18 kV DC, using a high voltage power 
supply (Gamma High Voltage Research, Ormond Beach, FL). The electric field 
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generated by the surface charge caused the solution drop at the tip of the needle to 
distort into a Taylor cone. Once the electric potential at the surface charge exceeded a 
critical value, the electrostatic forces would overcome the solution surface tension 
and a thin electrified jet of solution would erupt from the surface of the cone. The 
resultant NFS were collected on cover slips located 12 cm from the needle tip. After 
solvent evaporation, the nanofiber-coated cover slips were placed in a vacuum dryer 
overnight to remove any remaining solvent. As controls, pure PLGA NFS and pure 
collagen NFS were also fabricated. The optimized parameters for electrospinning 
these three types of NFS were summarized in Table 4.1. 
 
Table 4.1 Optimized operation parameters for fabrication of three types of NFS 









Concentration of Spinning 














12 12 12 
Feeding Rate (ml/h) 
 
1.2 2 1.2 
Humidity (%) 
 
55-60 55-60 55-60 
Temperature (°C) 
 
20-24 20-24 20-24 
      
4.2.3 Characterization of Collagen/PLGA blended NFS 
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Scanning electron microscopy (SEM) micrographs were obtained with a JSM-
5800LV scanning electron microscope (JEOL, Tokyo, Japan) to observe the 
morphology of electrospun Collagen/PLGA blended NFS (appendix C). The diameter 
range of the fabricated nanofibers was measured on the basis of SEM images, using 
image analysis software (ImageJ). 
 
The topography of blended NFS was studied using the Atomic Force Microscope 
(AFM) in tapping mode (Dimension 3100 AFM, Veeco Instruments Inc., CA, U.S.) 
using a silicon tip (Pointprobe-Plus® silicon-SPM sensor, Nanosensors™, 
Switzerland) under ambient conditions with scanned areas of 2.86 µm2. The images 
were recorded at a scan rate of 1Hz.   
 
Transmission electron microscopy (TEM) (JEM-2010F FasTEM, JEOL) was used to 
study the surface morphology of electrospun nanofibers. Nanofibers for TEM 
samples were prepared by direct depositing of the electrospun nanofibers on copper 
grids (Structural Probe, SPI Supplies Division, West Chester, PA) and observations 
were made at a voltage of 100 kV.  
 
Apparent density and porosity of the blended NFS were calculated based on the 
following equations: 
)(cm area membrane  (cm)  thicknessmembrane
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%100
)(g/cm 1):(1PLGA Collagen / ofdensity bulk 





⎛ −=  
Where the bulk density of Collagen / PLGA (1:1) = 1.3-1.35g/cm3  
 
Structural pore properties was assessed using a capillary flow porometer (1200-
AEHXL, Porous Media Inc., Ithaca, NY). Briefly, pore size distribution was 
determined by allowing a non-reacting gas to flow through the dry NFS, and 
subsequently the flowing gas streamed through the same membrane that had been 
wetted by a liquid of known surface tension. The difference in flow rate is thus 
measured as a function of pressure for both dry and wet processes. The pore size was 
determined using the software provided by Porous Media Inc. 
 
Attenuated Total Reflectance-Fourier Transform Infrared (ATR-FTIR) spectra were 
obtained with an AVATAR 380 FTIR machine (Thermo Electron, Waltham, MA) to 
characterize the chemical composition of blended NFS. Collagen NFS, PLGA NFS 
and Collagen/PLGAblended NFS samples were placed over the ATR-FTIR crystal 
and maximum pressure was applied using the slip-clutch mechanism. All spectra 
were collected using 1 minute sample and 1 minute background collection times. 
 
Tensile tests were carried out with a 5848 microtester (Instron, Norwood, MA) at a 
stroke rate of 10 mm/min and with a 40-mm gauge length. NFS were rectangular (10 
mm x 60 mm) in shape. This tensile test was performed in the same manner as 
standard mechanical test for fabric materials. 
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Hydrophilicity was determined by contact angle assessment machine (VCA optimaTM, 
AST Products Inc., USA). The water contact angles for samples of pure PLGA NFS 
and blended NFS were measured by the sessile drop method. Drops of distilled water 
were deposited onto the surface of the samples and the direct microscopic 
measurement of the contact angles was done with the computer software. The water 
droplet was 0.5 ml to prevent a gravitational distortion of the spherical profile. The 
result of each sample was obtained by averaging 10 tests. 
 
Degradation study of Collagen/PLGA blended NFS was conducted for 10 weeks. 
Randomly arranged blended NFS were cut and glued (Implant-grade silicone 
adhesive, Silbione, MED ADH 4300 RTV, Rhodia, France) onto glass slides. 
Samples were weighed before (g1) and after (g2) being glued onto the glass slides. 
Samples were then immersed in phosphate-buffered saline (PBS) and kept in 37ºC 
incubator with 5% CO2. PBS solution was renewed every week. Then at different 
time points (day 3, day 5, day 7, day 14, day 18, day 21, day 28, day 35, day 42, day 
49, day 56, day 63, day 70), five samples were taken out, dried in a vacuum oven at 
room temperature overnight and weighed again (g3). The percentages of mass 
remained were calculated with the following equations:  
  
Percentages of mass remained = [1− (g2− g3)/ g1] x 100% 
 
After mass measurement, the ATR-FTIR spectrum of each sample was obtained with 
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an AVATAR 380 FTIR machine (Thermo Electron, Waltham, MA) to characterize 
the chemical composition of NFS surface. Then each sample was mounted on a 
specimen holder with double-sided carbon tape and gold coated with a JEOL JFC-
1200 fine coater at 10mA for 100s. The fiber morphology was observed by SEM 
micrographs (appendix C). 
 
4.2.4 Modification of Collagen/PLGA blended NFS 
 
The conjugation of CD29 Ab onto the surface of Collagen/PLGA blended NFS was 
done according to the protocol in our previous study [181]. Briefly, monoclonal anti-
human CD29 Ab was first modified with Traut’s reagent to produce a terminal 
sulfhydryl group. Each milliliter of 100 μg monoclonal CD29 Ab solution was treated 
with 46µl of the 14 mM stock solution of Traut’s reagent at room temperature for 1 
hour, after which modified Ab was separated from excess Traut’s reagent using a 
YM-50 MICROCON centrifugal filtration unit. Collagen/PLGA blended NFS were 
treated with 240μl 0.1 mM Sulfo-SMCC at room temperature for 1 hour, and the 
excess Sulfo-SMCC were removed by washing the blended NFS with 1ml PBS 3 
times. Finally, the modified blended NFS were incubated with 200 μl PBS containing 
5μg modified monoclonal CD29 Ab at 4°C overnight (Fig. 4.1). Blended NFS 
without antibody attachment was used as a control. 
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Fig. 4.1 Schematic illustration of reaction for immobilization of monoclonal CD29 
antibody on the Collagen/PLGA blended NFS (Reprinted from [181], Copyright 2009, 
with permission from IOP Publishing Ltd).  
 
 
4.2.5 Characterization of CD29 Ab-conjugated Collagen/PLGA blended NFS 
 
The concentration of CD29 Ab coupled to the blended NFS was determined by 
BCATM protein assay kit (Pierce, Biotechnology, IL, U.S.). The CD29 Ab-conjugated 
blended NFS and blended NFS without CD29 Ab conjugation as a control were 
immersed in 0.05ml PBS together with 0.4 ml working reagent and incubated at 37°C 
for 30 min. The absorbance measurements were then taken at a wavelength of 590nm 
by using a FLUO Star Optima microplate reader (BMG Labtech GmbH, Offenburg, 
Germany) after the samples were cooled to room temperature. The CD29 Ab 
concentration was then calculated by subtracting the average 590 nm absorbance 
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measurement of the control group (blended NFS without CD29 Ab conjugation) and 
employing an antibody standard curve. CD29 Ab concentration results were 
normalized by the NFS area. The conjugation efficiency (%) was calculated as the 
concentration of conjugated CD29 Ab divided by its initial incubation concentration.   
 
4.2.6 Adhesion efficiency of human BM-MSCs on different substrates 
 
0.5 ml of BM-MSCs suspension with an initial density of 20,000 cells/ml in fresh 
medium (Low glucose DMEM, 10% FBS, 100 IU/ml Penicillin and 100µg/ml 
Streptomycin)  were seeded into each well of 1.88 cm2 of 24-well plates covered with 
different substrates: (1) Tissue culture polystyrene (TCP); (2) pure PLGA NFS; (3) 
pure Collagen NFS; (4) Collagen/PLGA blended NFS; (5) CD29 Ab-conjugated 
Collagen/PLGA blended NFS. The BM-MSCs suspension was exposed to these 
substrates at room temperature for defined periods of time (10 min, 20 min, 30 min 
and 60 min) and washed by PBS three times to remove unattached cells. The attached 
cells were then fixed by cold methanol (-20 °C) for 10 min and nuclei were stained by 
DAPI and counted under a phase-contrast microscope. The cell adhesion efficiency 
was calculated based on the initial seeding density. Studies of BM-MSCs adhesion 
efficiency on different substrates of 1.88 cm2 were also done at different initial cell 
seeding densities of 4.66 x 106 MSCs/well (3 x 106 MSCs/121 mm2) and 4.66 x 103   
MSCs/well (3 x 103 MSCs/121 mm2) using the same protocol described as above.   
 
4.2.7 Morphology of human BM-MSCs on different substrates 
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Attached BM-MSCs on different substrates at different time points (10 min, 20 min, 
30 min and 60 min) were fixed in 2.5% glutaraldehyde at 4oC for 45 min, dehydrated 
in a series of graded ethanol and allowed to dry at room temperature (appendix C). 
After that, each specimen was subsequently mounted on a specimen holder with 
double-sided carbon tape and gold coated with a JEOL JFC-1200 fine coater at 10mA 
for 100s. Then the cell morphology on different substrates was observed by SEM 
micrographs. 
 
4.2.8 Statistical analysis 
All tests were performed using 10 samples. The results are averaged and expressed as 
mean ± standard deviation. Each experiment was repeated three times. Statistical 
differences were determined by two-way ANOVA. Differences were considered 




4.3.1 Morphology of Collagen/PLGA blended NFS 
 
SEM micrographs of Collagen/PLGA blended NFS prepared under various 
concentrations in HFP (4.5g/ml, 5g/ml, 6g/ml, 8g/ml, 10g/ml) are shown in Fig. 4.2. 
For NFS prepared at a ratio of 4.5g/ml, defects in the form of beads and droplets are 
observed (Fig. 4.2A). The lower concentration is characteristic of electrospraying 
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rather than electrospinning [134]. The beads and droplets reduce significantly while 
the beads still exist when the ratio was increased up to 5g/ml (Fig. 4.2B). As the 
concentration of the polymer solution reached 6g/ml, neither droplets nor beads are 
observed (Fig. 4.2C), however, the diameters of nanofibers are not uniform. In 
contrast, NFS fabricated at 8g/ml are characterized by nanofibers of uniform diameter 
with interconnected pores. The nanofiber diameter was 382 ± 125 nm (Fig. 4.2D). 
When concentration was increased up to 10g/ml, we found that the nanofibers still 
showed smooth and uniform morphology similar to those at 8g/ml except the 
diameter increased up to 397 ± 145 nm (Fig. 4.2E). For cost consideration, we chose 
8g/ml as the preferred concentration for preparing the spinning solution and the 




Fig. 4.2 SEM images of Collagen/PLGA (1:1) NFS with different concentrations in 
HFP (A: 4.5g/ml, B: 5g/ml, C: 6g/ml, D: 8g/ml, E: 10g/ml). Scale bar: 50 µm.  
 
   115 
Chapter 4 
 
Representative 3D AFM renderings show the nano-texture of the blended NFS 
surface (Fig. 4.3A). The NFS surface roughness was measured as 390.9 ± 363.2 nm. 
The TEM micrograph clearly shows the smooth morphology of a single blended NFS 
(Fig. 4.3B).  
 
 
Fig. 4.3 Collagen/PLGA blended nanofibers: (A) AFM micrograph and (B) TEM 
micrograph. 
 
4.3.2 Porosity and pore size of Collagen/PLGA blended NFS 
 
The bulk density of Collagen/PLGA (1:1) blended NFS was estimated to be in the 
range of 1.3 to 1.35 g/cm3 based on the bulk densities of Collagen (1.3 to 1.4 g/cm3) 
and PLGA (75:25) (1.3 g/cm3).  The apparent density of blended NFS was measured 
as 0.27 ± 0.13 g/cm3 and its porosity was calculated to be 79.62% ± 9.81%. The pore 
size of blended NFS was measured as 0.47 ± 0.36 µm.  
 
4.3.3 Chemical composition of Collagen/PLGA blended NFS 
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The mixed composition of Collagen/PLGA NFS was verified by ATR-FTIR 
spectrometry. Fig. 4.4 shows the infrared spectra of pure PLGA NFS (in red), pure 
Collagen NFS (in pink), and Collagen/PLGA NFS (in blue). Spectra of blended NFS 
revealed overlapping peaks characteristic of Collagen at wave numbers of 3310 cm-1 
(N-H stretch), 1649 cm-1 (amide I bond), 1550 cm-1 (amide II bond) and a PLGA 
peak at 1759 cm-1 (ester C=O bond), verifying that blended NFS were a mixture of 
PLGA and Collagen. 
 
 
Fig. 4.4 ATR-FTIR spectra of pure PLGA NFS (red), pure Collagen NFS (pink) and 
Collagen/PLGA NFS (blue). 
 
 
4.3.4 Mechanical properties of Collagen/PLGA blended NFS 
 
Fig. 4.5 shows the stress-strain curves of Collagen/PLGA blended NFS (in pink) and 
pure PLGA NFS (in blue) under tensile loading. Pure Collagen NFS was too fragile 
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to be applicable for this test. Mechanical evaluations of both NFS in Fig. 4.5 show a 
linear segment up to the proportionality limit followed by a non-linear curve, which 
was characterized by a considerable elongation without a corresponding increase in 
loading stress. This feature is attributed to the random and interlacing arrangement of 
NFS. When subjected to a continuous tensile strength, the overlapping nanofibers 
would ‘slide’ along each other and those curving ones straightening to the direction of 
pull would stretch until they reach the ultimate strength of the material. 
 
Tensile properties of the pure PLGA NFS and Collagen/PLGA blended NFS as well 
as the human skin [166] are summarized in Table 4.2. The tensile modulus of the 
blended NFS overlaps well with that of the human skin. Even though the ultimate 
tensile stress value (MPa) of blended NFS is low compared to that of human skin, it 
doesn’t weaken its potential as a skin graft, since it is seldom under a high tensile 
strength when immobilized on the wound sites and doesn’t necessarily need to be ‘a 
high-load bearing instrument’. On the other hand, its desirable tensile modulus 
similar to that of human skin provides it with good resilience and compliance to 
movement as a skin graft. 




















PLGA NFS Blended NFS
 
 
Fig. 4.5 Stress-strain curves for electrospun pure PLGA NFS (blue) and Collagen/ 
PLGA blended NFS (pink).  
 
  
Table 4.2 Tensile properties of electrospun NFS and human skin.  
 
 PLGA NFS Collagen/PLGA  
NFS 
Human skin 
Tensile Modulus (MPa) 
 
190.42 ± 9.97 40.43 ± 3.53 15-150 
Ultimate Tensile  
Stress (MPa) 
 
4.82 ± 0.33 1.22 ± 0.12 5-30 
Ultimate Strain (%) 188 ± 19 96 ± 13 35-115 
 
 
4.3.5 Hydrophilicity of Collagen/PLGA blended NFS 
 
The mean ‘water in air’ contact angle observed for blended NFS was 25.78° ± 1.99°, 
which was significantly lower than 101.98° ± 1.87° of pure PLGA NFS. The 
decreased contact angle in Collagen/PLGA NFS suggested its increased 
hydrophilicity and enhanced capability for cell attachment. 
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4.3.6 In vitro degradation of Collagen/PLGA blended NFS 
 
Fig. 4.6 shows the morphological changes of Collagen/PLGA blended NFS during 
degradation in PBS at different time points. Compared with fibers on day 0 with 
uniform diameters at nano-scale (Fig. 4.6A), nanofibers on day 7 appeared to swell a 
little and lose their initial surface smoothness (Fig. 4.6B). On day 14, some cleavages 
were seen in single nanofibers (red arrows in Fig. 4.6C), while more fiber ruptures 
were found on day 18 (red arrows in Fig. 4.6D) and day 21 (red arrows in Fig. 4.6E). 
On day 28, some nanofibers were broken down into small fragments (red arrows in 
Fig. 4.6F), while more small pieces of broken fibers were seen and they continued to 
swell on day 35 (Fig. 4.6G) and day 49 (Fig. 4.6H). Some short fiber fragments were 
found to merge into fiber chunks on day 49 (red arrowhead in Fig. 4.6H) In contrast, 
on day 70, no fibrous structures were detected and only some small pieces of 
degraded materials were left (Fig. 4.6 I).     
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Fig. 4.6 Morphological changes of Collagen/PLGA blended NFS during the 
degradation in PBS after (A) 0 day, (B) 7 days, (C) 14 days, (D) 18 days, (E) 21 days, 
(F) 28 days, (G) 35 days, (H) 49 days, (I) 70 days.  The red arrows (C-F) show 
cleavages in the nanofibers and the red arrowhead (H) shows the fiber coalescence. 
Scale bar: 10 µm.  
 
 
Fig. 4.7 shows the percentages of mass remained in Collagen/PLGA blended NFS 
during the degradation in PBS solution at different time points. A sharp decrease in 
NFS mass was found in the initial 7 days, followed by a slow degradation rate from 
day 7 to day 35. From day 35 to day 49, there was no significant mass loss in blended 
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NFS, whereas after day 49, a fast weight loss was detected till day 70 when all the 





























Fig. 4.7 Percentage of mass remained in Collagen/PLGA blended NFS during the 
degradation in PBS at different time points. 
 
 
Fig. 4.8 displays the ATR-FTIR spectra of Collagen/PLGA blended NFS during 
degradation in PBS at different time points. On day 0, the purple line clearly shows 
the peaks characteristic of both collagen amide II bond at 1550 cm-1 , collagen amide 
I bond at 1649 cm-1 and PLGA ester C=O bond at 1759 cm-1, indicating the blended 
NFS was a mixture of collagen and PLGA on day 0. However, on day 7, the collagen 
peaks of amide II bond at 1550 cm-1 and amide I bond at 1649 cm-1 were not seen (in 
green), suggesting collagen on NFS surface already degraded. The spectra for day 21 
(in yellow) and day 35 (in blue) showed peaks characteristic of PLGA C=O bond at 
1759 cm-1, whereas no peaks were seen in the spectrum on day 70 (in red), which 
indicated the complete degradation of blended NFS by day 70.      






Fig. 4.8 ATR-FTIR spectra of Collagen/PLGA blended NFS during degradation in 
PBS at different time points: day 0 (purple), day 7 (green), day 21 (yellow), day 35 
(blue) and day 70 (red).  
 
4.3.7 Characterization of CD29 Ab-conjugated Collagen/PLGA blended NFS 
 
The CD29 Ab was chemically conjugated onto the PLGA/Collagen blended NFS by 
Traut’s Reagent and Sulfo-SMCC. BCA protein assay showed that the concentration 
of CD29 Ab coupled to the blended NFS was 2.66 ± 0.04 µg/cm2 (94.33 ± 1.42 µg/ml 
in 0.05 ml PBS on NFS surface of 1.77 cm2). As the initial incubating concentration 
of CD29 Ab was 2.82 µg/cm2 (5 µg/1.77 cm2). The conjugation efficiency was 
calculated as 94.33% ± 1.42%.  
 
4.3.8 Adhesion efficiency of human BM-MSCs on different substrates 
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The comparison of adhesion efficiencies of BM-MSCs on various substrates at 
different time points is shown in Fig. 4.9. We found that TCP (blue bars) exhibited 
the lowest capacity for cell attachment (10.22% attached at 30 min and 33.62% 
attached at 60 min). In contrast to TCP, all types of NFS (pure PLGA NFS: red bars, 
blended NFS: yellow bars, pure collagen NFS: green bars and CD29 Ab-coupled 
blended NFS: purple bars) showed an increased adherence of BM-MSCs. It suggests 
that the nanotopography of NFS surface facilitates MSCs attachment. At 10 min, all 
collagen-incorporated NFS (blended NFS: yellow bar, pure collagen NFS: green bar 
and CD29 Ab-coupled blended NFS: purple bar) displayed an increased adherence of 
BM-MSCs than pure PLGA NFS (red bars), which indicated that the presence of 
collagen in NFS contributed to the attachment of BM-MSCs. However, there were no 
statistical differences among the pure collagen NFS (green bar) and blended NFS 
with (purple bar) or without (yellow bar) the conjugation of CD29 Ab at 10 min, 
which may indicate two phenomena within a short incubation time. First, for the 
blended NFS (yellow bar), there were sufficient binding sites on its collagen to 
interact and bind with BM-MSCs within the initial 10 min, therefore, no increase in 
the MSCs attachment was seen at 10 min of incubation even when the concentration 
of collagen in NFS was increased to the highest level as the pure Collagen NFS 
(green bar).  However, when the incubation time was elongated up to 20 min, 30 min 
and 60 min, A significantly higher attachment of BM-MSCs was visible in  pure 
collagen NFS (green bars) than blended NFS (yellow bars). Second, the specific 
antibody-antigen binding interaction did not take place to contribute to the MSCs 
adhesion until the incubation time reached 30 min. As we can see, there was no 
Chapter 4 
statistical difference in MSCs attachment between blended NFS with (purple) or 
without (yellow) the conjugation of CD29 Ab at 10 min or 20 min of incubation. 
However, from 30 min, a remarkable increase in MSCs attachment was seen on 
CD29 Ab-coupled blended NFS if compared with blended NFS without CD29 Ab 
conjugation (purple bars versus yellow bars: 60.22% versus 31.75% at 30 min; 
80.54% versus 54.3% at 60 min).  At 30 min and 60 min of incubation, the adhesion 
efficiencies of BM-MSCs on CD29 Ab-coupled blended NFS (purple bars) were even 
higher than the pure Collagen NFS (green), although this was not statistically 
significant. Additionally, no statistical differences in BM-MSCs adhesion efficiency 
were found among groups with different initial cell seeding densities (4.66 x 106 
MSCs/well and 4.66 x 103 MSCs/well, data not shown). Therefore, among all the 
experimental groups, CD29 Ab-coupled blended NFS was demonstrated to be the 
most efficient substrate for the rapid and rich adherence of BM-MSCs.   
     
 
Fig. 4.9 Comparison of adhesion efficiencies of BM-MSCs at different time points on 
different substrates: TCP (blue), PLGA NFS (red), Collagen/PLGA blended NFS 
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(yellow), Collagen NFS (green) and CD29 antibody-coupled blended NFS (purple). * 
represents a statistical difference (p < 0.05). 
 
4.3.9 Morphology of human BM-MSCs on different substrates  
 
From Fig. 4.10, it was seen that BM-MSCs on TCP were rounded and towering with 
a small portion of the cell surface in contact with the TCP substrate at 10 min (Fig. 
4.10A), 20 min (Fig. 4.10B) and 30 min (Fig. 4.10C). In contrast to TCP, MSCs had a 
larger contact area and took on flatter morphology on blended NFS with (Fig. 4.10I, 
4.10J, 4.10K) or without (Fig. 4.10E, 4.10F, 4.10G) coupling of CD29 Ab. At 30 min, 
BM-MSCs in CD29 Ab-coupled NFS group started to extend their filopodia (red 
arrows in Fig. 4.10K) on NFS, while very few filopodia were seen in other groups. At 
60 min, BM-MSCs in all groups displayed their filopodia-like protrusions (white 
arrows in Fig. 4.10D, red arrows in Fig. 4.10H, 4.10L), while only cells on CD29 Ab-
coupled NFS demonstrated more and longer filopodia extending along or in 
associating with nanofibers and producing irregular features (arrow head in Fig. 
4.10L) suggestive of better cell attachment and sprouting. This indicates CD29 Ab-
coupled NFS promote the early adherence and spreading of BM-MSCs compared to 
the unmodified blended NFS and TCP.  
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Fig. 4.10 Morphology of BM-MSCs attached on different substrates: TCP (A, B, C, 
D), Collagen/PLGA blended NFS (E, F, G, H) and CD29 antibody-coupled blended 
NFS (I, J, K, L) at different time points of incubation: 10 min (A, E, I), 20 min (B, F, 




In this study, we have fabricated collagen/PLGA blended NFS for rapid and rich 
capture of BM-MSCs at room temperature. Electrospinning is an efficient and rapid 
method for fabricating collagen/PLGA blended NFS. It is also possible to use other 
methods including physical coating [182] and chemical grafting [183] to introduce 
collagen onto the substrate surface. However, one problem facing these techniques is 
the slow mass transfer of proteins into 3D porous matrix. For example, it took more 
than 3 days to effectively graft gelatin molecules onto poly(ethylene terephthalate) 
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nanofiber surfaces [183]. Compared with the surface modification of polymer NFS, 
direct electrospinning of a blended collagen - polymer mixture is much faster and 
simpler because it avoids the slow mass transfer process and also uses smaller 
amounts of reagents during protein immobilization. The existence of collagen 
molecules on the surface and in the interior of the blended NFS provides sustained 
cell recognition signals. 
 
The Collagen/PLGA blended NFS offers many advantages for bioengineered skin 
graft application. It had a well-controlled diameter distribution range from 250 to 500 
nm and a high porosity 79.62%. This diameter range has been shown to favor cell-
matrix interactions [145,184]. The high porosity is beneficial to an efficient nutrient 
delivery, gas exchange, easy extrusion of exudates and maintaining temperature 
homeostasis in the wounded area. In addition, among the most common 
microorganisms that cause wound infection are Staphylococcus aureus and β-
hemolytic Streptococcus with the diameters ranging from 0.6 to 1.0 µm [185]. 
Therefore, the small pore size of the blended NFS (0.47 µm) can protect the wound 
from infection and dehydration to some extent. Furthermore, compared with pure 
Collagen NFS, Collagen/PLGA blended NFS showed a good mechanical property, 
which would facilitate it to retain mechanical and structural integrity when surgeon 
handles and implants it to the skin defect. Besides, the tensile modulus of the blended 
NFS overlaps well with that of the human skin, offering the NFS good resilience for 
wound coverage in various anatomic site and appropriate compliance to skin 
movement after implantation to the wound sites. In addition, the high hydrophilicity 
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of blended NFS (25.78° ± 1.99°) indicates its easy adherence to the wound site upon 
implantation. Moreover, blended electrospun NFS can be easily customized to cover 
wounds with any size or shape.    
 
This study also characterized the in vitro degradation profile of Collagen/PLGA 
blended NFS. Many in vitro factors, such as the pH value, ionic strength and 
enazymatic activity of the solution could influence the biodegradation rate of natural 
and synthetic polymers [186]. Commonly used in vitro method for the assessment of 
polymer degradation is to immerse samples in PBS or equivalent buffer solution at 
pH ~ 7.4 at 37ºC for determined time points [186]. In this study, the in vitro 
degradation process of Collagen/PLGA blended NFS immersed in PBS was found to 
basically consist of four steps: (1) a significant mass loss of blended NFS immersed 
in PBS was detected in the initial 7 days (Fig. 4.7). This was most probably due to the 
water penetration into the amorphous region of the NFS polymer and disruption of 
the secondary force, which led to the surface erosion and mass loss of NFS polymers, 
especially the dissolving of collagen [187]. The fast degradation of collagen on the 
NFS surface in the initial 7 days was further confirmed by the missing peaks of 
collagen amide II bond at 1550 cm-1 and amide I bond at 1649 cm-1 in the ATR-FTIR 
spectra from day 7 (Fig. 4.8) and the rough surface morphology of nanofibers on day 
7 (Fig. 4.6B). Besides, the blended nanofibers were found to become swollen on day 
7 (Fig. 4.6B), which was highly attributed to the chain relaxation of the PLGA 
polymer after incubation into the PBS solution with elevated temperature [188]. (2) 
From day 7 to day 21, blended NFS underwent slower degradation than the initial 7 
   129 
Chapter 4 
days. At this stage, water continued to penetrate the amorphous region, preferably the 
glycolic acid-rich area of the PLGA polymer, scissor the hydrolytic chain of PLGA 
and thereby expose the inner collagen to the PBS solution, which consequentially 
caused rapid degradation of collagen and mass reduction in blended NFS. It was seen 
on day 14 (Fig. 4.6C), some nanofibers started to break and more fiber ruptures were 
found on day 18 (Fig. 4.6D) and day 21 (Fig. 4.6E), which was in agreement with the 
relatively rapid degradation rate of blended NFS from day 14 to day 21 if compared 
with that from day 7 to day 14 (Fig. 4.7). By day 21, all of the collagen incorporated 
to the blended NFS was degraded. (3)  From day 21 to day 49, there was no statistical 
difference in the mass remained in NFS (Fig. 4.7). At this stage, cleavage of the 
covalent bonds in the polymer backbone begins by hydrolysis and, as hydrolysis 
proceeds, more and more carboxylic end-groups may antocatalyse the hydrolysis 
reaction [187]. It was seen an increased number of fibers were broken down into short 
fragments from day 28 (Fig. 4.6F-H), however, they were not easily dissolved in the 
PBS solution, which may explain why there was no significant change in NFS mass 
from day 21 and day 49. (4) After day 49, a significant mass loss in NFS began to 
occur by massive cleavage of the backbone covalent bonds of PLGA till all materials 
were degraded [187]. It was seen on day 70, no fibrous structures were detected and 
only some small pieces of degraded material were left (Fig. 4.6I).   
 
It has been reported that electrospun PLGA [(D,L)PLA:GA = 75:25] are highly 
oriented, but without crystallinity [186] and PLGA degrades prevailingly via 
chemical hydrolysis of the hydrolytically unstable ester bonds into lactic acid and 
   130 
Chapter 4 
glycolic acid [187]. The lactic acid monomer can be eliminated from the body by 
incorporating into the tricarboxylic acid cycle and the glycolic acid monomer is either 
excreted in the urine or enters the tricarboxylic acid cycle [135]. Glycolic acid-rich 
PLGA copolymers are more hydrophilic and degrade faster in aqueous media than 
PLA and lactic acid-rich PLGA copolymers [159]. Previous studies reported that 
electrospun PLGA (75:25) nanofibers underwent 50% mass loss after 3-month 
degradation both in vitro and in vivo [159]. Compared with pure PLGA nanofibers, 
our study revealed that collagen-blended PLGA nanofibers had an accelerated 
degradation rate. This was because collagen degraded faster than synthetic polymers, 
and the incorporation of collagen into NFS increased the surface hydrophilicity of 
NFS, which facilitated water to penetrate through the blended scaffolds and break 
down of the PLGA unstable ester bonds.  
 
The biodegradation profile of Collagen/PLGA blended NFS allows it to degrade at a 
right time and serve as a temporary ECM for wound remodeling and new skin 
regeneration. The collagen on NFS surface was shown to completely degrade by day 
7, which could facilitate the new ECM to be deposited and remodeled in the wounds 
from day 7 according to its natural healing process [189]. Besides, blended NFS were 
able to maintain its nanofibrous ECM-like structures without any fiber rupture in the 
first 14 days. This is very important as both inflammation and proliferation stages 
predominate in the first 14 days [189] and the biomimetic nanofiber architecture with 
a high porosity (79.62%) and a large surface-to-weight ratio (15.2 ± 3.5m2/g) [190] 
could potentially accelerate granulation tissue formation, angiogenesis process, 
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reepithelialization and ECM deposition for wound healing by promoting the adhesion, 
accommodation and functions of inflammatory cells, vascular endothelial cells, 
keratinocytes and fibroblasts etc. In addition, the blended NFS were gradually 
degraded and completely lost its structure and dissolved in PBS by day 70, which 
could match well with the on-going wound remodeling process of synthesis and 
deposition of new ECM in the wounds, which normally starts from day 7 and lasts up 
to 1 year [189]. However, the blended NFS may have an accelerated degradation rate 
in vivo due to the presence of large amounts of enzymes in the wound area including 
proteinases, esterases, gelatinases and carboxypeptidases etc. which could expedite 
the degradation of both collagen and PLGA [135,160,189]. 
 
It was known that cell attachment is an initial and crucial step for anchorage-
dependent cells to migrate, proliferate and differentiate both in vivo and in vitro [191]. 
This study focused on the short-term adhesion (from 10 min to 60 min) of BM-MSCs 
on various substrates at room temperature in order to simulate the environment of an 
operating room. The superior property of CD29 Ab-coupled blended NFS for binding 
BM-MSCs is attributed to three factors. Firstly, the surface nanotopography of NFS is 
believed to be an important contributor to cell attachment since all types of NFS in 
this study demonstrated higher degree of adhesive property for BM-MSCs compared 
with TCP (Fig. 4.9). The presence of nano-scale features, such as ridges, grooves, 
steps and cliffs are known to facilitate cell attachment [134]. It also showed that in 
contrast to TCP, BM-MSCs had a larger contact area on NFS and started to deploy 
their tiny filopodia for attachment on CD29 Ab-coupled blended NFS as early as 30 
   132 
Chapter 4 
min of incubation (Fig. 4.10K). Secondly, incorporation of collagen into synthetic 
polymer NFS has been shown to decrease its surface hydrophobicity and enhance cell 
adhesion by 5.67 % at 30 min and 11.83 % at 60 min. Collagen type I is one principal 
structural and functional protein in natural ECM and is featured with many cell-
recognition sites, such as arginine-glycine-aspartic (RGD) acid sequence, which 
could bind integrin α1β1 and α2β1 expressed on MSCs surface and contribute to the 
attachment of BM-MSCs. Last, the adhesive property of blended NFS for BM-MSCs 
was further enhanced by grafting with CD29 Ab. CD29 antigen is a 130 kDa β1 
subunit of integrin expressed on the cell surface of MSCs. Therefore, functionalized 
NFS coupled with CD29 Ab could specifically recognize and bind CD29 antigen 
expressed on MSCs surface and this specific antigen-antibody interaction started to 
take effect from 20 min and became more obvious at 30 min and 60 min of incubation 
(Fig. 4.9). From this study, CD29 Ab-coupled Collagen/PLGA blended NFS was 
demonstrated to be an efficient captor for BM-MSCs in an ex vivo setting under time 
constraints and subphysiological temperature – room temperature, which was to 




In this study, Collagen/PLGA blended NFS has been successfully fabricated by 
electrospinning technique. Blended NFS showed a well-controlled diameter range at 
nano-scale, a high porosity, appropriate degradation rate and mechanical property for 
skin graft application. Blended NFS was further modified by surface-grafting with 
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CD29 Ab for a rapid and rich attachment of BM-MSCs, which suggested the 
feasibility of promoting the adhesive characteristic of BM-MSCs by manipulating the 
topographical and biochemical properties of the culture substrate. This study suggests 
a great potential of the CD29 Ab-coupled blended NFS as an efficient BM-MSCs 
captor and carrier as well as a cover for skin graft application.  
 
(Note: Some of the results have been published in Biomaterials and they are reprinted 
in this chapter from Biomaterials, 29, Ma K, Chan KC, Liao S, Hwang WYK, Feng Q, 
Ramakrishna S, Electrospun nanofiber scaffolds for rapid and rich capture of bone 
marrow-derived hematopoietic stem cells, 2096-2103, Copyright 2008, with 
permission from Elsevier.) 
 
 




In vivo Study of Nanofiber/Stem cell Composites as Skin 
Grafts for Full-thickness Skin Wounds in a Rat Model 
 
5.1 Introduction  
 
Skin can be injured by physical trauma, thermal, chemical, or pathological etiologies. 
Unlike superficial skin injury or partial-thickness skin loss, full-thickness skin 
wounds are unable to reconstitute the lost skin and restore its function due to the loss 
of both epidermal and dermal layers [1].  The current ‘gold standard’ clinical practice 
is to use of autologous split-thickness skin grafts. However its application is limited 
by the shortage of donor skin and donor site morbidity [6]. In skin tissue engineering, 
synthetic skin grafts have been designed with the aim to replace the use of autologous 
skin grafts. They are typically the biodegradable polymer scaffolds with the 
incorporation of supporting cells such as keratinocytes, fibroblasts and adult stem 
cells, growth factors and ECM [8].  
 
Recent investigations suggest that BM-MSCs may enhance skin regeneration and 
wound healing by transdifferentiating into cells of skin lineage and secreting a large 
number of growth factors and cytokines that are critical for the repair of injured tissue 
[10-12,14-16]. Our previous study (in chapter 3) has shown the differentiation 
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potential of BM-MSCs into the epidermal lineage within a biomimetic skin-specific 
microenvironment. The work in chapter 4 achieved a CD29 Ab-coupled Collagen/ 
PLGA biodegradable NFS for an efficient attachment of BM-MSCs within a short 
time at room temperature. Therefore, in this study, we are going to explore the in vivo 
feasibility and patency of using NFS/BM-MSCs composites to enhance wound 
healing and skin regeneration in an acute full-thickness skin injury model.  
 




PLGA (75:25) copolymer at a molecular weight of 90,000-126,000, HFP, H&E, 
mouse anti-human and rat involucrin Ab, mouse anti-human and rat α-smooth muscle 
actin Ab, FITC-conjugated goat anti-mouse secondary Ab, Sirius red and picric acid 
were all purchased from Sigma-Aldrich, USA. Human BM-MSCs were ordered from 
Cambrex Bio Science Walkersville, Inc., USA. Koken type I collagen powder 
(Medical Grade) was ordered from Koken, Japan. Mouse monoclonal anti-human 
CD29 Ab was purchased from BD Pharmingen, USA. Qtracker655 Cell labeling Kit 
and DAPI were all purchased from Invitrogen Corporation, USA. Mouse anti-rat and 
human CD31 Ab and mouse anti-human and rat keratin 10 and filaggrin antibodies 
were ordered from Thermo Fisher Scientific Inc., USA. Coupling reagents Traut’s 
reagent and Sulfo-SMCC were purchased from Pierce, USA. Tegaderm TM was 
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ordered from pharmacy, National University Hospital, Singapore. Integra® was 




Male Sprague-Dawley (SD) white rats, average weight of 150g-200g, were obtained 
from center for animal resources and housed in the animal holding unit of National 
University of Singapore, Singapore.  Rats consumed both sterile water and standard 
rat chow ad libitum and they were housed at least 1 week before experimental use.  
All procedures for animal experiments were performed in accordance with a protocol 
approved by the Institutional Animal Care and Use Committee at University of 
Singapore. 
 
5.2.3 Skin graft preparation 
 
Skin grafts in all experimental groups include Integra®, unmodified Collagen/PLGA 
blended NFS, CD29 Ab-coupled blended NFS with attached BM-MSCs at two 
different cell densities. For preparation of cell-incorporated skin grafts, 
Collagen/PLGA (1:1) blended NFS were fabricated by electrospinning technique 
(details in section 4.2.2) and modified by grafting of CD29 Ab on its surface with the 
coupling reagents Traut’s reagent and Sulfo-SMCC (details in section 4.2.4). BM-
MSCs of passage 6 at 90% confluence were labeled with 10nmol/l quantum dots 
provided by Qtracker655 Cell labeling Kit for 1h under the standard culture 
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conditions according to the manufacturer’s protocol (appendix A). BM-MSCs were 
then trypsinized, centrifuged, resuspended and seeded at different concentrations of 3 
x 106/100 µl and 3 x 103/100 µl in PBS on the CD29 Ab-coupled blended NFS of 
11mm x 11mm for 30 min at room temperature. After that, the modified NFS were 
washed by PBS three times to remove unattached cells. Then the modified NFS with 
attached BM-MSCs was ready for implantation.   
 
5.2.4 Surgical procedures  
 
The male SD rats (150g-200g) were anesthetized by isoflurane inhalation, and their 
left back were shaved and swabbed with povidine-iodine followed by 70% ethanol. 
The scrubbing was then repeated two more times. Then a sterile template measuring 
10mm x 10 mm was placed on the skin and the outline was traced using a sterile fine 
felt-tipped pen. The medial border of the template was oriented parallel to the sagittal 
axis of the animal. Full-thickness wounds of 10mm x 10mm were made by excising 
the skin within the confines of the square down to the level of subcutaneous 
panniculus carnosus. All dissections were performed using sterile forceps, size 15 
scalpel blades, and curved scissors, with particular care taken to ensure that the 
wound edges were sharply defined and not contused. There were five kinds of 
treatments for these full-thickness skin wounds, summerized in table 5.1. Negative 
control group 1 received neither NFS nor cells, group 2 received Integra® skin graft 
and group 3 received only blended NFS. Sterile NFS/BM-MSCs skin grafts (11mm x 
11mm) were placed and sutured over the wound with BM-MSCs in direct contact 
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with the wound bed in group 4 (3 x 103/100 µl of BM-MSCs) and group 5 (3 x 
106/100 µl of BM-MSCs). After that, the sterile transparent Tegaderm dressings were 
punctured gently with sterile needles to allow wounds for air exposure and then 
placed and sutured over the wounds. After the surgery, each animal was placed in one 
cage. Post-surgery care included analgesic and antibiotic injections. For group 4 and 5, 
immunosuppressive drug Tacrolimus was given every day at 1mg/kg by oral gavage. 
Checking of any post-surgery pain, distress or complications was done 24h after 
surgery and daily afterwards. Then on post-operative day 5 and day 10, two rats in 
group 2 (due to the high cost of Integra® skin grafts) and four rats in other groups 
were euthanized respectively and the reconstituted skin was excised for histology and 
immunostaining analysis and collagen synthesis evaluations. The left two rats in each 
group were not euthanized until the wounds were closed to observe the time required 
for wound healing in different groups.   
 
Table 5.1 Description of in vivo experimental groups. 
Group Treatment Number of SD rats 








2 Integra®  
 
6 
3 Receive NFS only 
 
10 
4 Receive Cell-enriched NFS  
(low cell density) 
 
10 
5 Receive Cell-enriched NFS  
(high cell density) 
 
10 




5.2.5 Wound size measurements 
 
Wounds were inspected, measured and photographed against the backdrop of a metric 
ruler on post-operative day 1, 3, 5, 7, 10, 12 and 14 using a high resolution digital 
camera (Nikon COOLPIX L5, Japan). On day 10, the rat hairs srounding the wounds 
were gently shaved before photographs were taken in order to capture images with 
clear wound contours. The un-epithelialized wound area was measured with the 
image analysis software (ImageJ) and is defined by the limits of grossly evident 
epithelialization, with all surface areas in a 2D plane calibrated against the adjacent 
metric ruler. Percentage of un-epithelialized wound area was defined as follows: 
Ax/A0 x 100% where A0 is the un-epithelialized wound area on day 0 and Ax is the 
un-epithelialized wound area on post-operative day x.   
 
5.2.6 Histological and immunological analyses 
 
The reconstituted skin was cut to the control depth determined as the excision down 
to the level of panniculus carnosus, and fixed in 4% paraformaldehyde at 4°C for 5 
days, dehydrated and then paraffin-embedded. Serial 10 μm paraffin sections were 
cut with a rotating microtome (MICROM) and stained with H&E according to routine 
histology protocol (appendix B). The wounds were evaluated for the presence of 
epithelialization, hyperkeratosis, fibroplasias, vascular hyperplasia, and adnexa etc. 
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according to the histomorphologic scale [192] in table 5.2. 
 
Table 5.2 Histomorphologic scale. Total score=sum of individual scores. Best 
possible outcome = 10, worst outcome = 0. (Adapted from [192], Copyright 2000, 
with permission from Wiley-Blackwell). 
 
Epithelialization  Fibroplasias  




Hyperkeratosis  Collagen Orientation  
Absent 1 Normal 3 
Present 0 Abnormal collagen in the papillary dermis only  2 
  Abnormal collagen in the upper reticular and papillary 
dermis   
1 




Hair Follicles  Vascular Hyperplasia  




Sebaceous Glands  Smooth Muscles  





Immunological analysis was performed using primary antibodies specific for human 
and rat CD31 (a marker of angiogenesis) [193], keratin 10 (an early marker of 
epidermal differentiation), filaggrin (an intermediate marker of epidermal 
differentiation), involucrin (a terminal marker of epidermal differentiation) [167,169] 
and α-smooth muscle actin (a marker for wound myofibroblasts) [194]. Antigen 
retrieval was achieved by pretreatment of the samples in 10 mM Citrate Buffer 
(pH=6.0) at 95°C for 20 min and cooling down the samples at room temperature for 
20 min. Subsequently, the samples were blocked by 2% BSA and incubated with 
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primary antibodies overnight at 4°C, followed by washing and incubation of FITC-
conjugated secondary Ab. Finally, the samples were counterstained with DAPI. Then 
H&E stained sections were observed under a phase contrast microscope (Leica DM 
IRB, ebq 100). Samples with Ab incubation were observed under a confocal laser 
microscope (FV 1000, Olympus). 
 
5.2.7 Quantification of the collagen synthesis 
 
Quantification of collagen synthesis and deposition in wounded site was performed 
according to the method described in [159]. Briefly, half size of the specimen (0.5cm 
x 1cm) were washed three times by PBS and fixed in 4% formalin. Following three 
washes with PBS, the samples were stained for collagen deposition in a 0.1% solution 
of Sirius Red F3B (C.I. 35780, Direct Red 80, Sigma-Aldrich) in saturated picric acid 
for 18 h. As collagen is a basic protein, the sulphonic groups of the dye interact at low 
pH with the amino groups of the lysine and hydroxylysine and the guanidine groups 
of arginine. Afterwards, the samples were washed with tap water until no more red 
color was eluted. For a quantitative analysis, the stain from samples was then eluted 
with 500µl of a destain solution (0.2 M NaOH/methanol 1:1) for 15 min. The optical 
density at 490 nm was then measured using a plate reader spectrophotometer.    
 
5.2.8 Statistical analysis 
 
All tests were performed using at least 3 samples in each group. The results are 
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averaged and expressed as mean ± standard deviation. Statistical differences were 
determined by two-way ANOVA. Differences were considered statistically 





   
All animals were kept in individual cages throughout the experimental periods. No 
postoperative adverse effects such as infection, pyogenesis and body fluid effusion 
occurred in any animals. Diet, drinking and defecation were normal. All animals 
survived until the completion of the study. By day 18, wounds had closed in all 
groups.  
 
5.3.2 Wound size measurements  
 
From Fig. 5.1, it was seen that among all experimental groups, Integra® (purple line) 
shows the lowest healing rate, especially in the initial 10 days. This was most 
probably because in adult mammalians, spontaneous wound contraction plays an 
important role in wound closure [1], while the non-biodegradable silicone layer of 
Integra® significantly impeded the wound contraction and therefore delayed the 
wound healing process. On day 10, according to its indication, the upper silicone 
layer of Integra® was ready to be removed and then we can see a significant decrease 
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(p < 0.05) in un-epithelialized wound area after day 10. Compared with the negative 
control group (dark blue line), all NFS-incorporated groups promoted wound healing 
process from day 1 to day 14. On day 14 and day 15, wounds in NFS group with a 
low cell density and pure NFS group were fully reepithelialized, respectively (data 
not shown). In contrast, it took 18 days for the wounds in the negative control group 
and Integra® group to become completely closed (data not shown). When a large 
amount of BM-MSCs were applied onto NFS (blue line), this composite skin graft 
was found to significantly decrease the un-epithelialzed wound area from day 1 to 
day 10 (p < 0.05). In this NFS group with a high cell density, as 4 rats were sacrificed 
on day 5 for histological analysis, the wounds in 4 of the remaining 6 rats were found 
to be completely healed on day 10, while wounds in the other 2 rats were healed on 
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Fig. 5.1 Percentages of un-epithelialized wound area in different groups from day 1 to 
day 14.  
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Fig. 5.2 shows clearly the appearances of wound sites in different groups. On day 0, a 
full-thickness skin wound of 1cm x 1cm was made in every group. On day 10, hairs 
were all grown in the surrounding area of un-epithelialized wounds in all groups. In 
order to take photos of the un-epithelialized wound area with clear contours, the 
surrounding hair in some groups were shaved. On day 10, the largest un-epithelialized 
wound (98.69%) was found in Integra® group, followed by the control group 
(23.57%). In pure NFS group and NFS group with a low cell density, 14.8% and 
13.69% of wounds remained un-epithelialized, respectively. In contrast, the wound in 
NFS group with a higher cell density was completely closed.   
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Fig. 5.2 Appearances of wounds in different groups on day 0 and day 10.  
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5.3.3 Histological analyses  
 
The H&E histological staining of wounds at the edge just beside normal surrounding 
tissue in different groups on post-operative day 5 and day 10 are shown in Fig 5.3 and 
Fig. 5.4, respectively. On day 5 (Fig. 5.3), the wound surface in negative control 
group was ulcerated with fibrinous exudates on top of a layer with dense infiltration 
of inflammatory cells and proliferation of fibroblasts. In contrast, fibrinous debris 
were not seen in the wound surface of Integra®, pure NFS group and NFS group with 
a low cell density. Wound in Integra® group was characterized by very loose 
connective tissue with infiltrated inflammatory cells and proliferated fibroblasts, 
while wounds in pure NFS group and NFS group with a low cell density were 
predominated by the granulation tissue characterized by capillary proliferation in a 
background of inflammatory cells and fibroblasts. Compared with the above groups, 
NFS group with a high cell density was the only group in which reepithelialization 
occured, as shown by the epithelial tongue pushing outwards the fibrinous debris and 
progressing over the wound area.    
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Fig. 5.3 Histology of wounds by H&E staining in different groups on post-operative 
day 5. Scale bars: 100 µm (left column), 50 µm (right column). Abbreviations: FD − 
fibrinous debris; CP − capillary; ET − epithelial tongue.  
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On day 10 (Fig 5.4), necrotic fibrinoid debris, inflammatory infiltration, fibroblast 
and capillary hyperproliferation were still seen in the negative group, indicating 
inflammation remained in this group. Integra® group had more collagen deposition 
on day 10 compared with day 5, but with abnormal orientation and a loose structure. 
Capillary and fibroblast hyperproliferation were also visible in the loose connective 
tissue of Integra® group. Compared with the control and Integra® groups, wounds in 
all NFS-incorporated groups demonstrated reepithelialization without capillary 
hyperplasia. However, a thick layer of keratinocytes were seen in NFS group and 
NFS group with a low cell density. In contrast, a thinner layer of keratinocytes which 
is comparable to normal skin tissue was formed in NFS group with a high cell density. 
Besides, normal orientation of collagen and several skin accessory structures such as 
hair follicles and sebaceous glands were very well established in NFS group with a 
high cell density and no capillary or fibroblast hyperplasia was found in this group, 
which indicated the regeneration of epidermal and dermal structures in the NFS group 
with a high cell density on day 10.      
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Fig. 5.4 Histology of wounds by H&E staining in different groups on post-operative 
day 10. Scale bars: 100 µm (left column), 50 µm (right column). Abbreviations: FD − 
fibrinous debris; CP − capillary; EP − epithelialization; HF − hair follicle; SB − 
sebaceous gland. 
 
The histology of wounds in different groups was further scored according to the 
histomorphologic scale in Table 5.2. The scores range from 0 to 10, indicating the 
histomorphology from worst scarring to normal structure, respectively. The scores in 
all groups on day 5 and day 10 are shown in Table 5.3 and the total score for each 
group is shown in Fig. 5.5. From it, we can see the control group had the lowest 
scores on both day 5 and day 10. On day 10, compared with the control and Integra® 
groups, all NFS-incorporated groups had promoted healing effects in terms of 
histomorphology. Among them, the NFS group with a high cell density demonstrated 
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Table 5.3 Histomorphologic scores of different groups on post-operative day 5 and 
day 10. 
 
Score (Day 5 / Day 10) 
 
 Control Integra® NFS NFS + Low 
Cell  
Density 







0 / 0 
 
0 / 0 
 
0 / 1 
 





1 / 1 1 / 1 1 / 1 1 / 1 1 / 1 
Hair Follicles 
 
0 / 0 0 / 0 0 / 0 0 / 0 0 / 1 
Sebaceous Glands 
 
0 / 0 0 / 0 0 / 0 0 / 0 0 / 1 
Fibroplasias 
 








0 / 0 0 / 0 0 / 1 0 / 1 0 / 1 
Smooth Muscles 
 
0 / 0 0 / 0 0 / 0 0 / 0 0 / 1 
      



































Fig. 5.5 The total histomorphologic scores of different groups on post-operative day 5 
and day 10. 
                                                  
5.3.4 Immunological analyses 
 
Fig. 5.6 – Fig. 5.10 show the immunofluorescence staining of CD31, Keratin 10, 
Filaggrin, Involucrin and α-smooth muscle actin, respectively on post-operative day 
10. CD31, also called platelet endothelial cell adhesion molecule-1 (PECAM-1), is a 
marker of angiogenesis, expressed on the surface of circulating platelets, monocytes, 
neutrophils, selected T cell subsets and endothelial cells [193,195]. Compared with 
the normal skin (Fig. 5.6A), CD31 was seen to be expressed in all experimental 
groups, indicated by the capillary formation and blood cell infiltration with green 
fluorescence in the neo-dermis (Fig.5.6 C, E, G, J, M). The overlay images with 
DAPI staining showed the cell nuclei with blue fluorescence of the surrounding 
fibroblasts and inflammatory cells in the granulation tissue (Fig. 5.6 B, D, F, H). BM-
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MSCs were detected with red fluorescence in NFS with a low-cell density (Fig. 5.6I) 
and they were found to be co-located with the expression of CD31 in some of the 
blood cells and endothelial cells (Fig.5.6J and K). In NFS group with a high cell 
density, more pre-labeled BM-MSCs with red fluorescence were found in the neo-
dermis and similarly, they were co-located with the expression of CD31 in some 
blood cells (Fig. 5.6M and N). It indicates BM-MSCs may differentiate into 
endothelial and blood lineages under local specific wounding microenvironment.  
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Overlay image  



























   155 
Chapter 5 






Overlay image  

























Fig. 5.6 Immunofluoresence staining of CD31 in the granulation tissue or neo-dermis 
of different experimental groups on post-operative day 10. A, C, E, G: Staining of 
CD31 with green fluorescence by anti-rat and human CD31 antibody and FITC-
conjugated secondary antibody. B, D, F, H: Overlay images of A, C, E, G with the 
nuclear staining by DAPI (blue fluorescence), respectively. I, L: Quantum dot-labeled 
BM-MSCs with red fluorescence. J, M: Overlay images of I, L with the staining of 
CD31. K, N: Overlay images of J, M with nuclear staining by DAPI (blue 
fluorescence). Scale bars: 50 µm.     
 
 
From Fig. 5.7, we can see that keratin 10, an early epidermal differentiation marker 
[53], was expressed in the suprabasal epidermis in the normal skin group, 
demonstrated by the upper thin layers of keratinocytes with green fluorescence (Fig. 
5.7A). Its overlay image with DAPI staining shows the nuclei of keratinocytes and 
dermal fibroblasts and the boundary between epidermal and dermal layer indicated by 
the white dash line (Fig.5.7B). However, there was no positive staining of keratin 10 
in the negative control and Integra® groups on day 10 (Fig.5.7C and E). The overlay 
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image of the negative control group in Fig. 5.7D shows many small nuclei of dead 
cells on the wound surface. In contrast, keratin 10 was expressed in all NFS-
incorporated groups, evidenced by the green fluorescence on top of the neo-dermis 
(Fig. 5.7G, J and M). Among them, a thickened layer of keratinocytes with positive 
keratin 10 staining was shown in pure NFS group (Fig. 5.7G) and NFS group with a 
low cell density (Fig. 5.7J), indicating the proliferating stage of the keratinocytes, 
while a thin layer of keratinocytes with keratin 10 expression was established in the 
NFS group with a high cell density on post-operative day 10 (Fig. 5.7M). In addition, 
compared with normal skin (Fig. 5.7B), the overlay images of Fig. 5.7H and Fig. 
5.7K show increased nuclei of proliferated keratinocytes, fibroblasts and 
inflammatory cells in pure NFS group and NFS group with a low cell density, 
respectively. However, in the NFS group with a high cell density, fewer nuclei of 
keratinocytes and fibroblasts were seen on day 10 (Fig. 5.7N), which can be 
comparable to normal skin (Fig. 5.7B). In cell-incorporated groups, BM-MSCs pre-
labeled by quantum dots were traced and shown by red fluorescence in Fig. 5.7I and 
Fig. 5.7L. In NFS group with a low cell density, labeled MSCs were found to be in 
the neo-epidermis and co-located with the expression of keratin 10 (Fig. 5.7J). In NFS 
group with a high cell density, more MSCs with quantum dots labeling (Fig. 5.7L) 
were found than those in the group with a low cell density and the labeled MSCs were 
present in both neo-dermis and neo-epidermis with the co-location of keratin 10 
expression (Fig. 5.7M and N).   
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Fig. 5.7 Immunofluoresence staining of keratin 10 in the epidermis of different 
experimental groups on post-operative day 10. A, C, E, G: Staining of keratin 10 with 
green fluorescence by anti-rat and human keratin 10 antibody and FITC-conjugated 
secondary antibody. B, D, F, H: Overlay images of A, C, E, G with the nuclear 
staining by DAPI (blue fluorescence), respectively. I, L: Quantum dot-labeled BM-
MSCs with red fluorescence. J, M: Overlay images of I, L with the staining of keratin 
10. K, N: Overlay images of J, M with nuclear staining by DAPI (blue fluorescence). 
White dash line: boundary between epidermis and dermis. Scale bars: 50 µm.     
 
Fig. 5.8 demonstrates the immunofluorescence staining of filaggrin, the intermediate 
epidermal differentiation marker [167,169], in different groups on day 10. It shows 
the normal expression of filaggrin in the upper suprabasal layer of epidermis in the 
normal skin group (Fig. 5.8A). In other experimental groups, positive staining of 
filaggrin was only found in the NFS group with a high cell density, showed by a thin 
epidermal layer with green fluorescence in the upper neo-epidermis (Fig. 5.8M). 
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Additionally, MSCs labeled by quantum dots with red fluorescence were visible in 
the neo-epidermis of both cell-incorporated groups (Fig. 5.8I and L) and especially, 
they were found to be co-located with the expression of filaggrin in the NFS group 
with a high cell density (Fig. 5.8N).   
 
The immunofluorescence staining of involucrin, the terminal marker of epidermal 
differentiation [167,169], is shown in Fig. 5.9.  A slight expression of involucrin with 
green fluoresence was found in the cornified layer of normal skin (Fig. 5.9A), while 
no other experimental groups expressed involucrin (Fig. 5.9C, E, G and J) except the 
NFS group with a high cell density, which demonstrated a strong expression of 
involucrin in the cornified envelope of neo-epidermis (Fig. 5.9M). BM-MSCs pre-
labeled by quantum dots were clearly seen with red fluorescence in the cell-
incorporated groups (Fig. 5.9I and L). In NFS group with a low cell density, labeled 
MSCs were found to locate in the neo-epidermis (Fig. 5.9K). In NFS group with a 
high cell density, MSCs were seen to disperse in both dermis and epidermis. However, 
no labeled MSCs were found to be co-located with the expression of involucrin (Fig. 
5.9N).     
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Fig. 5.8 Immunofluoresence staining of filaggrin in the epidermis of different 
experimental groups on post-operative day 10. A, C, E, G: Staining of filaggrin with 
green fluorescence by anti-rat and human filaggrin antibody and FITC-conjugated 
secondary antibody. B, D, F, H: Overlay images of A, C, E, G with the nuclear 
staining by DAPI (blue fluorescence), respectively. I, L: Quantum dot-labeled BM-
MSCs with red fluorescence. J, M: Overlay images of I, L with the staining of 
filaggrin. K, N: Overlay images of J, M with nuclear staining by DAPI (blue 
fluorescence). White dash line: boundary between epidermis and dermis. Scale bars: 
50 µm.     
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Fig. 5.9 Immunofluoresence staining of involucrin in the epidermis of different 
experimental groups on post-operative day 10. A, C, E, G: Staining of involucrin with 
green fluorescence by anti-rat and human involucrin antibody and FITC-conjugated 
secondary antibody. B, D, F, H: Overlay images of A, C, E, G with the nuclear 
staining by DAPI (blue fluorescence), respectively. I, L: Quantum dot-labeled BM-
MSCs with red fluorescence. J, M: Overlay images of I, L with the staining of 
involucrin. K, N: Overlay images of J, M with nuclear staining by DAPI (blue 
fluorescence). White dash line: boundary between epidermis and dermis. Scale bars: 
50 µm.     
 
Fig. 5.10 shows the immunofluorescence staining of α-smooth muscle actin, a 
specific marker for wound myofibroblasts [194] in different groups on day 10. It was 
found there was no myofibroblast marker expression in normal skin (Fig. 5.10A), 
whereas numerous spindle-shaped myofibroblasts with green fluoresence were seen 
in the negative control group (Fig. 5.10C) and NFS group (Fig. 5.10G).  In the 
Integra® group, a few myofibroblasts with positive staining were found to loosely 
disperse in the connective tissue (Fig. 5.10E). Compared with the negative control 
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group (Fig. 5.10C) and pure NFS group (Fig. 5.10G), NFS groups with a low cell 
density of MSCs demonstrated a reduced amount of myofibroblasts in the connective 
tissue (Fig. 5.10J), and the number of myofibroblasts were much decreased with the 
increase in the cell density of MSCs incorporated in NFS graft, showed by a small 
number of myofibroblasts in the NFS group with a high density of MSCs (Fig. 
5.10M). Quantum dot-labeled BM-MSCs were found in the neo-dermis with red 
fluorescence in both NFS groups with a low cell density (Fig. 5.10I) and a high cell 
density (Fig. 5.10L), however, none of the pre-labeled MSCs were found to be co-
located with the expression of myofibroblast marker (Fig. 5.10J and M).   
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Fig. 5.10 Immunofluoresence staining of α-smooth muscle actin in the granulation 
tissue or neo-dermis of different experimental groups on post-operative day 10. A, C, 
E, G: Staining of α-smooth muscle actin with green fluorescence by anti-rat and 
human α-smooth muscle actin antibody and FITC-conjugated secondary antibody. B, 
D, F, H: Overlay images of A, C, E, G with the nuclear staining by DAPI (blue 
fluorescence), respectively. I, L: Quantum dot-labeled BM-MSCs with red 
fluorescence. J, M: Overlay images of I, L with the staining of α-smooth muscle actin. 
K, N: Overlay images of J, M with nuclear staining by DAPI (blue fluorescence). 
Scale bars: 50 µm.     
 
 
Table 5.4 summerizes the results of immunofluoresence staining for all groups on day 
10. CD31 was expressed in all groups, indicating angiogenesis occurred in every 
group on post-operative day 10. However, keratin 10, the early marker of epidermal 
differentiation, was only expressed in NFS-incorporated groups besides normal skin. 
In contrast, filaggrin and involucrin, the intermediate and terminal epidermal 
differentiation markers, were found to be expressed only in NFS group with a high 
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cell density. Addtionally, the expressions of keratin 10 and filaggrin were found to be 
co-located with quantum dot-labeled MSCs in cell-incorporated NFS groups, while 
involucrin was not found to be co-located with any quantum dot-labeled MSCs in any 
of the cell-incorporated NFS groups. α-smooth muscle actin, indicative of wound 
myofibroblasts was found to be expressed in all groups except the normal skin group. 
Prelabeled MSCs were not shown to be co-located with the expression of α-smooth 
muscle actin. These results indicated the participation of BM-MSCs in angiogenesis 
process and epidermal lineage differentiation at early and intermediate stages.  
 
Table 5.4 Summary of immunofluoresence staining of CD31, keratin 10, filaggrin, 
involucrin and α-smooth muscle actin in different experimental groups on post-
operative day 10. + : Positive immunofluorescence staining. − : Negative 
immunofluorescence staining. √ : Co-location of quantum dot-labeled BM-MSCs 
with expressed marker protein. × : No Co-location of quantum dot-labeled BM-MSCs 




Control Integra® NFS NFS  NFS  





       
CD31 + + + + + / √ + / √ 
 
Keratin 10 + + + + / √ −  −  
 
Filaggrin + + / √ −  −  −  −  
 
Involucrin + + / × −  −  −  −  
 
+ + + α-smooth 
muscle 
actin 
+/ × +/ × − 
 
 
5.3.5 Quantification of collagen synthesis 
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Fig. 5.11 shows that more collagen was synthesized over time after wounding in all 
experimental groups. Compared with the control group, all NFS-incorporated groups 
demonstrated a higher amount of collagen expression (p < 0.05). However, the 
amount of collagen in pure NFS group was a little lower than that in the Integra® 
group. This is most probably because the initial collagen concentration in the 
Integra® skin graft was higher than that in pure NFS graft. In addition, BM-MSCs 
also contributed to the expression of collagen even though if a small amount of BM-
MSCs were incorporated, as shown by the increase of  absorbance in NFS group with 
a low cell density compared with the pure NFS groups on both day 5 and day 10 (p < 
0.05). When a large amount of BM-MSCs were incorporated in NFS, we can see a 
significant increase in collagen expression on day 10 if compared with other groups 
(p < 0.05).   
 
 
Fig. 5.11 Characterization of collagen synthesis using picrosirius red staining in 
different experimental groups on post-operative day 5 (blue) and day 10 (red). * 
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In full thickness-skin wounds, such as deep thermal injury or severe trauma, because 
of the complete loss of skin tissue including epidemis, skin appendages and dermis, 
the remaining soft tissues are unable to reconstitute the lost skin and restore its 
functions [1]. The biological response to wounds in higher organisms fall into two 
categories: regeneration and wound repair. Regeneration involves the gross 
replacement and restoration of adult tissue mass with normal architecture and 
function, whereas wound repair involves the migration of fibroblasts to the wound 
site, the formation of granulation tissue, and the laying down of collagen in a 
disorganized fashion with formation of scar tissue [196]. Scar tissue is preferable to 
no healing. However, the scar tissue is not fully functional, cross-linked with only 
80% of the tensile strength of the tissue it replaces and aesthetically disfiguring [5]. 
Therefore, how to promote skin regeneration and achieve a scarless wound closure 
with restoration of the original tissue function and structure has become a very 
important area in treating full-thickness skin wounds.  
 
In the present study, we used a murine model to investigate the healing process of 
acute full-thickness wounds under different treatments. Rats were employed because 
they can provide a suitable area of skin large enough for wound studies. Another 
important reason is the availability of a broad knowledge base on rat wound healing 
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gained from years of previous research [197]. Wound size is another important 
consideration in the study of wounds.  Cross et al. found that metabolic and physical 
stress of a large wound relative to total body surface area will independently 
influence the results of the wound healing research [198]. Cross et al. chose to use a 
15 mm x 15 mm wound rather than 20 mm x 20 mm wounds on 200- to 350- gram 
adult female Hooded Lister rats [198]. Based on this knowledge, we chose to make a 
full-thickness wound of 10 mm x 10 mm on each male SD rat of 150g-200g in this 
study.  
 
The combined application of NFS and a high cell density of BM-MSCs to the acute 
full-thickness wound of 10 mm x 10 mm in a rat model achieved successful wound 
healing and skin regeneration by day 10, which was 8 days earlier than the control 
group and Integra® group. On day 10, the reconstructed skin in this NFS group with 
a high cell density demonstrated an intact epithelium with the formation of new hair 
follicles and sebaceous glands, normal collagen deposition without scar formation, 
which were reminiscent of the structures of normal skin. In contrast, the newly-
formed skin appendages including hair follicles and sebaceous glands, and collagen 
deposition with normal orientation were not seen in all other experimental groups. 
Besides, the epithelialization did not occur in the control and Integra® groups on day 
10 (Fig. 5.4). The enhanced efficacy on promoting wound healing and skin 
regeneration in the NFS group with a high cell density was attributed to both of the 
scaffold and cellular components, namely, NFS and BM-MSCs.     
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In native skin tissue, collagen type I is a major component of ECM proteins exsiting 
in a 3D network structure composed of multi-fibrils in the nanofiber scale (50-500 nm) 
[32,139]. Our collagen/PLGA blended NFS with a well-controlled diameter 
distribution ranging from 250 to 500 nm mimicks the natural ECM both structurally 
and functionally. Its large surface-to-weight ratio of 15.2 ± 3.5m2/g [190] and a high 
porosity of 79.62% facilitated the cellular invasion and adhesion, capillary growth, 
nutrition delivery, gas exchange and waste excretion, and thereby accelerated the 
wound healing process. In this study, compared with the control group which was 
characterized with the fibrinous eschar on the wound surface, fibrinous debris has 
disappeared and given way to ample granulation tissue in the pure NFS group on day 
5 (Fig. 5.3). These results were in agreement with Rho et al.’s previous report that in 
a rat model, the early-stage healing of full-thickness skin wounds in the collagen NFS 
group was faster than that of the negative control group. In the 1-week negative 
control group, the wound surface was covered by fibrinous necrotic tissue and below 
that layer, dense infiltration of polymorphonuclear leukocytes and proliferation of 
fibroblasts were found. In the 1-week collagen NFS group, however, the surface 
tissue debris disappeared, and there was prominent proliferation of young capillaries 
and fibroblasts [139]. Both of our and Rho et al.’s studies suggest that NFS with a 
large surface area and a high porosity would facilitate the rapid adhesion and rich 
recruitment of wound healing − involved inflammatory cells, including lymphocytes 
and macrophages etc. to the wound area to break down the fibrin clot, endocytose the 
dead cells and accelerate the formation of granulation tissue. In our study, the effect 
of NFS on expediting wound healing process was continuously seen on day 10, when 
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reepithelialization only occurred in NFS-incorporated groups compared with the 
control and Integra® groups (Fig. 5.4). Additionally, compared with the control group, 
more collagen was deposited to the wounded area on day 10 than on day 5 in pure 
NFS group, which indicated NFS was able to serve as a provisional matrix to 
facilitate the accommodation and proliferation of fibroblasts as well as the deposition 
of collagen expressed by resided fibroblasts in the neo-dermis.  
 
In adult mammalians, spontaneous wound contraction plays an important role in the 
wound closure [1] and it was more seen in the loose-skinned animals like rodent and 
rabbit, than the tight-skinned animals, such as domestic pig [59]. This may explain 
why the wound dimensions reduced on both day 5 and day 10 in the negative control 
group even without the establishment of reepithelialization in the present study. 
Whereas in the Integra® group, the wound size remained almost unchanged until the 
upper silicone layer was removed on day 10. Integra® is a bi-layer skin replacement 
designed to provide immediate wound closure and permanent regeneration of dermis 
in deep partial-thickness or full-thickness skin injury. Its dermal replacement layer is 
made of a 3D porous matrix of cross-linked bovine tendon collagen and GAGs 
(chondroitin-6-sulfate). The epidermal substitute, however, is a temporary layer made 
of synthetic polysiloxane polymer (silicone) in order to control moisture loss from the 
wound, and this layer needs to be removed typically on post-operative day 14 to day 
21 in human and sometimes needs to be further replaced with an ultrathin epidermal 
autograft especially in an extensive deep wound (cited from Integra® treatment 
guidelines). In this study, this non-biodegradable and stiff epidermal layer made of 
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silicone was found to significantly delay the wound healing process by hindering the 
spontaneous wound contraction. On day 10, this silicone layer was ready to be 
removed according to its guidelines: first, neo-dermis blanched to the touch and 
returned to an orange/peachy or vanilla color upon finger release; Second, silicone 
wrinkled and begun to detach; third, granulation tissue had formed at seam lines. 
After the silicone layer was removed, a dramatic decrease in wound size was seen 
from day 10 and complete wound closure was achieved on day 18 in the Integra® 
group, which was 3 to 8 days later than different NFS-incorporated groups. Those 
results indicate that even though wound contraction is not a desirable way to achieve 
wound healing, it does play an important role in wound closure for adult mammalians, 
including both human and rodent. Wound contraction is preferable to delayed or no 
healing and is acceptable if there is no scar or contracture formed. In contrast to the 
Integra®, the Collagen/PLGA blended NFS is a suitable biodegradable skin graft for 
permanent wound coverage with one-step operative procedures. It was found to well 
adapt to the wound contraction and promote healing process throughout the whole 
experimental period if compared with the control and Integra® groups. One possible 
reason why blended NFS did not inhibit wound contraction as Integra® did and 
continuously promoted wound healing is that the blended NFS had an appropriate 
degradation profile to match the healing rate in damaged skin tissue, and supported 
keratinocyte, fibroblast and endothelial cell growth and ECM production with 
evidence of new collagen production. Our previous study in chapter 4 showed that the 
blended NFS started to have fiber breakage from day 14 and completely lost its 
structure and dissolved in PBS on day 70. In this study, however, we can not clearly 
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identify the implanted NFS in wounded area either by naked eyes or by H&E staining 
or SEM micrograph on day 5 and day 10, as it was completely blocked by the ample 
secretion and thick deposition of ECM proteins. Even though it is hard to precisely 
know the degradation profile of blended NFS in vivo, we presume that blended NFS 
had a faster degradation rate in vivo than in vitro due to the presence of large amounts 
of enzymes in the wound area including proteinases, esterases, gelatinase and 
carboxypeptidases etc. expressed by the inflammatory cells, endothelial cells as well 
as fibroblasts and keratinocytes, which would expedite the degradation of both 
collagen and PLGA [135,160,189]. 
 
The cellular component of our composite skin graft, namely BM-MSCs, is another 
important contributor to the promoted wound healing and skin regeneration in the 
NFS group with a high cell density. There are several roles that BM-MSCs may play 
in promoting the cutaneous wound healing. In this study, it was seen that 
reepithelialization only occurred in the group with a high cell density of BM-MSCs 
on day 5. This early appearance of reepithelialization was most likely due to the 
strong chemotactic interactions between the implanted BM-MSCs and the 
keratinocytes from the wound edges. Akino et al.’s previous study reported a 
significantly high affinity and migration between BM-MSCs and epidermal 
keratinocytes if compared with that between BM-MSCs and dermal fibroblasts or 
between BM-MSCs and endothelial cells [199]. Akino et al. also found that the 
significant cell migration between BM-MSCs and keratinocytes was inhibited by H-
89, a PKA pathway inhibitor, which indicated this epithelial-mesenchymal cell 
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migration was possibly chemotactic in nature [199,200]. However, in the current 
study, the reepithelialization was not seen in the NFS group with a low cell density on 
day 5, which indicated the cell number of BM-MSCs in this group was too low to 
initiate a strong attraction towards the surrounding keratinocytes for 
reepithelialization to occur. Therefore, the benefit of BM-MSCs to accelerating 
reepithelialization is in a dose-dependent manner. In the NFS group with a low cell 
density, a small cell number of 3x103 BM-MSCs was used in order to emulate the 
maximum number of BM-MSCs that can be isolated from 1 ml human bone marrow 
for the application to 1cm2 wound, based on the findings of 2x107−3x107 nucleated 
cells in 1ml bone marrow [201] and 0.001%−0.01% BM-MSCs in total nucleated 
cells [83]. The effect of a small amount of captured BM-MSCs (1.8x103 MSCs for 
1cm2 wound based on the adhesion efficiency of 60.22% in chapter 4) on promoting 
wound closure by epithelialization was not obvious. However, when a large amount 
of attached BM-MSCs (1.8x106 MSCs for 1cm2 wound based on the adhesion 
efficiency of 60.22% in chapter 4) was incorporated to the NFS skin graft and 
delivered to the wound, the migration of the surrounding epidermal keratinocytes 
towards the wound center was significantly promoted. 
 
BM-MSCs are nonhematopoietic multipotent stem cells that are capable of 
differentiating into both mesenchymal and nonmesenchymal lineages [83-88]. 
However, there is no specific single marker to clearly define MSCs. In this study, we 
used quantum dots (Qtracker655 Cell labeling Kit) to label human BM-MSCs before 
implantation to the wounds. On post-operative day 10, BM-MSCs were detected with 
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red fluorescence in both reconstituted epidermis and dermis, which indicated that 
BM-MSCs from the NFS skin graft integrated well with the host tissue. Besides, the 
labeled human BM-MSCs in red were found to be co-located with the expression of 
keratin 10 and filaggrin, the early [53] and intermediate [167,169] epidermal 
differentiation markers, respectively, which suggests BM-MSCs may undergo the 
epidermal differentiation lineage, though at early and middle differentiation stages. 
This result was in agreement with our previous in vitro study (see Chapter 3), in 
which BM-MSCs were induced into epidermal lineage with the expression of keratin 
10 and filaggrin by optimizing the culture conditions in organotypic culture. All of 
these data from both in vitro and in vivo studies indicate BM-MSCs were capable of 
differentiating into epidermal lineage within specific wounding environment.  
 
Using the Cre/lox system together with β-galactosidase, enhanced GFP expression 
and FISH analysis, several studies have found that bone marrow-derived stem cells 
(including BM-MSCs) differentiated into epithelial cells in the skin, liver, and lungs 
in vivo without cell fusion [10,14,125],  although one study suggested that cell fusion 
might account for the switch to an epidermal phenotype of BM-MSCs during 
epithelium repair [126].  The epidermal differentiation potential of BM-MSCs was 
further confirmed by Nakagawa et al.’s study in which they transplanted human BM-
MSCs and basic FGF to a full-thickness skin and soft tissue defect in a nude rat 
model and detected the expression of human pancytokeratin, which did not cross-
react with rat antigens, by western blotting from the reconstituted tissue [128], which 
was consistent to our results in this study. However, pancytokeratin Ab provided a 
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broad spectrum of reactivities with many keratins at different molecular weights and 
thereby it was difficult to detect the specific differentiation stage shown by the 
expression of specific marker protein. Our current study successfully identified the in 
vivo epidermal differentiation of BM-MSCs at the early and intermediate stages, 
evidenced by the expression of keratin 10 [53] and filaggrin [167,169], respectively.   
 
Previous investigations have shown that a specific microenvironment, which has been 
known as a ‘niche’, plays a very important role in deciding the phenotype and 
differentiation fate of stem cells [14,124]. It was found that, after wounding, BM-
MSCs would home to the injury site due to the chemotactic signals, especially 
SLC/CCL21, a chemokine expressed by the keratinocytes of wounded skin [14], and 
then the local wounding ‘niche’ would act as ‘a natural bioreactor’ to induce BM-
MSCs into functional skin cells to facilitate skin regeneration and wound healing 
[10,14,130]. Based on our previous in vitro study (Chapter 3), we assume that the 
local biochemical, environmental and physical conditions of the wounded site also 
contributed to the in vivo differentiation of BM-MSCs into epidermal lineage. It was 
known that after wounding, many immunomodulatory factors and cytokines such as 
FGF, KGF and IGF etc. were released to the wound site [41]. These soluble growth 
factors were all reported to contribute to the differentiation of BM-MSCs into 
epithelial lineage [174,177]. In addition, the local wet-dry environment of wounding 
was also believed to promote epidermal differentiation of BM-MSCs. Our previous in 
vitro study using an organotypic coculture model has confirmed the benefit of wet-
dry environment to the differentiation of BM-MSCs into multi-layered epidermis-like 
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cells [202]. In this rat model, the air exposure and gas exchange on the wound surface 
were enabled by wound coverage with a highly porous NFS followed by a pre-
punctured TegadermTM dressing. Besides, the epidermal differentiation of BM-MSCs 
might be simultaneously triggered by the local wound contraction. Unlike mature 
cells, MSCs were found to commit to a particular lineage and phenotype with extreme 
sensitivity to tissue-specific elasticity [165]. In our previous study, the stratified 
epidermis-like cells derived from BM-MSCs were not seen when the underlying 
dermal equivalent was prevented from contracting by a metal ring, even when the 
MSCs were exposed to the air [202]. However, without the metal ring, BM-MSCs 
cultured in an optimized medium at an air-lift interface were able to establish the 
multi-layered structure with the expression of keratin 10 and filaggrin [202]. The 
local contracted wound in this study created a confined microenvironment for close 
cell-cell interaction, which may facilitate MSCs differentiation.  Cell–cell interaction 
is important in cutaneous wound healing because this is an integral part of the 
temporal and spatial events of various cells. Akino et al. has shown that in monolayer 
coculture of MSCs and keratinocytes, MSCs was found to be elongated and adhere to 
human epidermal keratinocytes through a basement membrane-like structure built 
between each other [199]. Fu et al. further demonstrated that P38 and ERK signals 
may be involved in the phenotype changes displayed by MSCs. If the activity of P38 
was inhibited, the number of MSC-derived epidermal cells would be reduced. In 
contrast, if the activity of ERK was inhibited, the number of MSC-derived epidermal 
cells would be increased [131]. However, the clear mechanism underlying the 
epidermal differentiation of BM-MSCs needs further investigation. 
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Lineage differentiation of adult BM-MSCs is largely determined by the environment 
or biological context in which they reside [14,124]. In this study, besides epidermal 
markers, we also found the co-location of some MSCs in the neo-dermis with the 
expression of CD31, the marker for angiogenesis [193], which was consistent with 
the previous reports of Sasaki et al. [14] and Li et al. [203]. It indicates the 
extracellular factors in locally injured microenvironment or cell-cell interactions of 
MSCs with such pre-existing endothelial cells or blood cells might be strong enough 
to reprogram adult MSCs into a more pluripotent status. However, future work is 
required to identify the functions of these BM-MSCs – derived cells in newly 
reconstructed skin. 
 
In this study, no pre-labeled BM-MSCs were found to be co-located with the 
expression of α-smooth muscle actin, a specific marker for wound myofibroblasts 
[194], which indicated BM-MSCs may not undergo differentiation into myofibroblast 
lineage under in vivo wounding environment. Additionally, a decreased amount of 
myofibroblasts were seen in the connective tissue with an increase in the cell density 
of MSCs incorporated in NFS group. This was most probably because MSCs 
promoted the expression and deposition of collagen, which occupied a large amount 
of space in connective tissue and limited the myofibroblast accommodation.  
Myofibroblasts have the features of fibroblasts and smooth muscle cells and contain 
α-smooth muscle actin, which plays a major role in wound contraction [204]. 
Therefore, the incorporation of a large amount of BM-MSCs in the NFS graft may 
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partially limit wound contraction by reducing the density of myofibroblasts 
accumulated in the neo-dermis.   
 
BM-MSCs were also reported to have the capacity to secrete a variety of growth 
factors and cytokines either constitutively or upon stimulation with some cytokines 
that are relevant to tissue repair and regeneration [17]. Liu et al. has found that BM-
MSCs were capable of expressing TGF-β1, EGF, VEGF, PDGF, KGF, FGF and HGF 
constitutively or upon stimulation with LPS, IL-1α, or TNF-α. Quantitative analysis 
of growth factor production by ELISA showed that the expression of TGF-β1, EGF 
or VEGF by BM-MSCs was significantly increased upon stimulation with wound 
tissue superfusate [15]. As wound represents a highly reactive microenvironment rich 
in mediators of inflammation such as IL-1α, IL-6, TNF-α, MCP-1, MIP-1α and MIP-
β [205], it is likely that after homing to the wound site, BM-MSCs would be activated 
upon encountering the highly proinflammatory milieu of the wound. The activated 
BM-MSCs might potentially exhibit a paracrine effect by releasing growth factors 
and cytokines that play a role in skin repair and regeneration [17]. However, more 
rigorous investigations are needed to elucidate the roles and interactions between the 
growth factor production and differentiation of BM-MSCs into the cellular 
components within the skin wounds.  
 
In the case of acute full-thickness skin wounds, augmentation of wound healing in 
MSC-treated NFS groups was also associated with the expression of ECM proteins by 
BM-MSCs. BM-MSCs has been found to synthesize various ECM components 
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including collagen type I, III, IV, V VI, fibronectin, hyaluornan, laminin, vimentin 
and proteoglycans [91]. In this study, more collagen was found to be synthesized in 
MSC-incorporated NFS groups than other groups without MSCs and the expression 
level of collagen increased with the increase in the amount of MSCs incorporated in 
NFS. As we can see, a significantly higher amount of collagen was shown in NFS 
group with a high cell density if compared with the NFS group with a low cell density 
on day 10. Collagen is the most prevalent form in dermis and was found to improve 
wound epithelialization by promoting epithelial cell spreading and attachment. 
Besides, collagen deposition contributes to wound healing by reconstructing the 
structure of dermis with good tensile strength [82]. This may partially explain the fast 
healing rate in the NFS group with a high cell density of MSCs by producing a large 
amount of collagen in the neo-dermis with normal orientation and without scar tissue 
formation on day 10.  
 
Taken together, our results demonstrated a high efficacy on the treatment of acute 
full-thickness skin wounds by locally delivering a sufficient amount of BM-MSCs 
with modified NFS. NFS was found to accelerate the wound healing process, shown 
by the reepithelialization established only in the NFS-incorporated groups on day 10. 
Among them, the NFS group with a high density of BM-MSCs was found to promote 
keratinocyte migration and differentiation, demonstrated by the appearance of 
epithelial tongue on day 5 and establishment of thin layers of stratified keratinocytes 
with the expression of keratin 10, filaggrin and involucrin, markers for different 
epidermal differentiation stages. The H&E staining demonstrated the establishment of 
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neo-epidermis and skin appendages, as well as deposition of collagen with normal 
orientation on day 10 in the NFS group with a high cell density of MSCs, which 
resembled the structures in native skin.  However, compared with the normal skin 
group, the immunostaining of the NFS group with a high cell density showed a 
stronger expression of involucrin in the cornified envelope of the neo-epidermis. This 
was because in adult animals, disruption of the skin barrier resulted in a remarkable 
stimulation of HMG CoA reductase and serine palmtoyl transferase, which led to an 
increase in lipid (cholesterol and ceramide) synthesis and enhancement of the 
formation of cornified layer [29].  
 
Several clinical trials have reported BM-MSCs application is very effective for the 
healing of spinal injury and myocardial infarction, which are difficult to heal by 
normal tissue regeneration [206,207]. Moreover, due to the immunosuppressive 
properties of BM-MSCs, allogeneic BM-MSCs have been used in human when there 
was a limited cell source of healthy autologous BM-MSCs [20,97]. Therefore, the 
apparently safe and broad application of BM-MSCs is expected to be an alternative to 
the use of autologous skin cells, which was always associated with the donor site 
morbidity and limited by the availability of healthy skin [6]. This study demonstrated 
a great efficacy of NFS/BM-MSCs composites in the treatment of acute full-thickness 
skin wounds, which was difficult to heal with the traditional clinical strategies 
including the use of autologous split-thickness skin grafts. The modified NFS was 
proved to be an efficient BM-MSCs captor and carrier as well as a cover for skin graft 
application. In addition, NFS can be customized at any shape or size and have a long 
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shelf-life at room temperature, which bodes well for the persistence of a 
bioengineered off-the-shelf product. Its efficient capture capacity for BM-MSCs with 
30 min at room temperature suggests its great potential for rich and rapid BM-MSCs 
attachment under time constraints and subphysiological temperature in a surgical 
room. Therefore, the NFS/BM-MSCs composite is promising in the treatment of full-
thickness skin wounds. However, further study needs to be done to test the efficacy of 
NFS/stem cell composite for wound healing and skin regeneration in a large wound 
of tight-skinned animals, like full-grown domestic pigs, which demonstrate less level 
of wound contraction and are better matched to the human wounds chronologically 
and physiologically than the loose-skinned animals. Such parameters as dosage of 
BM-MSCs, suitable induction condition in vivo, and long-term follow-up must all be 




This study demonstrated a great efficacy of NFS/BM-MSCs composites as skin grafts 
in the treatment of acute full-thickness skin wounds in a rat model. Both NFS and 
BM-MSCs were found to contribute to the wound healing process. Biodegradable 
NFS accelerated wound healing by providing a provisional matrix for cellular 
invasion and adhesion, collagen synthesis and deposition. BM-MSCs had a dose-
effect on wound healing. Inclusion of a large amount of BM-MSCs significantly 
expedited the epithelialization process and increased collagen synthesis. Besides, 
BM-MSCs were found to be co-located with the expression of keratin 10, filaggrin 
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and CD31, which indicated the participation of BM-MSCs in the epidermal lineage 
differentiation and angiogenesis process under the local specific wounding 
environment. Taken together, these findings suggest a great potential of the NFS/BM-















Conclusions and Recommendations 
 
The scope of this research encompasses the in vitro differentiation of human BM-
MSCs into epidermal lineage under an artificial skin-specific environment in 3D 
organotypic coculture, and optimization of electrospun Collagen/PLGA blended NFS 
for an efficient attachment of BM-MSCs. The final product is a Nanofiber/BM-MSCs 
composite for skin graft application. This product has shown superior effects on 
wound healing and skin regeneration in a rat model with acute full-thickness skin 
wounds.  
 
6.1 Main conclusions 
 
• The epidermal differentiation potential of human BM-MSCs was confirmed 
and achieved by manipulating the biochemical, environmental and physical 
cues in 3D organotypic coculture. BM-MSCs which were cultured in an 
optimized induction media at an air-liquid interface on contractible dermal 
substitutes for 14 days, demonstrated multi-layered epidermis-like structures 
with the expression of keratin 10 and filaggrin, the early and intermediate 
markers of epidermal differentiation, respectively.    
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• Random Collagen/PLGA blended NFS were successfully fabricated with 
electrospinning technique by optimizing the processing parameters. The 
resultant NFS had a well-controlled diameter range between 250 to 500 nm 
and displayed features of ECM-like non-woven architecture, a high porosity 
(79.62%), small pore size (0.47 ± 0.36 µm), proper degradation profile and 
mechanical properties similar to human skin.  
 
• CD29 antibody was successfully conjugated on the blended NFS surface with 
the coupling reagents Traut’s reagent and Sulfo-SMCC. The modified NFS 
demonstrated an efficient capture capacity for human BM-MSCs within a 
short period of time (30 min for 60.22% and 60 min for 80.54%) at room 
temperature. The modified NFS was also found to promote the early spreading 
of attached BM-MSCs, showed by the formation of filopodia-like protrusions 
in BM-MSCs on modified blended NFS at 30 min of incubation at room 
temperature. 
 
• NFS/BM-MSCs composites significantly promoted wound healing and skin 
regeneration in acute full-thickness skin wounds in a rat model. Both NFS and 
BM-MSCs were found to accelerate the wound healing process. 
Biodegradable NFS improved wound healing by providing a provisional 
matrix for cellular invasion and adhesion, collagen synthesis and deposition. 
BM-MSCs had a dose-effect on wound healing. Inclusion of a large amount of 
BM-MSCs remarkably expedited the epithelialization process and increased 




• Pre-labeled BM-MSCs were found to be co-located with the expression of 
CD31, Keratin 10 and Filaggrin after transplantation on day 10. It indicates 
the microenvironment niche may regulate the differentiation fate of BM-
MSCs. Under the local specific wounding microenvironment, some BM-
MSCs may participate in the angiogenesis process and epidermal lineage 
differentiation to facilitate wound healing and skin regeneration.  
 
• No pre-labeled BM-MSCs were found to be co-located with the expression of 
α-smooth muscle actin, a specific myofibroblast marker, which suggests BM-
MSCs may not undergo myofibroblast differentiation under in vivo wounding 
environment. Additionally, a decrease in the number of myofibroblasts 
located in the neodermis was found with an increase in the density of BM-
MSCs incorporated in NFS graft. It indicates inclusion of a high density of 
BM-MSCs in NFS graft may reduce the accomodation of wound 
myofibroblasts which plays a major role in wound contraction.     
 
6.2 Recommendations for future work 
 
The Nanofiber/BM-MSCs composite described herein has showed promosing results 
in promoting wound healing and skin regeneration in a rat model. However, further 
investigations are required to understand the growth factor and gene expression 
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profiles of BM-MSCs under in vitro organotypic culture and in vivo wounding 
environment. We need to further identify the underlying molecular mechanisms of 
BM-MSCs transdifferentiation as well as the interactions between differentiated BM-
MSCs and the surrounding cells in the wounding milieu, such as fibroblasts, 
inflammatory and vascular cells etc.  
 
Further study on characterization of oxygen, nutrition and water transmission as well 
as waste excretion through blended NFS can be done using in vitro organotypic 
culture system to provide comprehensive information on membrane permeability as a 
suitable skin graft. In vivo proteolysis study of blended NFS is also required in future 
investigations to accurately measure the degradation profile of blended NFS in 
wounding environment.     
 
Some critical growth factors or cytokines such as HITED supplements 
(hydrocortisone, insulin, T3, EGF and VD3) can be incorporated to the blended NFS 
to evaluate their effectiveness in promoting skin regeneration and wound healing. The 
core-shell electrospinning technique can be employed to carry proteins and growth 
factors into nanofibers (Fig. 6.1) [208]. The previous study in our lab showed a 
controlled release pattern of FITC-BSA encapsulated in the core of core-shell 
nanofibers [209]. The protein release rate could be adjusted by the ratio of the 
thickness of the shell to core. In the future, some important growth factors or 
cytokines for promoting wound healing and skin regeneration can be loaded into the 
core of the nanofibers to achieve its sustained release and function for wound healing 
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after transplantation.    
 
 
Fig. 6.1 Experimental setup for electrospinning core-shell nanofibers (Reprinted with 
permission from [208]. Copyright 2004 American Chemical Society).  
 
 
Additionally, the present study showed the efficiency and efficacy of nanofiber/BM-
MSCs composite on wound closure and complete reepithelialization of acute full-
thickness skin wounds on day 10 after wounding in a rat model. However, rat skin 
wound healing does not perfectly mimic human skin wound healing because the skin 
morphology is different. Table 6.1 lists several physiological characteristics of rat and 
human that may be important in considering comparisons of wound healing abilities 
in different species [197]. Due to the elasticity or redundancy of rat skin and its lack 
of strong adherence to the underlying structures, rats are described as loose-skinned 
animals [59]. The properties of a ‘loose’ skin allow wound contraction to play a 
significant role in closing rat skin wounds. Besides, the subcutaneous panniculus 
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carnosus in rats was also reported to contribute to wound contraction and collagen 
synthesis [210]. Consequently, wound contraction, which is usually more rapid than 
epithelialization, causes a decrease in the overall healing time of rat wounds [197]. In 
contrast, human have tight skin and lack subcutaneous panniculus carnosus, and these 
differences make the direct transfer of the rat-derived data to human skin wound 
healing is not appropriate. Therefore, further investigations are required to test the 
efficacy and patency of the optimized nanofiber/BM-MSCs composite for wound 
healing and skin regeneration in a relatively large full-thickness wound using a tight-
skinned large animal model, such as a full-grown domestic pig, which is better 
matched chronologically and physiologically to the human wound healing than the 
loose-skinned animals [59]. In addition, several important parameters, such as the 
minimum therapeutic dose of BM-MSCs, suitable induction condition in vivo, and 
long-term follow-up must all be ascertained before the clinical application is 


















   191 
Chatper 6 
Table 6.1 Physiological comparison of rat skin and human skin (Reprinted from [197], 
Copyright 2004, with permission from Wiley-Blackwell).  
 
Characteristic Rat Human 
 
Epidermis Yes Yes 
 
Basement membrane Yes Yes 
 
Dermis Yes Yes 
 
Panniculus Carnosus Yes No 
 
Hair growth Patches Mosaic 
 
Apocrine glands No Yes 
 
Eccrine glands No Yes 
 
Vitamin C source Endogenous Exogenous 
 
Thermoregulation Peripheral vascular 
circulation especially in 
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                                                     Appendix A 
 
BM-MSCs Labeling by Qtracker655 Cell Labeling Kit 
 
 
The nanocrystals in Invitrogen Q-Tracker 655 cell labeling kit are nanometer-scale 
atom clusters composed of a cadmium-selenium core and an inner zinc sulphide shell 
(CdSe/ZnS) and an outer polyethylenglycol shell. A custom peptide bonded to the 
outer shell allows the quantum dots to be endocytosed by cells. This kit is effective 
for labeling a variety of cell types and exhibits no significant leaking or transfer from 
cell to cell. It provides long-term labeling of live cells with no apparent toxic effects. 
Other advantages include photostability and resistance to chemical and metabolically 
degeneration. 
 
BM-MSCs labeling protocol: 
 
1. Take 10µl component A and 10µl component B and mix them, incubate for 5 min 
at room temperature.  
2. Add 2ml of fresh culture medium, shake or votex it for 30 seconds. 
3. Add 2ml of the above solution to one T-75 flask with BM-MSCs at 90% 
confluence. 
4. Incubate for 1 h at 37ºC incubator with 5% CO2. 
5. Wash the cells with medium or PBS (depending on continuous culture or 
subculture or transplantation) 
 




Hematoxylin & Eosin (H&E) Staining Method 
 
 
This section is for samples that had undergone Paraffin Wax Embedding: 
1. Dewax sections in Xylene 2 X 3 min OR until the wax are gone. 
Blot excess xylene before going into ethanol. 
Note: DO NOT touch the timer if there’s Xylene on your gloves. 
2. Clear sections in Ethanol 100% 1 X 3 min 
                                          95% 1 X 3 min 
                                                 70% 1 X 3min 
3. Wash in deionized water for 5 min 
Blot excess water before going into hematoxylin. 
 
4. Fix in 100% Ethanol 1 X 1 min (For Cryo-sections only) 
5. Stain in Mayer’s Hematoxylin for 10 min OR Harris’ Hematoxylin for 2 min 
6. Rinse in water. 
7. Optional: 1 X 5min in tap water. 
8. Optional: Dip in 1% acid alcohol for 1 second, rinse in water till water is clear. 
9. Dip in Alkaline solution for a few seconds. 
10. Rinse in water. 
Blot excess water before going into eosin. 
11. Counter-stain in Eosin for 2-3 seconds ONLY. 
12. Rinse in water. 
13. Optional: View under microscope to check staining. If unsatisfactory, destain 
in 1% acid alcohol. Rinse in water. 
14. Dehydrate in Ethanol  70% 1 X 3 min 
95% 1 X 3 min 
                                              100% 1 X 3 min 
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 15. Clear in Xylene 2 X 5 min 
16. Mount sections in DePex mounting medium. 
17. Allow drying before viewing. 
 
Results: 
Nuclei--------blue to blue black (stained by Hematoxylin)  
































Scanning electron microscopy (SEM) is used to image nanofiber scaffolds 
with/without cells.  
 
1. Wash the samples 3 times with PBS (5 min each wash). 
2. Immerse samples in 2.5% glutaraldehyde. Incubate for 1 h. 
3. Wash 3 times with DI water (5 min each wash). 
4. Immerse samples in 50% ethanol and incubate for 15 min. 
5. Repeat step 4 with 75% ethanol. 
6. Repeat step 4 twice with 95% ethanol. 
7. Repeat step 4 twice with 100% ethanol, incubating for 30 min each time. 
8. Aspirate the solution from the culture wells and allow the samples to dry 
overnight. 
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